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1. SUMMARIES 
1.1 Summary 
Leukemia is a severe blood cell malignancy which is characterized by a high number of 
abnormal immature white blood cells, so-called leukemic blasts. Starting from the bone 
marrow, the infiltration into several organs like spleen, liver and lymph nodes leads to severe 
bleeding problems due to disseminated intravascular coagulation and thrombocytopenia as 
well as to increased risk of infections due to a lack of mature blood cells. Despite enormous 
improvement in cancer cell therapy, especially in targeted therapy strategies over the last 
decades, the two subtypes acute myeloid (AML) and acute lymphoblastic leukemia (ALL) are 
still life-threatening diseases for children and adults. Therefore, new therapeutic approaches 
for AML and ALL are urgently needed. The goal of the study is to establish a 
pharmacological-based therapy for AML and a CAR T cell-based approach for ALL.  
Since successful therapeutic approaches for AML are still limited due to the high 
heterogeneity of AML subtypes, in the present study the combination of arsenic trioxide 
(ATO) and granulocyte-colony stimulating factor (G-CSF) was considered as a potential new 
pharmacological therapeutic approach for AML. The in vitro studies and the in vivo 
observations in a xenotransplantation mouse model shown in this study demonstrated that 
the combination of ATO and G-CSF has a synergistic anti-leukemic effect on AML cells 
potentially via a G-CSF-mediated upregulation of the main ATO transporter AQP9. Even G-
CSF as a single agent displayed an anti-leukemic effectiveness in vivo rendering G-CSF to 
an important adjuvant in future AML therapy. 
Despite the massive progress in targeted ALL therapy by introduction of chimeric antigen 
receptor (CAR) T cell therapy, severe therapy-associated complications like cytokine release 
syndrome and ‘on target off tumor’ toxicities demand further optimization of CAR T cell 
therapy. For that, bispecific CAR T cells as well as universal adapter anti-biotin CAR T cells 
are promising tools and need to be validated for their efficacy and specificity in leukemia 
therapy. Both methods were tested in this study and demonstrated good effectiveness in 
killing B cell-ALLs in vitro and in vivo. Bispecific CAR T cells seem to be a good approach to 
prevent specific escape strategies of leukemic blasts during therapy like antigen loss, while 
the modularity of the adapter anti-biotin CAR T cells allows to target any antigen which is 
accessible to a biotinylated antibody. Therefore, adapter CAR T cells might be the future 
method of choice for targeting a wide range of tumors. 
In conclusion, two therapeutic approaches for two types of acute leukemia resulted in a 
therapeutic success. The high heterogeneity among acute leukemia requires a development 
of a wide spectrum of treatment possibilities.  
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1.2. Zusammenfassung  
Leukämie ist eine ernsthafte Erkrankung des blutbildenden Systems und zeichnet sich durch 
eine hohe Anzahl an abnormalen, unreifen weißen Blutzellen aus, die sogenannten 
leukämischen Blasten. Ausgehend vom Knochenmark infiltrieren sie mehrere Organe wie 
Milz, Leber und Lymphknoten. Dies führt zu einer Verdrängung der gesunden Zellen und 
folglich zu einer erhöhten Blutungsneigung, sowie Infektionen aufgrund eines Mangels an 
ausgereiften und funktionellen Blutzellen. Die letzten Jahrzehnte brachten große Fortschritte 
in der Krebszelltherapie, vor allem bei gezielten Immuntherapien. Dennoch stellen die 
Formen der akuten myeloischen (AML) und akuten lymphoblastischen Leukämie (ALL) 
immer noch eine lebensbedrohliche Krankheit für Kinder und Erwachsene dar. Deshalb sind 
neue Therapieansätze von hoher Dringlichkeit. Das Ziel dieser Studie ist es, eine 
pharmakologisch-basierte Therapie für AML und ein CAR-T-Zell-basierter Ansatz für ALL zu 
etablieren. 
Da aufgrund starker Heterogenität innerhalb der AML-Untergruppen Therapierfolge begrenzt 
sind, sollte in dieser vorliegenden Arbeit die Kombination aus Arsentrioxid (ATO) und dem 
Granulozyten-Kolonie-stimulierende Faktor (engl. ‘granulocyte-colony stimulating factor‘, 
G-CSF) als möglicher neuer pharmakologischer Therapieansatz für die AML getestet 
werden. Sowohl die In-vitro- als auch die mithilfe eines Xenotransplantation-Mausmodells 
generierten In-vivo-Ergebnisse demonstrierten, dass die Kombination aus ATO und G-CSF 
eine synergistisch anti-leukämische Wirkung auf die AML-Zellen ausübt, womöglich über 
eine G-CSF-vermittelte Hochregulierung des primären ATO-Transporters AQP9. Selbst G-
CSF als Einzelmedikament zeigte dabei eine anti-leukämische Wirkung in vivo. Daher liegt 
es nahe, dass G-CSF in zukünftigen Therapieansätzen der AML eine wichtige Rolle spielen 
könnte. 
Trotz großer Verbesserungen in der ALL-Immuntherapie durch die Einführung der ’Chimeric 
Antigen Receptor’ (CAR)-T-Zell-Therapie, kommt es zu schweren Therapie-assoziierten 
Komplikationen wie das ‘Cytokine Release Syndrome‘ und die ‘On-Target-Off-Tumor’-
Toxizität, die eine weiterführende Optimierung der CAR-T-Zell-Therapie bedürfen. Hierfür 
stellen die bispezifischen und universalen Adapter-CAR-T-Zellen vielversprechende 
Werkzeuge dar, die jedoch noch auf ihre Effektivität und Spezifität in der Leukämie-Therapie 
untersucht werden müssen. Beide in der vorliegenden Arbeit getesteten Methoden bewiesen 
eine effiziente Wirksamkeit beim Abtöten von B-Zell-Leukämien in vitro und in vivo. 
Bispezifische CAR-T-Zellen stellen einen guten Ansatz dar, um spezifische Fluchtstrategien 
von leukämischen Blasten, wie zum Beispiel der Verlust von Antigenen, während der 
Therapie zu verhindern. Die Modularität der Adapter-anti-Biotin-CAR-T-Zellen ermöglicht es 
hingegen, jedes Antigen anzugehen, das für einen biotinylierten Antikörper zugänglich ist. 
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Daher könnten die Adapter-CAR-T-Zellen die Methode der Wahl sein, um zukünftig 
verschiedenartige Tumore zu behandeln. 
Abschließend lässt sich sagen, dass die Behandlung von AML und ALL anhand zwei 
gänzlich verschiedener therapeutischer Ansätze zu einem Erfolg führte. Die Heterogenität 
unter den akuten Leukämien ist hoch und fordert daher die Entwicklung eines breiten 
Behandlungsspektrums.  
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2. INTRODUCTION 
2.1 Leukemia 
Cancer is one of the foremost causes of morbidity and mortality worldwide. The number of 
new cases is expected to increase in the next decades due to a higher life expectancy 
(Jemal et al., 2011; WHO, 2017). Leukemia represents 3.7% of all new cancer cases in the 
United States and it is the seventh most common cancer leading to death. In the year 2017, 
62.130 people developed leukemia with 24.500 fatal cases (NIH, 2017). In Germany, 13.700 
new cases of leukemia were registered in 2014, 7.743 with fatal outcome (Robert Koch-
Institut, 2014). Leukemia is a severe blood cell malignancy which is characterized by a high 
number of abnormal immature white blood cells. Starting from the bone marrow, the so-
called leukemic blasts eliminate the healthy blood cells and infiltrate into spleen, liver and 
lymph nodes leading to an impairment of the intruded organs. This blood formation disorder 
results in anemia, bleeding problems and increased risk of infections due to a lack of mature 
blood cells. As known for cancer in general, the disease pathogenesis is based on 
chromosomal aberrations and gene mutations. However, the exact trigger of leukemia 
initiation is unknown, but both inherited and environmental factors are believed to be 
involved, including smoking, ionizing radiation and some chemicals as well as prior 
chemotherapy (Radivoyevitch et al., 2015). Also an abnormal immune response to (viral) 
infections is supposed to be an important causal factor in developing leukemia (Greaves, 
2006). There are four main types of leukemia which are divided by their form (acute versus 
chronic) and derivation (lymphoblastic versus myeloid lineage) of the disease: acute 
lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphoblastic 
leukemia (CLL) and chronic myeloid leukemia (CML) (Hunger and Mullighan, 2015; De 
Kouchkovsky and Abdul-Hay, 2016). Chronic leukemia is characterized by slowly growing 
abnormal white blood cells and due to improved targeted therapies their prognosis is quite 
good (Nowell, 2007; National Cancer Institute, 2013; Mahon, 2015). Whereas the acute 
leukemia exhibit a rapid expansion of immature aberrant cells and eventually result in an 
early death if left untreated (Roboz, 2012). Therefore, new therapeutic strategies should 
particularly focus on the acute forms of leukemia, which will be the pivot of this work. 
 
2.2 The concept of the leukemic stem cell 
The initiation of leukemia formation, also known as leukemogenesis, is based on an aberrant 
hematopoiesis. In this process, hematopoietic stem cells (HSCs) are differentiated into 
manifold mature blood cells. HSCs are located in the bone marrow and embedded within a 
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complex regulatory unit called the bone marrow niche, which includes vascular endothelial 
cells, mesenchymal stromal progenitor cells and a range of mature hematopoietic cells such 
as macrophages, neutrophils and megakaryocytes. HSCs are characterized by their self-
renewal ability and are normally quiescent, spending most of the time in the G0 phase of the 
cell cycle (Dean et al., 2005; Birbrair and Frenette, 2016; Tay et al., 2017). They can be 
separated into a long-term subset (LT-HSC), capable of unlimited self-renewal and 
sustainment of the stem cell pool, and a short-term subset (ST-HSC), which has a limited 
time to self-renew and undergoes differentiation to produce mature hematopoietic cells 
(Passegué et al., 2003; Challen et al., 2010). An important marker to characterize and 
identify HSCs is their drug-transporting capacity which is mediated by membrane-bound 
transport proteins termed ATP-binding cassette (ABC) transporters. High expression levels 
of ABC transporters, e.g. ABCB1, ABCG2 and ABCC1, are responsible for an ATP-
dependent efflux of drugs or dyes and therefore important for the multidrug resistance ability 
of HSCs (Goodell et al., 1996; Wulf et al., 2001). Most cells cannot extrude a fluorescent dye 
like Hoechst 33342 or rhodamine 123, but stem cells can actively do it. Hence, they show a 
low level of fluorescent dye in fluorescence-activated cell sorting (FACS) analysis and reside 
in the so-called ‘side population’ (SP) (Goodell et al., 1996; Passegué et al., 2003; de Jonge-
Peeters et al., 2007). The drug resistance and an active DNA-repair capacity are basic 
requirements for a long lifespan of HSCs (Dean et al., 2005). 
 
HSCs are constantly exposed to stress and carcinogens, which can cause DNA damage 
leading to an accumulation of mutations and over the time to malignant transformation 
(Welch et al., 2012; Schepers et al., 2015). These transformed malignant HCSs retain many 
characteristics of normal HSCs, like self-renewal, niche dependence and differentiation to 
mature but dysregulated clonogenic progenitor cells, and behave as disease-initiating 
leukemic stem cells (LSCs) (Passegué et al., 2003; Schepers et al., 2015). Based on this 
model, the concept of a LSC that initiates leukemia has been proposed (FIGURE 1). J. Dick 
and colleagues showed that LCSs can initiate and serially propagate diseases upon 
transplantation into immune-deficient mice, thereby recreating the primary malignancy with 
its full heterogeneity. In terms of AML, they thought that only cells with an immature 
phenotype, characterized by cluster of differentiation (CD) markers CD34+CD38-, were 
capable to expand the disease in the recipient mice, not mature CD34+CD38+ cells. 
However, new studies elucidated that LSCs are no longer restricted to the HSC compartment 
and can also emerge from transformed progenitors (Bonnet and Dick, 1997; Cozzio et al., 
2003; Passegué et al., 2003; Eppert et al., 2011; Schepers et al., 2015). It was also shown 
for ALL that both immature CD34+CD19- and mature CD34-CD19+ cells can repopulate and 
propagate the leukemia in immune-deficient mice (Bomken et al., 2010). As well as normal 
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HSCs, LSCs are naturally resistant to chemotherapy agents through an ABC-transporter-
mediated efflux of drugs. In addition, LSCs can also acquire drug resistance by genetic 
changes for example mutations or overexpression of drug targets before or after 
chemotherapy (Dean et al., 2005). Therefore, LSCs have different properties than the bulk 
leukemic population and are most responsible for relapse after therapy. Because of the 
genetic diversity of LSCs, therapy options targeting LSCs as well as the therapeutic success 
are limited. Treatment approaches are often very specific and target only definite properties 
of LSC clones, such as ABC transporters, mutations in embryonic stem cell signaling or 
tissue differentiation pathways, for example the Hedgehog, Notch or wingless-related 
integration site (Wnt) signaling. Even the inhibition of antigens that are strongly expressed on 
LSCs, like CD123, CLL-1, CD44, CD47 or c-Kit, targets only a small portion of LSCs (Dean 
et al., 2005; Van Rhenen et al., 2007; Pollyea et al., 2014; Schepers et al., 2015). To 
overcome these limitations, new strategies should be proposed and pursued like testing drug 
response of genetically diverse LSCs (Pollyea et al., 2014; Shlush et al., 2017). 
 
 
 
Figure 1: The concept of the leukemia initiating stem cell. 
Leukemogenic mutations may occur within long-term hematopoietic stem cells (HSC) or in 
multipotential/ committed downstream progenitors giving rise to a pre-leukemia state with unlimited 
self-renewal. As a hierarchical structure the leukemic stem cell (LSC) at the apex produces both the 
clonogenic leukemic progenitors and the non-clonogenic blast cells, which built up the bulk of the 
leukemia. Figure based on Huntly and Gilliland, 2005; Lane and Gilliland, 2010.  
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2.3 Acute myeloid leukemia 
The acute myeloid form of leukemia is characterized by an impaired myeloid differentiation 
and accumulation of malignant immature progenitor cells of the myeloid origin in the bone 
marrow. The diversity of progenitor cells that are susceptible to malignant transformation 
leads to a high heterogeneity among AMLs (Fernandes et al., 2014). The concept of the 
leukemia initiating stem cell was primarily investigated and well characterized in AML. LSCs 
are able to initiate, maintain and serially propagate leukemia in vivo while they keep their 
capacity to produce both the clonogenic leukemic progenitors and the non-clonogenic blast 
cells which constitute the bulk of the leukemia (Huntly and Gilliland, 2005; Lane and Gilliland, 
2010). AML is the most common acute leukemia in adults with a poor outcome and median 
age of 66 years at diagnosis. Even less than 10% of elderly patients can be cured. The 
outcome for younger patients are more favorable, but still two-thirds of them die from relapse 
(Roboz, 2012; Pollyea et al., 2014). There are several differences in childhood and adult 
AML in terms of incidence, cytogenetic pattern and molecular aberrations. The majority of 
childhood AML occurs de novo, while AML in adults develops often from antecedent myeloid 
disorders such as myelodysplastic syndromes (MDS) (de Rooij et al., 2015). Also, a higher 
frequency of cytogenetic abnormalities creating fusion genes (for example RUNX1-
RUNX1T1 and NUP98-NSD1) or specific chromosomal translocations (for example 
t(1;22)(p13;q13)/RBM15-MKL1, t(7;12)(q36;p13)/ETV6-MNX1 and t(11;12)(p15;p13)/NUP98-
KDM5A) distinguish childhood from adult AML. In adult AML, many patients have a normal 
karyotype with increasing numbers of driver mutations in the RUNX1, TP53, IDH1/2 and 
NPM1 genes. These distinctions between adult and childhood AML imply an age-dependent 
difference in pathogenesis (de Rooij et al., 2015; Laing et al., 2017).  
Further, an unexplained high risk of AML has been found in families who inherited driver 
mutations like TP53, GATA2, RUNX1 and CEBPA suggesting a familial predisposition to 
develop AML or MDS/AML (Owen et al., 2008; de Rooij et al., 2015). Also several congenital 
conditions increase the risk of developing leukemia like Down-syndrome or congenital and 
cycling neutropenia (Zwaan et al., 2010; Klimiankou et al., 2016). 
 
2.3.1 Classification of AML 
Two of the main systems that have been used to classify AML into subtypes are the French-
American-British (FAB) and the World Health Organization (WHO) classification. The basic 
FAB classification system relies on cytomorphological and cytochemical studies and defines 
eight subtypes (FAB M0 through M7). The modern WHO classification systems are based on 
cytomorphology, cytochemistry, immunophenotyping, immunogenetics and molecular 
cytogenetics, hence, combining the earlier classification methods with the newer ones 
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(Segeren and Van ’t Veer, 1996; Szczepański et al., 2003). The WHO classification defines 
six major disease entities which are listed with genetic abnormalities (if present) in TABLE 1 
(Segeren and Van ’t Veer, 1996; Vardiman et al., 2009; De Kouchkovsky and Abdul-Hay, 
2016). Knowing the subtype of AML is important for the therapeutic approach and prognosis 
of the patients. 
 
Table 1: Classification of AML. 
TYPES FURTHER DESCRIPTION 
 
AML with recurrent genetic abnormalities 
 
- AML with t(8:21)(q22;q22); RUNX1-RUNX1T1 
- AML with inv(16)(p13.1q22) or      
   t(16;16)(p13.1;q22); CBFB-MYH11 
- APL with PML-RARα (FAB M3) 
- AML with t(9;11)(p21.3;q23.3); MLLT3-KMT2 
- AML with t(6;9)(p23;q34.1); DEK-NUP214 
- AML with inv(3)(q21.3q26.2) or  
   t(3;3)(q21.3;q26.2); GATA2, MECOM 
- AML (megakaryoblastic) with  
   t(1;22)(p13.3;q13.3); RBM15-MKL1 
- AML with BCR-ABL1 (provisional entity) 
- AML with mutated NPM1 
- AML with biallelic mutations of CEBPA 
- AML with mutated RUNX1 (provisional entity) 
 
AML with myelodysplasia-related changes n/a 
Therapy-related myeloid neoplasms n/a 
 
AML, not otherwise specified 
 
- AML with minimal differentiation (FAB M0) 
- AML without maturation (FAB M1) 
- AML with maturation (FAB M2) 
- Acute myelomonocytic leukemia (FAB M4) 
- Acute monoblastic/monocytic leukemia (FAB M5) 
- Acute erythroid leukemia (FAB M6) 
- Acute megakaryoblastic leukemia (FAB M7) 
 
Myeloid sarcoma n/a 
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Myeloid proliferation related to Down 
syndrome 
 
- Transient abnormal myelopoiesis 
- AML associated with Down syndrome 
 
  
2.3.2 Standard and alternative therapies for AML 
A first-line treatment of AML is the induction chemotherapy, a combination of the cytostatic 
agents anthracycline, such as daunorubicin, which intercalates into DNA/RNA and inhibits 
the topoisomerase II enzyme, and a high dose of cytarabine, also known as cytosine 
arabinoside (Ara-C), which acts as a nucleoside analogue. The treatment with both agents 
impairs the replication of the rapidly growing tumor cells leading to cell cycle and cell growth 
arrest (Ellison et al., 1968; Minotti, 2004; van Dalen et al., 2014). The induction 
chemotherapy is followed by either a consolidation chemotherapy or allogeneic 
hematopoietic stem cell transplantation (HSCT), depending on the treatment outcome of 
chemotherapy alone. So far, HSCT remains the most successful therapy for prevention of 
relapse in non-favorable risk AML and in young AML patients. However, relapse after 
allogeneic HSCT does occur. Moreover, the vast majority of elderly patients are not even 
qualified for HSCT or cannot tolerate the high toxicity of the standard therapy scheme 
(Roboz, 2012; Fernandes et al., 2014; Lichtenegger et al., 2017). Aside from age, the 
classification of AML in different prognostic-risk groups based on cytogenetic and molecular 
profile also help to predict the susceptibility and outcome of the standard therapy (Roboz, 
2012; De Kouchkovsky and Abdul-Hay, 2016). Because of the very poor prognosis of 
patients which are not eligible for the intensive standard therapy as well as patients with 
relapsed or refractory disease, new innovative therapeutic approaches are urgently needed, 
especially targeted therapeutics which specifically target leukemic cells and minimize off-
target effects. For that, many immunotherapy approaches have been developed using 
monoclonal antibody (mAb) conjugates, T cell-recruiting antibody constructs or 
reprogrammed T cells (Tettamanti et al., 2013).  
Since conventional, unconjugated mAbs are not efficient enough to eradicate the disease, 
the fragment crystallizable (Fc) part of mAbs were conjugated with cytotoxic drugs or toxins 
to induce DNA damage or cell cycle arrest in tumor cells. A common target antigen for mAb-
conjugate therapy is CD33, a transmembrane cell surface receptor expressed on cells from 
myeloid lineage, but also on some lymphoid cells. CD33 is expressed with a high density on 
AML cells and LSCs (Hamann et al., 2002; Lichtenegger et al., 2017). The first antibody-drug 
conjugate was Gemtuzumab Ozogamicin (GO, Mylotarg®), an anti-CD33 antibody linked 
with the antitumor antibiotic calicheamicin (Bernstein, 2000). In the year 2000, the Food and 
Drug Administration (FDA) approved GO as a promising mAb conjugate. However, ten years 
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later, GO was voluntarily withdrawn from the market because it did not prolong the survival 
and increased the rate of early death (Petersdorf et al., 2013). A common problem of mAb 
conjugates may be their limited effect on resting, low proliferative cells or quiescent LSCs 
that may express CD33 at low levels (Walter et al., 2012; Krupka et al., 2014). Nevertheless, 
different clinical trials with relapsed or untreated AML patients have been performed in the 
last years to evaluate the benefit of adding GO in low doses to chemotherapy. Their results 
suggested an improvement in survival with GO in selected patients (Burnett et al., 2011; 
Castaigne et al., 2012; Walter et al., 2014). 
Another immunotherapeutic approach for AML is a T cell-recruiting antibody construct, 
composed of two single-chain variable fragments (scFv) of two antibodies with different 
specificities connected by a short peptide linker. This bispecific antibody simultaneous binds 
a tumor-associated antigen and CD3ε in the T cell receptor (TCR) complex leading to 
activation and expansion of cytotoxic T cells for cancer cell lysis without the requirement of 
co-stimulatory signals (Baeuerle and Reinhardt, 2009). A bispecific antibody for AML is AMG 
330, which recognizes CD33 as a tumor-associated antigen. Preclinical studies have shown 
that AMG 330 is effective against CD33-expressing blasts even in extremely low doses or at 
a low effector-to-target (E:T) cell ratio. Besides, it has been demonstrated in vitro that both 
AMG 330’s activity and cytotoxicity are increased proportionally to the expression level of 
CD33 and are not altered by drug efflux capability of ABC transporters. However, the use of 
bispecific antibodies leads to a strong T cell activation and production of proinflammatory 
cytokines, which might trigger tumor cells to escape the antibody-mediated tumor cell lysis by 
immunosuppressive strategies. Clinical trials are now in progress to investigate the safety 
and efficacy of AMG 330 in patients with AML (Krupka et al., 2014; Laszlo et al., 2014; 
Harrington et al., 2015; Laing et al., 2017). 
It is reported that some AML patients have CD34+CD33- LSCs, hence, targeting CD33 
antigen alone would not be effective enough for all the heterogeneous AML subtypes. 
CD123, an often targeted LSC antigen, or CD135 (FLT-3), the most frequently acquired 
alterations identified in AML, are additional targets for novel immunotherapeutic approaches 
(Walter et al., 2012; Tettamanti et al., 2013). 
A novel highly promising approach for targeted immunotherapy of cancer are chimeric 
antigen receptor (CAR) T cells. CAR T cells are engineered T cells consisting of extracellular 
tumor antigen-recognition domains, most commonly antibody-derived scFvs, linked through a 
transmembrane domain to T cell-triggering intracellular domains. This enables both a major 
histocompatibility complex (MHC) independent antigen binding and a highly potent cytotoxic 
effector cell function. Hence, recognition of an antigen leads to T cell activation, expansion 
and resultant cancer cell death (Barrett et al., 2015; June et al., 2015). The major advantage 
of CAR T cells is their ability to target any molecule which is accessible to an antibody-like 
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recognition (paragraph 2.4.3). To date, several antigens for AML CAR T cell therapy are 
under preclinical investigation. CD33 and CD123 are the most prominent ones showing an 
efficient lysis of AML blasts in xenotransplanted NSG mice (Mardiros et al., 2013; O’Hear et 
al., 2015; Lichtenegger et al., 2017). However, significant ‘on-target off-leukemia’ toxicity with 
reduction of myeloid lineage and hematopoietic stem cells was observed. To circumvent this 
myelotoxicity, new strategies have been followed such as a transient CD33-CAR expression 
(Kenderian et al., 2015) or a new engineered anti-CD123 CAR T cell receptor, using VH and 
VL chains derived from different CD123-specific mAbs (Thokala et al., 2016), showing 
reduced lysis of normal hematopoietic stem cells. 
In addition to the other immunotherapeutic approaches described so far, mAbs against 
checkpoint molecules has also been proven to be a highly effective tool in cancer 
immunotherapy. In normal cells, cell cycle checkpoint kinases act as tumor suppressors and 
are crucial for the maintenance of genetic stability. In cancer, however, they have been found 
to protect tumor cells from different stresses and, consequently, to promote tumor 
progression. MAbs against these checkpoint molecules were primarily confirmed for solid 
tumors but they are also in the ascendant for hematologic malignancies (R. Berger et al., 
2008; Alatrash et al., 2016). Currently ongoing clinical trials are studying the effect of the 
most prominent checkpoint inhibitors, programmed cell death 1 (PD-1) and cytotoxic T 
lymphocyte-associated antigen 4 (CTLA-4), as a monotherapy for various malignancies 
including AML. Furthermore, the combination of checkpoint inhibitors with hypomethylating 
agents (Yang et al., 2014), such as azacytidine and guadecitabine - which are in combination 
with low-dose Ara-C good alternatives for AML patients who are ineligible for conventional 
cytotoxic induction chemotherapy (Stein and Tallman, 2016) -, or with the bispecific antibody 
AMG 330 showed an increased tumor cell lysis compared to the agents alone, encouraging 
future studies to test combinatorial treatments (Krupka et al., 2016). 
 
Many potential drugs for AML therapy targeting mutant or overexpressed driver proteins, for 
example mutant Fms-related typrosine kinase 3 (FLT3) and isocitrate dehydrogenase (IDH), 
or upregulated polo-like kinase 1 (PLK1) were developed. FLT3 is expressed on 
hematopoietic progenitors and on most leukemic myeloblasts. An internal tandem duplication 
of FLT3 (FLT3-ITD) is found in approximately 30% of patients with de novo AML and is 
associated with a poor prognosis (Kottaridis et al., 2001; Fröhling et al., 2002). The 
contribution of FLT3-ITD to the pathogenesis of leukemia is generally thought to be due to a 
gain-of-function of the FLT3 receptor, leading to a ligand-independent auto-phosphorylation 
and constitutive activation of the receptor (Lagunas-Rangel and Chávez-Valencia, 2017). 
Several FLT3 inhibitors were developed and some of them, such as midostaurin, quizartinib 
and crenolanib, are currently under clinical trial. Mutations in IDH1 (protein is localized in the 
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cytoplasm) and IDH2 (protein is predominantly located in the mitochondria) are found in 5% 
and 10% of adult AML patients, respectively. The wild type function of IDH enzymes of 
catalyzing the conversion of isocitrate to α-ketoglutarate is altered to a conversion of α-
ketoglutarate into β-hydroxyglutarate in AML patients with IDH mutations. This causes a 
hypermethylation of target genes and consequently an impaired myeloid differentiation 
(Figueroa et al., 2010; Richarson et al., 2016). First results of currently ongoing clinical trials 
with inhibitors of mutant IDH1 and IDH2 have shown an encouraging efficacy and a low 
toxicity in patients with relapsed AML (Stein et al., 2014). PLKs are a family of five conserved 
serine/threonine kinases which are important for many processes involved in cell cycle 
control, DNA replication and in stress response to DNA damage checkpoint regulation. 
Inhibition of the overexpressed PLK1 leads to a disorganized spindle assembly and cellular 
apoptosis of AML cells (Gjertsen and Schöffski, 2015). Clinical studies with the PLK1 
inhibitor volasertib in combination with low-dose Ara-C showed promising results for treating 
patients with relapsed/refractory or previously untreated AML, who were considered to be 
unsuitable for intensive conventional therapy (Döhner et al., 2014). 
 
In general, the agents of the so-called targeted therapy have a limited efficacy as single 
drugs. However, they do demonstrate biologic activity with a tolerable toxicity making them 
attractive for combination with other agents for newly diagnosed and relapsed/refractory AML 
patients ineligible for conventional chemotherapy. 
 
2.3.3 New therapeutic approaches for AML 
2.3.3.1 Arsenic trioxide 
Arsenic is a naturally occurring substance and one of the oldest drugs, in both Western and 
traditional Chinese medicine used for treatment of periodic fever, chronic myelogenous 
leukemia and other diseases (Haller, 1975; Zhu et al., 2002). Arsenic trioxide (ATO) is an 
inorganic form of arsenic. Its modern history started in the 1970s with studies in China which 
demonstrated its efficiency as a therapeutic agent for APL patients by the achievement of 
clinical remissions. APL is morphologically defined as a FAB M3 AML-subtype and is 
cytogenetically characterized by a balanced reciprocal translocation between chromosomes 
15 and 17, which results in the fusion of the genes encoding the promyelocytic leukemia 
protein (PML) and retinoic acid receptor α (RARα) (Bennett et al., 1976; Litzow, 2008). The 
chimeric PML-RARα protein disrupts the retinoic acid signaling pathway, which is essential 
for granulocytic differentiation (Zheng et al., 2005). The efficacy of conventional 
chemotherapy with anthracycline and Ara-C for treating APL is relatively poor, leading to an 
aggravation of the bleeding syndrome and, thus, to an early death. In 1985, the combination 
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of all-trans retinoic acid (ATRA) and chemotherapy significantly improved the clinical 
outcome of APL patients by inducing the differentiation of leukemic cells. However, some 
patients developed an APL syndrome associated with a severe hyperleukocytosis due to an 
acquired resistance of leukemic cells to ATRA (Fenaux et al., 2007; Litzow, 2008; Wang and 
Chen, 2008). To overcome these limitations, the introduction of ATO in the early 1990s 
further optimized the ATRA-based therapies by a profound degradation of the PML-RARα 
protein which led to a longer survival of refractory/relapsed and newly diagnosed APL 
patients (Niu et al., 1999; Shen et al., 2004). Furthermore, a recent Italian-German study 
(APL0406 trial) demonstrated a superior and more sustained anti-leukemic efficacy of ATRA 
in combination with ATO compared with ATRA and chemotherapy in low- and intermediate-
risk APL patients (Platzbecker et al., 2017). ATO is currently regarded as the most effective 
single agent in APL and was approved by the FDA in 2000 for treatment of 
refractory/relapsed APL as a second-line therapy (Y. Zhang et al., 2016; Platzbecker et al., 
2017).  
Since the discovery of its efficacy in treating APL, many studies tried to elucidate ATO’s 
mechanism of action, not only for treatment of APL but also for other AML subtypes and 
moreover for other forms of cancer (Jiao et al., 2015; Leung et al., 2017). At the cellular level, 
ATO exerts dose-dependent dual effects on APL cells by inducing apoptosis through 
activation of the mitochondria-mediated intrinsic apoptotic pathway at high concentrations 
and promoting cell differentiation with a longer treatment at low concentrations (Wang and 
Chen, 2008; Chen et al., 2011). Aside from the degradation of the PML-RARα fusion protein 
in APL, ATO also causes inhibition of transcription factors like Gli1 in the Hedgehog signaling 
pathway (Kim et al., 2010; Beauchamp et al., 2011) as well as reduction of other AML 
oncoproteins such as AML1/MDS1/EVI1 (Shackelford et al., 2006), thereby inducing growth 
arrest, differentiation and apoptosis of leukemia cells. Furthermore, a study of Halicka et al. 
demonstrated that ATO treatment of different leukemia cell lines leads to a cell cycle arrest in 
the G2/M phase and consequently to a cell growth inhibition, regardless of the PML-RARα 
status (Halicka et al., 2002). In 2014, S. Kumar and colleagues confirmed that ATO induces 
the mitochondrial pathway of apoptosis in AML HL-60 cells, as well as in APL cells, via 
oxidative stress, DNA damage and changes in mitochondrial membrane potential (Kumar et 
al., 2014). Similar observations were made in ATO-treated human chondrosarcoma (Jiao et 
al., 2015), hepatocellular carcinoma (Lin et al., 2007; Zhang et al., 2014) and lung carcinoma 
cells (Leung et al., 2017), suggesting that ATO is also a promising agent for other 
hematological malignancies and other types of cancer. However, despite ATO’s encouraging 
efficacy in many forms of cancer, its myocardial toxicity and other side effects, such as the 
APL syndrome with its severe hyperleukocytosis and increased cytokine expression, as well 
  Introduction 
15 
as the increased risk of secondary malignancies due to chronic arsenic exposure, need to be 
considered (Litzow, 2008; Mathews et al., 2013). 
 
2.3.3.2 Granulocyte-colony stimulating factor 
Colony-stimulating factors are glycoproteins essential for proliferation, differentiation and 
survival of hematopoietic cells. One of its members is the granulocyte-colony stimulating 
factor (G-CSF), a hematopoietic cytokine whose major function is to regulate granulopoiesis 
by stimulating the bone marrow to produce neutrophils from committed myeloid precursor 
cells. In year 1985, K. Welte and colleagues isolated and purified G-CSF from the human 
bladder carcinoma cell line 5637 and identified its capability of stimulating growth of 
progenitor cells and differentiation of promyelocytic leukemia cell lines in vitro (Welte et al., 
1985). Furthermore, Nagata et al. and Souza et al. isolated the cDNA and determined the 
amino acid sequence of the purified G-CSF protein (Nagata et al., 1986; Souza et al., 1986). 
In response to the need of highly purified G-CSF for clinical use, a glycosylated (lenograstim, 
synthesized in Chinese hamster ovary cells) and a non-glycosylated form (filgrastim, 
synthesized in Escherichia coli) of the human protein have been manufactured. These both 
recombinant human G-CSF (rhG-CSF) variants exhibit the same pharmacokinetics and 
pharmacological effects (Tanaka et al., 1997). Nowadays, it is known that G-CSF is 
produced by stromal cells, macrophages, neutrophils, endothelial cells and fibroblasts, as 
well as by tumors (Nagata et al., 1986; Mendoza et al., 1990; Baba et al., 1995). After 
secretion, G-CSF binds with high affinity to the G-CSF receptor (G-CSFR), which is 
expressed on myeloid precursor cells in the bone marrow, and induces neutrophilic 
precursors to proliferate and differentiate into mature neutrophils. To the signaling pathways 
involved in the G-CSF signal transduction upon binding to G-CSFR belongs the Janus 
tyrosine kinase (JAK)/ signal transducer and activator of transcription protein (STAT) 
signaling cascade, mitogen-activated protein kinase (MAPK), phosphoinositide 3-kinase 
(PI3K) and Wnt signaling pathway (Marino and Roguin, 2008; Skokowa et al., 2017). 
Dysregulation in the G-CSFR signaling pathway at the level of downstream effector proteins 
leads to severe defects in myeloid cell proliferation and differentiation. The protein lymphoid 
enhancer-binding factor 1 (LEF-1), generally collaborates with β-catenin as a transcriptional 
complex downstream of the canonical Wnt signaling pathway, can also act independently of 
β-catenin and is known to be crucial for correct G-CSF-mediated neutrophil granulopoiesis 
(Van de Wetering et al., 2002; Skokowa et al., 2006). Myeloid cells with a reduction of LEF-1 
protein levels, along with a hyperactivated JAK2 and a constitutively active STAT5A, show a 
maturation arrest of granulopoiesis at the level of promyelocytes, which is causative for 
severe congenital neutropenia (CN) (Skokowa et al., 2006; Gupta et al., 2014). Due to the 
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impaired differentiation and therefore reduced number of neutrophilic granulocytes, CN 
patients suffer from severe bacterial infections starting shortly after birth and, without proper 
treatment with rhG-CSF, throughout lifetime (Dale et al., 2006; Welte et al., 2006). In patients 
with CN, compensatory mechanisms of granulopoiesis can be induced by increasing the G-
CSF signaling via G-CSF administration, rendering G-CSF a qualified drug for neutropenia.  
With the clinical use of the pharmaceutical rhG-CSF forms, not only febrile neutropenia in 
patients with non-myeloid malignancies under chemotherapies can be reduced, but also 
bone marrow recovery after HSCT can be accelerated and the onset of severe 
myelosuppression prevented. Moreover, G-CSF is clinically used as bone marrow mobilizer 
to increase the number of circulating CD34-positive progenitor cells in the blood for further 
HSCT (To et al., 1997; Crobu et al., 2014). Besides, G-CSF has also been shown to improve 
cardiac function after myocardial infarction by bone marrow cell mobilization (Deindl et al., 
2006) as well as act neuroprotective in stroke models (Schäbitz and Schneider, 2007). 
Growth factors have also been used for treatment of leukemia. For AML therapy, G-CSF can 
be applied after induction therapy to handle neutropenia and reduce the incidence of 
infections, especially for elderly AML patients who are susceptible to infection-related 
mortality (Von Lilienfeld-Toal et al., 2007). G-CSF has also been investigated in several 
combinations for treating AML with genetic abnormalities or relapsed/refractory AML such as 
fludarabine + high-dose Ara-C + G-CSF (FLAG) or cladribine + Ara-C + G-CSF (Visani et al., 
1994; Borthakur et al., 2008; Roboz, 2012). The so-called FLAG therapy could also be a 
good alternative for induction treatment of poor risk AML (Burnett et al., 2013). Aside from 
reducing the toxicity of standard therapy, G-CSF also induces the quiescent AML cells into 
the cell cycle and, thus, increases their sensitivity to Ara-C (Nakayama et al., 2017). Also, 
Kitagawa et al. showed that the combination of G-CSF with Ara-C and the cytostatic agent 
etoposide is superior regarding its AML cytotoxicity when compared to the therapy with Ara-
C and etoposide alone. By adding G-CSF, reduced cell viability and cell number, as well as 
an increased level of apoptotic cells were observed. Moreover, G-CSF mobilized resting 
G0/G1 phase cells into S phase suggesting a priming effect of G-CSF on AML cells 
(Kitagawa et al., 2010). However, despite promising results for G-CSF as an adjuvant for 
AML therapy, the application of G-CSF for leukemia treatment is still controversial. G-CSFR 
is also expressed on leukemic cells what can sensitize them to proliferate upon G-CSF 
stimulus (Budel et al., 1989; Kita et al., 1993). 
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2.3.3.3 Combinatorial ATO-G-CSF treatment – a new therapeutic approach for AML by 
stimulating the aquaglyceroporin 9 channel? 
The revival of the notorious and likewise life-giving ‘poison’ arsenic for treating APL is a 
unique story in cancer research. It also highlights some of the essential concepts in 
pharmacology regarding the cytotoxicity of compounds: the achievement of a favorable 
therapeutic ratio between normal healthy and malignant target cells. As the specificity of 
compounds for malignant cells is mostly not given, the development of combinatorial 
treatments is mandatory to reduce off-target effect, which may harm healthy cells. Indeed, for 
APL the combination ATO-ATRA has exhibited an enhanced therapeutic efficacy compared 
with either single agent. In treating other hematological diseases, several combinations can 
improve the clinical outcome like arsenic sulfide in combination with imatinib for treating 
‘breakpoint cluster region/Abelson murine leukemia viral oncogene homolog 1’ (BCR/ABL)-
associated CML, whereby arsenic sulfide potentiates the efficacy of imatinib to decrease the 
constitutive activity of BCR/ABL (Zhang et al., 2009; Chen et al., 2011). Arsenic can not only 
act as a potentiator in therapeutic approaches, but it can also be amplified in its function by 
several agents such as vitamin D3, which enhances the anti-tumorigenic effects of ATO in 
human HL-60 leukemia cells through induction of nucleosomal DNA fragmentation (Rogers 
et al., 2014). Also, ATRA and the hypomethylating agent azacytidine augment the cytotoxic 
effect of ATO in AML cells by upregulating the main arsenic transporter aquaglyceroporin 9 
(AQP9) (Iriyama et al., 2012; Chau et al., 2015).  
Aquaglyceroporins are members of the major intrinsic protein superfamily, which allow the 
passage of not only water – like the true aquaporins – but also glycerol and other neutral 
solutes. Thirteen aquaporin (AQP) subtypes (AQP0 – 12) have been identified in mammals, 
but only AQP3, AQP7, AQP9, and AQP10 are members of the aquaglyceroporin family. They 
are expressed in almost all tissues, even though their distribution pattern is tissue-specific 
(Saito et al., 1292; Bhattacharjee et al., 2004). AQP3 is present among others at the 
basolateral membrane of kidney, colon and skin, whereas AQP7 is found in testes, adipose 
tissue and heart. Human AQP10 is expressed only in small intestine (Ishibashi et al., 2002). 
AQP9 transcript is found in humans in liver, lung, spleen, brain and peripheral leukocytes 
and is therefore the only known AQP expressed in the hematopoietic system (Tsukaguchi et 
al., 1999; Elkjær et al., 2000). The AQP9 gene is located on chromosome 15q22.1-22.2 and 
has a size of 25 kb. It encodes a protein monomer of 295 amino acids, which contains six 
full- and two half-transmembrane stretching α-helices. Together with three further monomers 
it forms an AQP9 tetramer. The pore for transportation of solutes is formed within the helices 
of each monomer, hence, the tetrameric AQP9 comprises four independent pores (FIGURE 2) 
(Tsukaguchi et al., 1999; Viadiu et al., 2007). 
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Figure 2: Structure of the AQP9 channel. 
(A) The AQP9 monomer is constituted of 295 amino acids and contains six full- and two half-
transmembrane stretching α-helices. (B) The projection map shows the rat AQP9 tetramer constituted 
of four helix-clusters and featuring oval pores with an approximate dimension of 7 Å by 12 Å. The large 
pores of AQP9 allow the passage of bulkier solutes. Figures adapted from Tsukaguchi et al., 1999; 
Viadiu et al., 2007.  
 
AQP9 has the broadest specificity among the AQP family and transports water, glycerol, 
urea, carbamides, polyols, purines and pyrimidines, as well as arsenic. However, 
transportation of arsenic was shown to be additionally mediated by AQP3 and AQP7 (Liu et 
al., 2002; Lee et al., 2006). Many studies with cell lines cultures revealed that an increased 
AQP3 or AQP9 expression leads to an enlarged arsenic influx and sensitivity and, thereby, to 
an accumulation of arsenic within the cells (Bhattacharjee et al., 2004; Lee et al., 2006; 
Leung et al., 2007). On the other hand, experiments with mice lacking an AQP9 expression 
demonstrated that AQP9 is not only responsible for the uptake but also for the elimination of 
arsenic. These results suggest that AQP9 may also act as a protector against arsenic 
poisoning (Carbrey et al., 2009).  
In respect of therapeutic approaches for leukemia, AQP9 is widely expressed on the plasma 
membranes of leukemic cells and plays a crucial role for arsenic uptake. AQP9 is also 
assumed to be a promising candidate biomarker for predicting the efficacy of ATO treatment 
in APL patients (Iriyama et al., 2013). By upregulating AQP9 with agents like ATRA or 
azacytidine the arsenic level and, thereby, the cytotoxicity can be increased. Another AQP9-
stimulating candidate may be G-CSF. G-CSF as well as ATO are already known to be 
efficient agents for promoting cycling of dormant HSCs and LSCs (Essers and Trumpp, 
2010). Iriyama et al. also showed that G-CSF in addition to ATO and ATRA has an enhanced 
anti-leukemic effect on HT93A APL cells by potentiating the ATO-ATRA-induced 
differentiation and rendering them more sensitive to ATO. Even though Iriyama et al. could 
not directly detect an upregulation of AQP9 expression upon G-CSF addition, increased 
intracellular ATO levels were observed when compared to ATRA/ATO treatments alone. This 
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led to the assumption that G-CSF has a stimulating effect on AQP9 protein expression or 
stability (Iriyama et al., 2012). 
 
2.4 Acute lymphoblastic leukemia 
Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy in developed 
countries. The malignant transformation and subsequent clonal expansion of immature 
lymphoid lineage-derived progenitors can arise during B cell- (B-ALL) or T cell development 
(T-ALL). 85% of childhood and adolescence ALL are B-ALL and 15% T-ALL, while 75% of 
adulthood ALL are B-ALL and 25% T-ALL (Chiaretti and Foà, 2009; Kunz et al., 2015). Over 
the last decades, massive improvements in survival have been achieved in children, but less 
for adolescents and adults. More than 80% of children with standard risk ALL can be cured, 
whereas just 30 – 45% of adolescents and adults show an event-free survival (Pui and 
Evans, 2006; Smith et al., 2010). There are several reasons for this disparity of outcomes: 
Adolescents and adults show an increased prevalence of specific genetic alterations (for 
example BCR-ABL1 or MLL translocation), unspecified chromosomal abnormalities and 
treatment-related toxicities, including higher rates of infections, steroid-induced 
osteonecrosis and hyperglycemia, when compared with younger children (Harrison, 2009; 
Mullighan and Downing, 2009; Gramatges and Rabin, 2013). Moreover, drug metabolism 
and response to chemotherapy may also differ in adolescent and adult ALL patients leading 
to a poor prognosis for these patients (Friend and Schiller, 2017).  
Further, children with down syndrome or familial history of autoimmune thyroid disease have 
an higher risk to develop ALL (Hasle et al., 2000; Perillat-Menegaux et al., 2003). 
 
2.4.1 Classification of ALL 
ALL was firstly divided into three groups by the FAB classification based on 
cytomorphological studies: FAB L1 (B-/T-ALL with small uniform cells), FAB L2 (B-/T-ALL 
with large varied cells) and FAB L3 (B-ALL large varied cells with vacuoles, also called 
Burkitt leukemia). In 2008, the WHO classification categorized ALL in distinct subgroups 
based on their cytomorphology, immunophenotyping and immunogenetics, which consider 
also the type (B or T cell) and the maturity of the malignant lymphocyte (TABLE 2). These 
groups have largely replaced the FAB classification (Vardiman et al., 2009; Loghavi et al., 
2015). Additionally, B- and T-ALLs are also divided in classes based on their expressing of 
maturation level-specific CD markers (immature → mature): pro-B-ALL → common B-ALL → 
pre-B-ALL → mature ALL; pro-T-ALL → pre-T-ALL → cortical T-ALL → mature T-ALL.  
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Table 2: Classification of ALL 
TYPES FURTHER DESCRIPTION 
 
(Precursor) B lymphoblastic 
leukemia/lymphoma, not otherwise specified 
(FAB L1/2) 
 
n/a 
 
(Precursor) B lymphoblastic 
leukemia/lymphoma with recurrent genetic 
abnormalities (FAB L1/2) 
 
- B-ALL with t(9;22)(q34;q11.2); BCR-ABL 1 
- B-ALL with t(v;11q23); MLL rearranged 
- B-ALL with t(12;21)(p13;q22) TEL-AML1 
(ETV6-RUNX1) 
- B-ALL with hyperdiploidy 
- B-ALL with hypodiploidy 
- B-ALL with t(5;14)(q31;q32) IL3-IGH 
- B-ALL with t(1;19)(q23;p13.3); TCF3-PBX1 
 
 
(Precursor) T lymphoblastic 
leukemia/lymphoma  
(FAB L1/2) 
 
n/a 
Burkitt's leukemia/lymphoma (FAB L3) n/a 
 
2.4.2 Standard and alternative therapies for ALL 
The first-line treatment of ALL is a remission-induction chemotherapy, which constitutes a 
combination of an antiinflammatory glucocorticoid (prednisone, prednisolone or 
dexamethasone), the cytostatic agent vincristine, and usually the asparagine-degrading 
enzyme asparaginase together with an anthracycline such as daunorubicin, to rapidly 
eradicate most tumor cells and to restore normal hematopoiesis. When ALL patients achieve 
remission, the consolidation chemotherapy, which includes the cytostatic agents 
mercaptopurine, cyclophosphamide and cytarabine, high-dose asparaginase (generally given 
only to children for an extended period) followed by the maintenance therapy (repetition of 
the initial induction therapy) further eliminate tumor burden (Schrappe et al., 2000; Pui and 
Evans, 2006; Stock et al., 2008). For patients with a poor response to the remission-
induction chemotherapy, especially adults, relapsed or very high-risk ALL, HSCT is the 
ultimate form of consolidation treatment (Hunault et al., 2004). Since ALL cells can also enter 
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the central nervous system (CNS), CNS therapy already starts in the remission-induction 
phase by administration of the CNS-penetrating cytarabine, the immunosuppressive drug 
methotrexate as well as cranial irradiation. For eliminating residual leukemic cells as a final 
step, a combination of weekly-administered methotrexate and daily-given mercaptopurine 
forms the basis of most maintenance therapy regimens (Pui et al., 2002; van der Werff ten 
Bosch et al., 2005). It should be mentioned that the effect of the individual agents within the 
therapy regimens depends on the dosage and schedule of administration (Pui and Evans, 
2006). The response to therapy is also influenced by the genetics of leukemia cells and the 
pharmacogenetics of the host. Both parameters can be further used as prognostic markers. 
Regarding this, the measurement of minimal residual disease (MRD) during and after 
remission-induction therapy using FACS or polymerase-chain-reaction (PCR) analysis, helps 
to anticipate and consequently combat relapses. Moreover MRD assessment can be utilized 
as a surrogate marker for clinical outcome (Chung et al., 2006; Ebinger et al., 2010). In this 
context, it has been shown that low or undetectable levels of MRD appear to result in 
improved clinical outcome of ALL patients, while rising MRD levels after HSCT seem to 
predict hematological relapses (Bader et al., 2015). 
 
In contrast to the increasingly improved outcome of patients with newly diagnosed and 
standard-risk ALL upon chemotherapy, little progress has been made in the treatment of 
refractory and relapsed ALL. Compared to the good survival rate of standard-risk ALL, 
refractory and especially relapsed ALL after HSCT are still associated with a poor prognosis 
due to a resistance of malignant cells to chemotherapy (Bhojwani and Pui, 2013). Therefore, 
new and efficient therapeutic strategies, which specifically target leukemic cells and minimize 
off-target effects, are urgently needed. Similar to AML immunotherapy approaches, targeted 
therapeutics such as unconjugated or conjugated mAbs against cell surface marker and 
bispecific T cell-recruiting antibody constructs are becoming increasingly important. ALL 
blasts express a variety of lineage-specific antigens which can be used as targets for 
mAb (-conjugate) therapy such as CD19, CD20, CD22 and CD52 (Hoelzer, 2011; Raponi et 
al., 2011).  
CD19 appears during the early stages of B cell maturation and development and is thusly 
expressed in almost all precursor B-ALLs (BCP-ALL) or mature B-ALLs. Although the 
unconjugated mAbs can directly induce cytotoxicity through inhibition of proliferation, 
triggering of cell death pathways or indirectly via antibody-dependent cell-mediated 
cytotoxicity (ADCC), their efficacy is limited. Therefore, the Fc part of mAbs can be either 
conjugated with cytotoxic drugs or optimized by specific modifications to increase the clinical 
effectiveness (Kantarjian, Thomas, Wayne, et al., 2012; Lichtenegger et al., 2017). Two Fc-
optimized CD19 mAbs are already used in (pre-) clinical trials, MEDI-551, which features a 
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genetic modification of its glycosylation pattern, and MOR208, which carries an exchange of 
two amino acids in the CH2 domain of the human Fc-part of IgG1 (SDIE modification). Both 
antibodies have demonstrated a markedly superior efficiency compared to the non-Fc-
optimized counterparts by increased ADCC cytotoxicity and effectiveness of recruiting 
immune cells like natural killer (NK) cells or macrophages (Lang et al., 2004; Kellner et al., 
2013; Matlawska-Wasowska et al., 2013). Another therapeutic approach for targeting CD19-
positive B-ALL is blinatumomab (Blincyto®), a bispecific T cell-recruiting antibody which 
simultaneously binds the tumor-associated antigen CD19 and CD3ε in the T cell receptor 
complex. It consists of two scFv, each formed by a pair of variable domains from heavy and 
light immunoglobulin chains binding CD3 and CD19, which are connected by a flexible 
25 amino acid-long linker. In the first clinical trials, blinatumomab was evaluated in adult 
patient cohorts with primary resistant or relapsed B-ALL, who had a detectable MRD. Most 
patients showed a rapid response within the first cycle of treatment with a tolerable toxicity 
(Topp et al., 2011; Queudeville et al., 2017). Blinatumomab also achieved a molecular 
remission in childhood relapsed ALL with tolerable side effects (Handgretinger et al., 2011). 
More recently, Kantarjian et al. compared blinatumomab with conventional second-line 
standard chemotherapy in patients with refractory/relapsed ALL showing that treatment with 
blinatumomab resulted in a significantly longer overall survival than with chemotherapy 
(Kantarjian et al., 2017). For future therapeutic strategies, blinatumomab may be used as a 
monotherapy during the consolidation or maintenance phase or for elderly frail patients, who 
are not eligible to chemotherapy. 
Another candidate for mAb therapy is CD20 which functions as a calcium channel and 
influences cell cycle progression and differentiation. CD20 is heterogeneously expressed on 
20 - 50% of normal and malignant precursor B lymphocytes as well as most commonly on 
mature ALL or Burkitt's leukemia/lymphoma, but not on normal HSC and plasma cells 
(Raponi et al., 2011; Kantarjian, Thomas, Wayne, et al., 2012). A CD20-targeting therapeutic 
antibody is the unconjugated chimeric mAb rituximab (Rituxan®), an IgG1 immunoglobulin 
that contains murine variable region sequences and human constant κ and Fc region 
sequences. It was already approved by the FDA in 1997 as the first mAb for therapeutic 
treatment of cancer (Leget and Czuczman, 1998; Binder et al., 2006). The efficacy of 
rituximab was firstly described in CLL patients who received either rituximab alone or in 
combination with chemotherapy. Surprisingly, rituximab had minimal anti-CLL activity as 
single-agent, whereas the addition of rituximab to chemotherapy demonstrated a benefit in 
overall survival (Robak et al., 2010; Elter et al., 2011). Several studies combined rituximab 
with chemotherapy in CD20-positive B-ALL subsets which led to an improved outcome 
particularly in younger adults. However, clinical data for rituximab administration in children is 
still limited (Griffin et al., 2009; Hoelzer et al., 2010; Thomas et al., 2010). Moreover, some 
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studies showed that the low expression level of CD20 on precursor B lymphocytes can be 
stimulated with corticosteroids, which may further improve the sensitivity of low CD20-
expressing cells to rituximab (Gaipa et al., 2005; Dworzak et al., 2008).  
Another B-lineage-specific antigen is CD22, which is a member of the sialoglycoprotein 
family of adhesion molecules and regulates B cell activation as well as interaction of B cells 
with T cells and antigen-presenting cells. Expression of CD22 has been demonstrated in 
more than 90% of patients with BCP-ALL and mature B-ALL (Raponi et al., 2011). The 
unconjugated mAb epratuzumab has been explored only in few studies so far. Even though 
in one pediatric relapsed ALL study, the administration of epratuzumab showed an enhanced 
response to chemotherapy compared to chemotherapy alone (Raetz et al., 2008). Also 
studies with inotuzumab ozogamicin (CMC-544), an humanized anti-CD22 mAb conjugated 
to the cytotoxic antibiotic calicheamicin, revealed as single-agent antitumor activity in 
patients with refractory/relapsed B-ALL by inducing double-strand DNA cleavage with 
subsequent apoptosis (DiJoseph et al., 2004; Kantarjian, Thomas, Jorgensen, et al., 2012). 
Lately, Kantarjian et al. further evaluated CMC-544 in combination with chemotherapy 
showing a prolonged progression-free and overall survival (Kantarjian et al., 2016) 
CD52 is a B- and T cell lineage antigen, a cell-surface glycoprotein which is involved in T cell 
activation and expressed on up to 70% of more mature B and T cells, but not on HSCs (Hale 
and Waldmann, 2000). An antibody against CD52 is alemtuzumab, an unconjugated, 
genetically engineered, humanized IgG1 mAb, which is currently used for second-line 
therapy of CLL and for the prevention of graft-versus-host disease (GvHD) in allogeneic 
HSCT. Alemtuzumab has also been evaluated in patients with de novo CD52-positive ALL 
after induction chemotherapy, however with little anti-leukemic efficacy. Moreover, 
alemtuzumab was associated with an increased risk of CMV viremia and developing 
neutropenia (Stock et al., 2009; Wei et al., 2017). Hence, Gorin et al. tested alemtuzumab in 
combination with G-CSF in refractory/relapsed ALL to increase the neutrophil-mediated 
ADCC, but again with modest results. The further clinical use of alemtuzumab in treatment of 
ALL has not been clarified yet (Gorin et al., 2013). It must be mentioned that B- and T-ALL 
subtypes show individual antigen expression patterns during different maturation steps und 
may therefore respond differentially to mAb therapy. Additionally, target antigens are not 
expressed exclusively on malignant cells, so the cytotoxic effects are less selective and may 
lead to mAb-specific side effects like B or T cell lymphopenia with related clinical 
consequences, which are mostly infections (Hoelzer, 2011). 
Like in AML therapy, checkpoint inhibitors also play a role in immunotherapy approaches of 
ALL, albeit to a lesser extent. Several studies tested different checkpoint inhibitors for 
potentiating the efficacy of different anti-neoplastic drugs and to increase the cytotoxicity of 
standard therapies against B- and T-ALL. Using checkpoint inhibitors like PD-1, CTLA-4 and 
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checkpoint kinase 1 and 2 is a highly promising approach to increase antitumor T cell activity 
as a treatment of hematological malignancies (Shimauchi et al., 2007; Feucht et al., 2016; 
Ghelli Luserna Di Rorà et al., 2016; Knaus et al., 2017). 
Another approach for targeted therapy of ALL is focusing on genetic abnormalities such as 
BCR-ABL1 or MLL translocations. Preclinical studies demonstrated that BCR-ABL1-positive 
ALLs responded to ABL1 tyrosine kinase inhibitors, like imatinib mesylate (Gleevec®), while 
those with BCR-JAK2 fusion protein expression were sensitive to JAK2 inhibitors (Maude et 
al., 2012; Roberts et al., 2012). Gene expression studies showed that FLT3, a receptor 
tyrosine kinase, which plays a role in promoting cell proliferation and transformation, is 
overexpressed in MLL-rearranged ALL. Targeting FLT3 with an FLT3-inhibitor like 
midostaurin, which is also highly effective in the therapy of FLT3-ITD AML, is a possible 
therapeutic approach for MLL-rearranged ALL (Armstrong et al., 2003; Stam et al., 2005). 
 
Analogous to AML-targeted immunotherapy approaches, many agents have a limited 
efficacy as a single drug, but in combination with other therapeutics they may improve the 
clinical outcome of ALL patients, who are ineligible for conventional chemotherapy. 
 
2.4.3 CAR T cell-based therapy – a new therapeutic approach for ALL 
In the last twenty years, several experimental and clinical studies indicated that ex vivo-
cultivated and re-administered patient-derived tumor-infiltrating lymphocytes (TILs) can 
identify and kill cancer cells by triggering an acute inflammatory reaction. The adoptive 
transfer of TILs has been proven as an effective therapy for metastatic melanoma patients. It 
has also been extensively studied as a treatment for other cancer types, but only with elusive 
success because of the difficult identification and expansion of TILs (Rosenberg et al., 1988; 
Morgan et al., 2006). The adoptive transfer of genetically engineered autologous CAR 
T cells, however, has proven to be extremely effective against cancer. Like already 
mentioned for AML therapy, redirected CAR T cells are a novel highly promising approach 
for targeted immunotherapy of hematological malignancies, especially for ALL. CARs are 
chimeric transgenes which are usually composed of a scFv specific for a tumor-associated 
antigen and fused to a transmembrane (TM) domain via an extracellular spacer domain, 
such as the immunoglobulin (Ig)G Fc hinge region. The TM domain is linked to intracellular 
signaling components, which are capable of activating the cell and triggering the immune 
response (FIGURE 3A) (Marcus and Eshhar, 2014; Park and Brentjens, 2015). Since CARs 
combine the binding domain of an antibody and T cell signaling moieties, they can redirect 
T cell specificity to the tumor in a MHC-independent manner and activate the CAR-modified 
T lymphocytes to lyse targeted tumor cells (Chmielewski et al., 2013). The formation of the 
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intracellular signaling components changed during evolution of CAR T cells. In the first-
generation CAR, TM domain is linked to a single signaling domain which is most commonly 
the intracytoplasmic CD3ζ domain of the TCR complex (FIGURE 3B). These basic CAR 
T cells can effectively prevent tumor growth in vivo by sufficient cytotoxicity and interferon-γ 
production. However, T cell proliferation is limited and they fail to persist in the long term. 
Thus, the implementation of an additional co-stimulatory signaling domain, like CD28, 4-1BB 
or CD134 (OX-40), further improved signaling, proliferation and survival of the so-called 
second-generation CAR T cells and promotes interleukin (IL)-2 production. The third-
generation CAR contains tandem cytoplasmic signaling domains from two co-stimulatory 
receptors like CD28 – 4-1BB or CD28 – OX40 for optimal co-stimulation (Finney et al., 1998; 
Bridgeman et al., 2010).  
 
 
 
Figure 3: Formation and evolution of chimeric antigen receptors. 
A) Chimeric antigen receptors consist of a single-chain variable fragment (scFv) specific for a tumor-
associated antigen, which is fused to a transmembrane (TM) domain via a spacer domain. The TM 
domain is further linked to intracellular signaling components of the T cell receptor (TCR) complex. 
B) In the first-generation CAR, TM is linked to a cytoplasmic signaling domain of the TCR, such as 
CD3-ζ or Fc receptor γ chains. With the evolution of CAR T cells, the second-generation CAR was 
developed with an additional co-stimulatory signaling domain, for example CD28, 4-1BB or OX-40. 
The third-generation CAR contains tandem cytoplasmic signaling domains from two co-stimulatory 
receptors like CD28-4-1BB or CD28-OX40. Figure taken from http://www.discoverymedicine.com and 
adapted based on Park and Brentjens, 2015. 
 
Primary clinical experiences with first-generation CAR T cells showed limited efficacy, 
whereas second-generation CAR T cells targeting CD19 displayed significantly enhanced 
expansion and strong antitumor efficacy in patients with low-grade and aggressive B cell 
malignancies, including B-CLL and relapsed B-ALL (Porter et al., 2011; Brentjens et al., 
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2013; Davila et al., 2014). Cumulative data reported a 60% complete remission rate in 
patients with CLL and ALL (Kalos et al., 2013). These results demonstrated that adoptive 
CAR T cell therapy can eradicate advanced hematological malignancies and provided clinical 
proof of concept for the CAR approach. The third-generation CAR was successfully tested in 
several mouse experiments, but clinical experiences are still limited (Carpenito et al., 2009; 
Till et al., 2012). Very recently, the FDA approved two CAR T cell therapies (second-
generation CAR) for treatment of hematological cancer: Kymriah™ (CTL019) for the 
treatment of patients with BCP-ALL which is refractory or in second or later relapse up to 25 
years of age, and Yescarta™ for adult patients with large B cell lymphoma after at least two 
other failed treatment approaches (U.S. Food & Drug Administration, 2017). 
 
It has been shown that the optimal CAR design, such as the sequence of the signaling 
domains, have an impact on the CAR function. For example the CD28 co-stimulatory domain 
is not effectively functional when placed downstream of the CD3ζ domain (Marr et al., 2012). 
Although both 4-1BB- and CD28-CAR models have shown to be clinically effective, some 
studies demonstrated that 4-1BB is superior to CD28 in terms of enhancing anti-leukemic 
CAR efficacy in a xenograft mouse model (Carpenito et al., 2009; Milone et al., 2009). 
Moreover, a study from Long et al. indicated that CD28 co-stimulation augments, whereas 4-
1BB co-stimulation reduces, exhaustion which is induced by persistent CAR signaling (Long 
et al., 2015). Frigault et al. confirmed this observation and further indicated that CD28-based 
endodomains can mediate constitutive signaling which leads to terminal differentiation of 
effector T cells (Frigault et al., 2015). This concludes that the third-generation CAR with 
CD28 – 4-1BB as tandem cytoplasmic signaling domains may promote effective and 
persistent CAR T cells for clinical application. Furthermore, several studies showed that even 
the length and composition of IgG-derived extracellular spacer domains can have an 
influence on the CAR function. CAR T cells with a short spacer length were superior to CAR 
T cells with a long spacer length in vivo regarding their cytokine secretion, proliferation and 
function. CD19 CAR T cells with a long spacer exhibited antitumor activity only in vitro, as 
under in vivo conditions, the interaction between the Fc domain within the spacer and the Fc 
receptor-bearing myeloid cells led to activation-induced CAR T cell death (Hudecek et al., 
2013, 2015; Almåsbak et al., 2015).  
The major issue for clinical application is that there is no standard accepted CAR 
configuration. This makes it difficult to compare the results effectively from the wide number 
of currently ongoing clinical trials. 
Also, the composition of the CAR T cell product has been demonstrated to influence on CAR 
function. In initial CAR T cell therapy studies, only highly differentiated CD8-positive CAR 
T cells were administered, but they did not have sufficient replicative capacity after infusion 
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and a poor persistence in patients. Therefore, the administration of a mixture of CD4-positive 
and CD8-positive T cells is often preferred, probably because the CD4-positive T cells 
provide growth factors and other signals to maintain the function and survival of the infused 
CD8-positive T lymphocytes, as well as can eliminate tumor cells in a direct manner to a 
certain extent (Hombach et al., 2006; Barrett et al., 2015).  
Furthermore, also the state of differentiation of CAR T cell is important for the efficient CAR 
function. Studies with mice and primates indicated that naïve (CD62L-positive) or central 
memory T cells are preferable for adoptive immunotherapy because of their capability of an 
extensive replication and establishment of a persistent T cell memory pool (Maus et al., 
2004; C. Berger et al., 2008). The observation that naïve CD62Lhigh-positive antigen-specific 
T cells are more persistent than differentiated CD62Llow cells implied a linear developmental 
model of T cell differentiation. This concept states that naïve or less differentiated memory 
cell types, which express CD62L, give rise to effector cells and not vice versa (FIGURE 4) 
(Klebanoff et al., 2006; Youngblood et al., 2013; Stemberger et al., 2014; Restifo, 2015). The 
two isoforms of CD45, namely CD45RA and CD45RO, are important to further characterize 
the differentiation status of T cells. CD45RA is expressed on naïve and effector T cells, while 
CD45RO is expressed on memory T cells (Mahnke et al., 2013). Studies of leukemia patients 
treated with CD19 CAR T cells indicated that the presence of persistent central memory 
T cells is the most important predictive biomarker of therapy success (Kalos et al., 2011; 
Barrett et al., 2015). In addition, Chan et al. showed that persistent CD45RO-positive 
memory T cells are important for the anti-leukemic CAR T cell activity as well as for the 
pathogen memory response (Chan et al., 2015). To promote the maintenance of a less 
differentiated population of naïve and central memory T cells, cells have to be cultured under 
special conditions with specific co-stimulatory signals, such as CD28 or 4-1BB stimulation 
(Thomas et al., 2002; Kawalekar et al., 2016) or addition of cytokines like IL-2, IL-7 and IL-15 
(Kaneko et al., 2009; Barrett et al., 2014). 
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Figure 4: Current model of central and effector memory T cell generation. 
This model of T cell differentiation is also known as the “linear” or “developmental” model. It indicates 
that naïve or less differentiated memory cell types that express CD62L give rise to effector cells, and 
not vice versa. CD45RA is expressed on naïve and effector cells, CD45RO on memory cell. The Fas 
receptor (CD95) describes the activation status. APC, antigen-presenting cell; TCM, central memory T 
cell; TEFF, effector T cell; TEM, effector memory T cell; TN, naive T cell; TSCM, T memory stem cell. 
Figure based on Restifo, 2015s. 
 
While efficacy of generating genetically engineered T cells has improved in the field of 
adoptive immunotherapy, accompanying toxicities for patients have also increased. The most 
prominent toxicity of CAR T cells for bone marrow-derived tumors is the cytokine release 
syndrome (CRS). Highly proliferative T cells can induce proinflammatory cytokine release, 
such as IL-6 and interferon gamma (IFN-γ), which in turn activates further immune cells 
leading to high fever and myalgia or up to unstable hypotension and respiratory failure 
(Morgan et al., 2010; Kochenderfer et al., 2012; Davila et al., 2014). Positively, the anti-IL-6 
receptor mAb tocilizumab has been shown to effectively decrease the IL-6 level and quickly 
reverse CRS (Lee et al., 2014; Maude et al., 2014). Moreover, CD19 CAR therapy is also 
accompanied by ‘on-target off-tumor’ toxicities which can lead to acute B cell aplasia. The 
depletion of the patients’ B cells induces a profound hypogammaglobulinemia which must be 
treated intravenously with immunoglobulin replacement (Davila et al., 2014; Barrett et al., 
2015). To prevent off-tumor toxicities and achieve strict safety requirements, various 
approaches to induce apoptosis of genetically modified T cells have been proposed. With the 
incorporation of a so-called ‘suicide gene’, for example inducible caspase 9, it is possible to 
quickly eliminate the infused cells in case of adverse events (Di Stasi et al., 2011; Gargett 
and Brown, 2014).  
 
A major problem of CAR T cell therapy is the obtainability of suitable cells for transplantation: 
on the one hand, using autologous T cells may bear the risk of a contamination with residual 
malignant T cells. On the other hand, employing MHC-matched allogeneic T cells may cause 
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GvHD in immunocompromised patients. Despite the risk of alloreactivity, many clinical 
studies showed that allogeneic CD19 CAR T cells have a limited propensity to induce GvHD 
in B cell malignancy patients (Davila et al., 2014; Lee et al., 2015; Ghosh et al., 2017). 
Several approaches to circumvent the issue of GvHD reactivity have been proposed, such as 
the transfer of T cell precursors in combination with autologous HSCT. Hereby, infused cells 
differentiate into mature T cells in the host thymus and, thereby, lose their GvHD reactivity 
(Zakrzewski et al., 2008). Another approach to prevent GvHD is to use genome editing 
techniques like zinc finger nucleases to knockout the endogenous TCR (Torikai et al., 2012; 
Philip et al., 2015). Moreover, using not MHC-restricted γδ T cells or NK cells for CAR cell 
therapy can also avoid GvHD reactivity (Deniger et al., 2013; Oberoi and Wels, 2013). 
 
While there are several trials currently ongoing targeting B cell malignancies, clinical studies 
for CAR T cell therapy of solid tumors are limited due to tumor histopathological structure 
and strong immunosuppressive environment as well as the lack of ideal targets. CAR T cell 
therapy studies for targeting HER2/neu-positive large solid tumors demonstrated promising 
results (Textor et al., 2014), although Morgan et al. showed that a patient experienced fatal 
CRS shortly after infusion of HER2/neu-specific CAR T cells, which was attributed to low-
level expression of HER2/neu on lung epithelial cells (Morgan et al., 2010). As well, several 
clinical trials for treatment of GD2-positive neuroblastoma or FRα-positive ovarian and breast 
cancer patients are currently ongoing (Singh et al., 2014; H. Zhang et al., 2016). 
 
2.4.3.1 Mechanisms for targeted activation of CAR T cells to reduce toxicities  
Aside from targeting CD19, further promising targets for CAR T cell therapy of B cell 
malignancies are CD20, CD22 and the receptor tyrosine kinase-like orphan receptor 1 (ROR-
1), which is a tumor-associated molecule expressed in B-lymphoid cancer but not on normal 
mature B cells (Müller et al., 2008; Haso et al., 2013; Hudecek et al., 2013). Relapsed B cell 
malignancies are often accompanied with an antigen-loss on tumor cells likewise observed 
upon therapy with therapeutic antibodies (Davis et al., 1999; Ruella and Maus, 2016). These 
patients have a very poor prognosis and novel approaches to treat and ideally prevent 
antigen-loss are strongly needed. Due to a large heterogeneity in the antigen pattern of 
leukemia, one strategy is to target two leukemic blast antigens simultaneously rendering 
CAR T cells more specific for tumor cells and consequently reducing ‘on-target off-tumor’ 
toxicities. Basically, there are at least three options to redirect T cells by CARs for targeting 
two antigens concurrently and preventing specific escape strategies of leukemic blasts:    
First, administration of a mixture of two CAR T cell products, for example anti-CD19 and anti-
CD22 CAR T cells. Second, infusion of T cells which co-express two independent CARs, 
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each of them competent to trigger T cell activation. Third, administration of T cells 
engineered with one bispecific CAR construct which is composed of two single-chain 
antibody fragments specific for two tumor antigens (Hegde et al., 2013; Anurathapan et al., 
2014). The feasibility of targeting two antigens by a bispecific CAR was previously shown by 
Qin et al. for CD19- and CD22-positive B-ALLs (Qin et al., 2015) and by Zah et al. for CD19 
and CD20-positive B-ALLs (Zah et al., 2016).  
 
Another mechanism to functionally control CAR T cell intensity or off-tumor toxicity is based 
on the integration of an ‘on-switch’ molecule. Different to the strategy of inducing apoptosis 
and hence eradication of the engineered T cells, the ‘on-switch’ strategy implements a non-
lethal control of CAR T cells by separating T cell activation signals or adding a switch 
molecule to enable T cell activation (Kloss et al., 2012; Wu et al., 2015; Juillerat et al., 2016). 
Some studies confirmed an improved control of T cell activation by using antibody-based 
switch molecules, whereby tumor-targeting antibodies are specifically modified with a 
conjugate, such as fluorescein isothiocyanate (FITC) or biotin (FIGURE 5). CAR T cells are 
then redirected against this conjugate (Cao et al., 2016; Ma et al., 2016; Rodgers et al., 
2016). Ma et al. demonstrated a potent tumor antigen-specific efficacy of universal CAR T 
cells in vitro and in vivo, targeting CD19- and CD22-positive B cell malignancies (Ma et al., 
2016). Cao et al. confirmed this observation for targeting HER2-positive breast cancer in vitro 
and in vivo (Cao et al., 2016). The modularity of this approach allows universal CAR T cells 
to target a wide range of tumor antigens or even T cell malignancies. CAR T cell therapy of 
T-ALL remains a challenge due to the shared surface antigen pool between normal and 
malignant T cells which could result in self-targeting and compromising the therapeutic 
ability. To circumvent autolysis of CAR T cells, Chen et al. demonstrated that genetically 
engineered NK cells can be used instead of T cells to target T cell malignancies. When 
targeting CD3 and CD5, a potent tumor-directed cytotoxicity of CAR NK cells was observed 
(K. H. Chen et al., 2016; Chen et al., 2017). Instead of using other competent immune cells, 
universal adapter CAR T cells could help to overcome the limitations of CAR T cell therapy 
for T cell malignancies. Therefore, the ‘on-switch’ mechanism of universal adapter CAR T 
cells represents an important progress to further improve the CAR T cell technology and its 
safety for clinical application. 
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Figure 5: Universal adapter CAR system.  
An adapter CAR system allows functional control over CAR T cell intensity via addition of an ‘on-
switch’ molecule to initiate T cell activation. Antibody-based switch molecules are specifically modified 
with a conjugate, such as biotin or fluorescein isothiocyanate, and CAR T cells are redirected against 
this conjugate. The modularity of this universal system enables targeting of a wide range of tumor 
antigens and, hence, several cancer cell types. Figure based on Cao et al., 2016; Ma et al., 2016. 
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3. OBJECTIVES OF THE STUDY 
Despite the enormous progress in cancer cell therapy over the last decades, AML and ALL 
are still two life-threatening diseases for children and adults. Therefore, new therapeutic 
approaches for AML and ALL are urgently needed. 
 
Successful therapeutic approaches for AML are still limited due to the high heterogeneity of 
AML subtypes. Since malignant and normal myeloid cells share the same surface antigen 
pool, targeting of AML cell markers may also compromise hematopoiesis of normal blood 
cells. Hence, new pharmacological strategies with less off-tumor effects have to be 
proposed. In this study, a synergistic anti-leukemic effect of ATO and G-CSF was considered 
as a potential new pharmacological therapeutic approach for AML, since both drugs have 
been already studied for cancer cell therapy. The impact of ATO alone and in combination 
with G-CSF on AML cells and LSCs should be analyzed in vitro and in vivo. Based on 
previous findings that G-CSF might have an AQP9-stimulating effect, a resulting increased 
ATO sensitivity had to be further determined.  
 
The improved outcome of newly diagnosed and relapsed ALL patients is not only due to a 
solid standard therapy but also to a massive progress in targeted therapy strategies. 
Especially the implementation of CAR T cells promises further improvements in future ALL 
therapy. However, heterogeneous tumor antigen pattern and severe therapy-associated 
complications demand further optimization of CAR T cell therapy. In this study, bispecific 
CAR T cells targeting CD19 and CD20 should be analyzed for eliminating a CD19-CD20-
positive B-ALL patient sample in vivo. Furthermore, universal adapter CAR T cells targeting 
biotin-conjugated mAbs and mAb fragments should be tested for the capability of killing a 
CD19-positive B-ALL cell line in vitro and in vivo. In addition, adapter CAR T cells had to be 
analyzed for differentiation and exhaustion markers upon co-culture experiments in vitro. 
Universal CAR T cells should also be studied for their ability to kill γδ-TCR and CD231 (Talla-
1)-positive T-ALL cell lines in vitro. 
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4. MATERIAL 
4.1 Cell lines 
Table 3: Cell lines 
Cell line 
Cell type/ 
DSMZ number 
Media 
HEK 293T 
Embryonal kidney/ 
ACC 635 
Complete DMEM GlutaMAX + 
10 % fetal calf serum (FCS) 
HL-60 
Acute myeloid leukemia/ 
ACC 3 
Complete RPMI 1640 media + 
10 % FCS 
Jurkat 
T cell leukemia/ 
ACC 282 
Complete RPMI 1640 media + 
10 % FCS 
Kasumi-1 
Acute myeloid leukemia/ 
ACC 220 
Complete RPMI 1640 media + 
20 % FCS 
KG-1a 
Acute myeloid leukemia/ 
ACC 421 
Complete RPMI 1640 media + 
20 % FCS 
Molt-14 
T cell leukemia/ 
ACC 437 
Complete RPMI 1640 media + 
10 % FCS 
Nalm-6 
B cell precursor leukemia/ 
ACC 128 
Complete RPMI 1640 media + 
10 % FCS 
U-937 
Histiocytic lymphoma/ 
ACC 5 
Complete RPMI 1640 media + 
10 % FCS 
 
4.2 Patient-derived primary leukemia and healthy donor cells 
The patient-derived primary leukemia and the healthy donor (HD) cells were obtained from 
the University Children’s Hospital Tübingen and the University Department of Medicine 
Tübingen with the informed consent and Institutional Review Board approval of the University 
Hospital Tübingen (#27/2008B01, 213/2014BO2).  
 
Table 4: Patient-derived primary leukemia cells 
Anonymous  
Patient ID 
Cell type Media 
P17R 
Pediatric acute myeloid  
Leukemia 
Complete RPMI 1640 media + 
10 % FCS 
P18R 
Pediatric acute myeloid  
leukemia 
Complete RPMI 1640 media + 
10 % FCS 
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P49S 
Pediatric acute myeloid  
Leukemia, FAB M5 
Complete RPMI 1640 media + 
10 % FCS 
P84D 
Pediatric acute myeloid  
Leukemia, FAB M2 
Complete RPMI 1640 media + 
10 % FCS 
P93A 
Pediatric acute myeloid  
Leukemia, FAB M4 
Complete RPMI 1640 media + 
10 % FCS 
P94H 
Pediatric acute lymphoid  
leukemia 
Complete RPMI 1640 media + 
10 % FCS 
1035 
Adult acute myeloid  
leukemia 
Complete RPMI 1640 media + 
10 % FCS 
1067 
Adult acute myeloid  
leukemia 
Complete RPMI 1640 media + 
10 % FCS 
 
4.3 NSG mice 
The NOD.Cg-PrkdcscidIL2rgtmWjl/SzJ (NSG) mice were obtained from The Jackson Laboratory 
(Bar Harbor, USA) and maintained under specific pathogen-free conditions in the research 
animal facility of the University of Tübingen, Germany, according to German federal and 
state regulations (Regierungspräsidium Tübingen, K4/13, K4/15 and §10a, 1.10.2012). 
 
4.4 Cell culture media, sera, supplements 
Table 5: Cell culture media, sera, supplements 
Medium/serum/supplement for cell culture Manufacturer 
DMEM GlutaMAXTM Invitrogen Life Technologies, Karlsruhe, Germany 
Fetal bovine serum (FCS) Biochrom AG, Berlin, Germany 
HEPES buffer (1M) Sigma-Aldrich, Saint Louis, MO, USA 
L-glutamine (200 mM) Biochrom AG, Berlin, Germany 
MACS buffer (Clini-MACS) Miltenyi Biotec, Bergisch Gladbach, Germany 
Opti-MEM® I Reduced Serum Medium Invitrogen Life Technologies, Karlsruhe, Germany 
Penicillin/Streptomycin Biochrom AG, Berlin, Germany 
RPMI 1640 Biochrom AG, Berlin, Germany 
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Stem line medium II Invitrogen Life Technologies, Karlsruhe, Germany 
Tex-MACS Miltenyi Biotec, Bergisch Gladbach, Germany 
 
4.5 Media and buffers 
Table 6: Media and buffers 
Medium/buffer Composition 
4 x LDS sample buffer 
1 M Tris base pH 8.5  
2 mM EDTA  
8 % LDS  
40 % glycerol  
0.075 % CBB G  
0.025 % phenol red 
Bicine/Bis-Tris transfer 
buffer 
25 mM Bicine  
25 mM Bis-Tris pH 7.2,  
1 mM EDTA  
15 % methanol 
Blocking buffer 5% SlimFast in TBS 
Complete Dulbecco’s Modified Eagle Medium 
(DMEM) GlutaMAX medium 
DMEM GlutaMAX medium  
10 % FCS  
100 U/ml Penicillin  
100 U/ml Streptomycin  
2 mM L-Glutamine 
Complete RPMI 1640 medium 
RPMI 1640 medium 
10 % FCS  
100 U/ml Penicillin  
100 U/ml Streptomycin  
2 mM L-Glutamine 
20 mM HEPES buffer 
Complete stem line medium II 
Stem line medium II 
10 % FCS  
100 U/ml Penicillin  
100 U/ml Streptomycin  
2 mM L-Glutamine 
Dilution solution 
distilled deionized water 
0.1% Ultrapure HNO3  
0,2% Triton X-100 
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FACS buffer 
PBS 
5 % FCS 
2 mM EDTA 
Freezing medium 
20 % DMSO 
80 % human albumin  
1:1 with cell culture media 
MES buffer 
50 mM MES  
50 mM Tris base pH 7.3  
0.1 % SDS  
1 mM EDTA 
RIPA buffer 
50 mM Tris base pH 7.5  
150 mM NaCl  
1% (v/v) Triton X-100  
0.1% (w/v) sodium dodecylsulfate  
0.5% (w/v) sodium deoxycholate  
Complete Protease Inhibitor Cocktail EDTA-free, 
PhosStop phosphatase inhibitor 
TBS-T buffer TBS with 0.1 % Tween 20 
Tex-MACS medium 
Tex-MACS medium 
10 µg/ml IL7 
25 µg/ml IL15 
1% P/S 
 
4.6 Chemicals, reagents, solutions and cytokines 
All general chemicals were attained by Sigma-Aldrich, Saint Louis, MO, USA; Carl Roth 
GmbH & Co. KG, Karlsruhe, Germany; AppliChem GmbH, Darmstadt, Germany; Merck 
KGaA, Darmstadt, Germany and VWR International GmbH, Darmstadt, Germany. 
 
Table 7: Chemicals, reagents, solutions and gels 
Chemical/reagent/solution/cytokine Manufacturer 
4x Annexin V buffer eBioscience, San Diego, CA, USA 
7-Aminoactinomycin D staining solution 
(7-AAD) 
BD Biosciences, San Jose, CA, USA 
Ampuwa® Water 
Fresenius Kabi Deutschland GmbH, Bad Homburg, 
Germany 
Annexin V 647 (1:20) BioLegend, San Diego, CA, USA 
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Arsenic trioxide (Trisenox®) (1 mg/ml) 
Teva Pharmaceutical Industries Ltd., Petach Tikva, 
Israel 
Biocoll Separating Solution Biochrom AG, Berlin, Germany 
Bradford reagent Bio-Rad Laboratories, Hercules, CA, USA 
D-Luciferin synthetic Sigma-Aldrich, Saint Louis, MO, USA 
FACS Clean® BD Biosciences, San Jose, CA, USA 
FACS Flow® BD Biosciences, San Jose, CA, USA 
FACS Rinse® BD Biosciences, San Jose, CA, USA 
Granocyte® (G-CSF) (13/34 Mio. IE/ml) Chugai Pharmaceutical Co., Ltd., Tokio, Japan 
Hoechst 33342 (bisBenzimide  
H 33342 trihydrochloride) 
Sigma-Aldrich, Saint Louis, MO, USA 
Human serum albumin  
(HSA; 20 % solution for infusion) 
CSL Behring GmbH, King of Prussia, PA, USA 
IL15 (10 µg/ml) Miltenyi Biotec, Bergisch Gladbach, Germany 
IL7 (10 µg/ml) Miltenyi Biotec, Bergisch Gladbach, Germany 
Oligo(dT)18 Primer (SO131) Thermo Fisher Scientific, Rockford, IL, USA 
Phosphate buffered saline (PBS) Sigma-Aldrich, Saint Louis, MO, USA 
Random Hexamer Primer (SO142) Thermo Fisher Scientific, Rockford, IL, USA 
SlimFast  Unilever, London, UK 
TransActTM Miltenyi Biotec, Bergisch Gladbach, Germany 
Trypan blue Sigma-Aldrich, Saint Louis, MO, USA 
XenoLight D-Luciferin PerkinElmer, Waltham, MA, USA 
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4.7 Reaction Kits 
Table 8: Reaction Kits 
Reaction Kit Manufacturer 
BD Cytofix/Cytoperm™ Kit BD Biosciences, San Jose, CA, USA 
LightCycler® 480 SYBR Green I 
Master Kit 
F. Hoffmann-La Roche AG, Basel, Switzerland 
Lipofectamine® 3000 Transfection  
Reagent Kit 
Thermo Fisher Scientific, Rockford, IL, USA 
Omniscript Reverse Transcription (RT)  
Kit (200) 
Qiagen, Hilden, Germany 
RNeasy® Micro Kit Qiagen, Hilden, Germany 
Two-step cell cycle analysis Kit ChemoMetec, Allerod, Denmark 
WesternBright Sirius HRP substrate Advansta Inc., Menlo Park, CA, USA 
Zombie Aqua™ Fixable Viability Kit BioLegend, San Diego, CA, USA 
 
4.8 MACS® cell separating reagents 
Table 9: MACS® cell separating reagents 
Separation Kit Manufacturer 
CD33 MicroBeads, human Miltenyi Biotec, Bergisch Gladbach, Germany 
CD34 MicroBeads, human Miltenyi Biotec, Bergisch Gladbach, Germany 
CD4 MicroBeads, human Miltenyi Biotec, Bergisch Gladbach, Germany 
CD8 MicroBeads, human Miltenyi Biotec, Bergisch Gladbach, Germany 
LNGFR MicroBeads, human Miltenyi Biotec, Bergisch Gladbach, Germany 
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4.9 Antibodies 
4.9.1 Antibodies for FACS 
Table 10: Antibodies for FACS 
Antibody Dilution Clone Isotype Manufacturer 
Anti-human CD10 
PE-CF594 
1:50 HI10A 
Mouse BALB/c 
IgG1, κ 
BD Biosciences, San 
Jose, CA, USA 
Anti-human CD114 
(G-CSFR) APC 
1:25 LMM741 Mouse IgG1, κ 
BioLegend, San 
Diego, CA, USA 
Anti-human CD19 
PE-Cy7 
1:50 HI30 Mouse IgG1, κ 
BioLegend, San 
Diego, CA, USA 
Anti-human CD20 
APC 
1:20 2H7 Mouse IgG2b, κ 
BioLegend, San 
Diego, CA, USA 
Anti-human CD25 
BUV737 
1:20 2A3 
Mouse BALB/c 
IgG1, κ 
BD Biosciences, San 
Jose, CA, USA 
Anti-human CD271 
(LNGFR) FITC 
1:10 ME20.4-1.H4 Mouse IgG1, κ 
Miltenyi Biotec, 
Bergisch Gladbach, 
Germany 
Anti-human CD279 
(PD-1) APC 
1:10 PD1.3.1.3 Mouse IgG2b, κ 
Miltenyi Biotec, 
Bergisch Gladbach, 
Germany 
Anti-human CD3 
Brilliant Violet 711 
1:25 SK7 Mouse IgG1, κ 
BioLegend, San 
Diego, CA, USA 
Anti-human CD3 
Violet-Blue 
1:10 BW264/56 Mouse IgG2a, κ 
Miltenyi Biotec, 
Bergisch Gladbach, 
Germany 
Anti-human CD33 
APC 
1:25 P67.6 Mouse IgG1, κ 
BioLegend, San 
Diego, CA, USA 
Anti-human CD34 
PE-Cy7 
1:50 8G12 Mouse IgG1, κ 
BioLegend, San 
Diego, CA, USA 
Anti-human CD4 
BUV395 
1:20 SK3 
Mouse BALB/c 
IgG1, κ 
BD Biosciences, San 
Jose, CA, USA 
Anti-human CD45 
PE-Cy7 
1:50 HIB19 Mouse IgG1, κ 
BioLegend, San 
Diego, CA, USA 
Anti-human CD45 
APC-H7 
1:20 2D1 Mouse IgG1, κ 
BD Biosciences, San 
Jose, CA, USA 
Anti-human CD45 
APC 
1:25 REA747 
Recombinant 
human IgG1 
Miltenyi Biotec, 
Bergisch Gladbach, 
Germany 
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Anti-human 
CD45RA  
Brilliant Violet 785 
1:20 HI100 Mouse IgG2b, κ 
BioLegend, San 
Diego, CA, USA 
Anti-human 
CD45RO PE 
1:10 UCHL1 Mouse IgG2a, κ 
Miltenyi Biotec, 
Bergisch Gladbach, 
Germany 
Anti-human CD62L 
APC 
1:10 145/15 Mouse IgG1, κ 
Miltenyi Biotec, 
Bergisch Gladbach, 
Germany 
Anti-human CD69 
Brilliant Violet 785 
1:20 FN50 Mouse IgG1, κ 
BioLegend, San 
Diego, CA, USA 
Anti-human CD8 
APC-Vio770 
1:10 BW135/80 Mouse IgG2a, κ 
Miltenyi Biotec, 
Bergisch Gladbach, 
Germany 
Anti-human CD95 
PE-Vio770 
1:10 DX2 Mouse IgG1, κ 
Miltenyi Biotec, 
Bergisch Gladbach, 
Germany 
Anti-human/mouse 
AQP9 AF350 
1:50 polyclonal Rabbit IgG 
Bioss Antibodies, 
Woburn, MA, USA 
Anti-mouse CD34 
AF647 
1:25 RAM34 Rat IgG2b 
BD Biosciences, San 
Jose, CA, USA 
Anti-mouse CD45 
FITC 
1:500 30-F11 Rat IgG2b, κ 
BioLegend, San 
Diego, CA, USA 
Anti-mouse CD45 
APC-eFluor780 
1:50 30-F11 Rat IgG2b 
eBioscience, San 
Diego, CA, USA 
 
4.9.2 Antibodies for Western blot 
Table 11: Antibodies for Western blot 
Antibody Dilution Clone Isotype Manufacturer 
Anti-human 
AQP9 mAb, 
purified 
1:25 G-3 Mouse IgG2a 
Santa Cruz 
Biotechnology, Inc., 
Dallas, USA 
Anti-human 
Caspase 3 
polyclonal antibody 
(pAb) 
1:200  Rabbit IgG 
Santa Cruz 
Biotechnology, Inc., 
Dallas, USA 
Anti-human 
Spectrin alpha 
chain mAb 
1:1000 AA6 Mouse IgG1 
Merck, Darmstadt, 
Germany 
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Anti-human 
Vinculin XP®  
mAb, purified 
1:1000 E1E9V Rabbit IgG 
Cell Signaling 
Technology, Inc., 
Danvers, MA, USA 
Anti-mouse IgG, 
pAb, HRP 
1:5000  Goat IgG 
Jackson 
ImmunoResearch, 
West Grove, PA, USA 
Anti-rabbit IgG, 
pAb, HRP 
1:10 000  Goat IgG 
Abcam, Cambridge, 
UK 
 
4.9.3 Antibodies for cell culture and mouse experiments 
The working concentration of each antibody for in vitro experiments was 100 ng/ml, for 
mouse experiments see below. 
 
Table 12: Antibodies for cell culture and mouse experiments 
Antibody Dose Species/Clone Isotype Manufacturer 
Anti-human  
γδ-TCR 
Biotin 
 REA591 
Recombinant 
human IgG1 
Miltenyi Biotec, 
Bergisch Gladbach, 
Germany 
Anti-human CD19 
4G7SDIE mAb 
Biotin 
5-50 µg/mouse 
Chimeric 
mouse/human 
Fc-optimized 
IgG1 
SYNIMMUNE GmbH, 
Tübingen, Germany 
Anti-human CD19 
4G7SDIE mAb 
unconjugated 
5-50 µg/mouse 
Chimeric 
mouse/human 
Fc-optimized 
IgG1 
SYNIMMUNE GmbH, 
Tübingen, Germany 
Anti-human CD19 
4G7SDIE Fab 
Biotin 
15 µg/mouse 
Chimeric 
mouse/human 
Fc-optimized 
IgG1 
SYNIMMUNE GmbH, 
Tübingen, Germany 
Anti-human CD19 
Biotin 
50 µg/mouse REA675 
Recombinant 
human IgG1 
Miltenyi Biotec, 
Bergisch Gladbach, 
Germany 
Anti-human CD231 
Biotin 
 SN1a Mouse IgG1κ 
Miltenyi Biotec, 
Bergisch Gladbach, 
Germany 
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4.10 Primer 
All Primers were achieved from Eurofins, Ebersberg, Germany. 
 
Table 13: Primer 
Primer Sequence 5’-3’  
AQP9-V4 forward 
AQP9-V4 reverse 
AGCCACCTCTGGTCTTGCTA 
ATGTAGAGCATCCCCTGGTG 
β-actin forward 
β-actin reverse 
TTCCTGGGCATGGAGTC 
CAGGTCTTTGCGGATGTC 
Gli1 forward 
Gli1 reverse 
CCAACTCCACAGGCATACAGGAT 
CACAGATTCAGGCTCACGCTTC 
Gli2 forward 
Gli2 reverse 
AAGTCACTCAAGGATTCCTGCTCA 
GTTTTCCAGGATGGAGCCACTT 
TATA box binding protein (TBP) forward 
TBP reverse 
TGCACAGGAGCCAAGAGTGAA 
CACATCACAGCTCCCCACCA 
 
4.11 Provided Material 
4.11.1 Mono- and bispecific CAR T cells 
Anti-CD19-, anti-CD20- and anti-CD20-CD19 bispecific CAR T cells were provided by Prof. 
Dr. Hinrich Abken from the Center for Molecular Medicine Cologne, University of Cologne, 
Cologne, Germany as a part of a collaboration project. The monospecific CAR T cells were 
engineered as follows: anti-CD19scFv-Fc-CD28-CD3ζ and anti-CD20scFv-Fc-CD28-CD3ζ. 
The bispecific anti-CD20-CD19 CAR was obtained by linking the anti-CD19 and anti-CD20 
scFvs by a (glycin4serin)4 linker. The anti-CD19 and anti-CD20 CARs, as well as the 
retroviral expression cassettes for the scFv-Fc-CD28-CD3ζ CARs were previously described 
in detail (Hombach et al., 2001; Cooper et al., 2003; Müller et al., 2008; Koehler et al., 2012). 
 
4.11.2 Effluc-leukemia cell lines/ -vector 
The enhanced firefly luciferase (effluc)-leukemia cell lines Nalm-6-effluc-mCherry, Molt-14-
effluc-mCherry and Jurkat-effluc-GFP, all transduced with an effluc pCDH-EF1-MCS-T2A-
copGFP or mCherry vector, and the effluc-vector itself were kindly provided and described in 
detail by Prof. Dr. Irmela Jeremias from the Department of Gene Vectors, Helmholtz Zentrum 
München, German Research Center for Environmental Health, Munich, Germany (Vick et al., 
2015). 
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4.11.3 Plasmids 
All CAR plasmids were provided by Miltenyi Biotec (Bergisch Gladbach, Germany). CAR 
plasmids are engineered as follows: anti-CD19scFv-SPACER-TM-4-1BB-CD3ζ-F2A-LNGFR. 
#7-, #9- and #10 CARs differ in the spacer domain. #7 CAR has a long spacer: hinge-CH2-
CH3; #9 CAR has a very short spacer composed of only the hinge region; #10 CAR has also 
a short spacer: hinge-CD8. Low-affinity nerve growth factor receptor (LNGFR) serves as a 
transduction marker. The envelope and packing (gag/pol) plasmids were also obtained by 
Miltenyi Biotec. 
 
4.12 Equipment 
Table 14: Equipment 
Equipment Manufacturer 
ABX Micros CRP Cell Counter Horiba Medical, Kyoto, Japan 
Arsenic hallow cathode lamp Thermo Fischer Scientific, Ulm, Germany 
BD LSR II cytometer BD Biosciences, San Jose, CA, USA 
Bolt™ Mini Gel Tank Thermo Fischer Scientific, Ulm, Germany 
Caliper Life Science IVIS Spectrum  
imaging system 
PerkinElmer, Waltham, MA, USA 
Clean bench HERAsafe Heraeus Holding GmbH, Hanau, Germany 
Incubator HERA cell Heraeus Holding GmbH, Hanau, Germany 
LI-COR ODYSSEY® FC LICOR Biosciences, Lincoln, NE, USA 
LightCycler® 480 PCR machine F. Hoffmann-La Roche AG, Basel, Switzerland 
Mastercycler® nexus X2 PCR machine Eppendorf AG, Hamburg, Germany 
Mouse injection cage type B 32 mm 100680 G&P Kunststofftechnik, Kassel, Germany 
Mouse injection cage type C 25 mm 100690 G&P Kunststofftechnik, Kassel, Germany 
NanoDrop™ 2000 Thermo Fischer Scientific, Ulm, Germany 
NucleoCounter® NC-3000™ ChemoMetec, Allerod, Denmark 
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Olympus IX50 inverse microscope Olympus GmbH, Shinjuku, Tokio 
Rotina 420R centrifuge Hettich AG, Bäch, Switzerland 
SOLAAR M Series AA Spectrometer Thermo Fischer Scientific, Ulm, Germany 
TE22 transfer tank Hoefer, Holliston, MA, USA 
Ultrasonic Homogenizer Sonopuls Bandelin, Berlin, Germany 
Wallac Victor 2 1420 Multilabel counter PerkinElmer, Waltham, MA, USA 
 
4.13 Consumables 
Table 15: Consumables 
Consumable Manufacturer 
AmershamTM ProtranTM 
Premium 0.2 µm nitrocellulose 
membrane 
GE Healthcare, Little Chalfont, UK 
BD Plastipak™ 1 ml single syringe with  
cannula 45 x 12,7 mm (26 G) 
BD Biosciences, San Jose, CA, USA 
Capillary, natrium-heparin Hirschmann GmbH & Co. KG, Eberstadt, Germany 
C-Chip® Neubauer improved  
counting chamber 
NanoEnTek Inc, Pleasanton, USA 
Cell culture flasks Greiner Bio-One GmbH, Frickenhausen, Germany 
Cell culture plates  Greiner Bio-One GmbH, Frickenhausen, Germany 
Cell strainer 45 μM BD Biosciences, San Jose, CA, USA 
Cryopreservation tubes Corning GmbH, Kaiserslautern, Germany 
LightCycler® 480 adhesive foil F. Hoffmann-La Roche AG, Basel, Switzerland 
LightCycler® 480 multi-well plate 
(96-well plate) 
F. Hoffmann-La Roche AG, Basel, Switzerland 
MACS® Columns (LS and MS 
Columns) 
Miltenyi Biotec, Bergisch Gladbach, Germany 
Microvette 500 potassium-EDTA Sarstedt AG & Co., Nümbrecht, Germany 
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NC-Slide A8™ ChemoMetec, Allerod, Denmark 
Pipette tips (10 μl) Abimed GmbH, Langenfeld, Germany 
Pipette tips (200 μl, 1 ml) Sarstedt AG & Co., Nümbrecht, Germany 
Polypropylene tubes (15 ml, 50 ml) Greiner Bio-One GmbH, Frickenhausen, Germany 
Polystyrene FACS tubes BD Biosciences, San Jose, CA, USA 
BD Microlance cannula 27G x ¾“  
0,4 x 19 mm 
BD Biosciences, San Jose, CA, USA 
Graphite cuvette Thermo Fischer Scientific, Ulm, Germany 
Safe-Lock tubes (0.5 ml, 1.5 ml, 2 ml) Eppendorf, Hamburg, Germany 
Bolt™ 4-12% Bis-Tris Plus gels, 15-well Thermo Fisher Scientific, Rockford, IL, USA 
 
4.14 Software 
Table 16: Software 
Software Manufacturer 
BD FACSDiva Software 6.1.3 BD Biosciences, San Jose, CA, USA 
CorelDRAW X6 Corel GmbH, Munich, Germany 
Graph Pad Prism 5.0 GraphPad Software 
LightCycler® 480-Software Roche, Basel, Switzerland 
Living Image 4.5.2 PerkinElmer, Waltham, MA, USA 
Microsoft Word, Excel, Power Point Microsoft 
NucleoView™ NC-3000 Software ChemoMetec, Allerod, Denmark 
ODYSSEY® image studio software version 4.1 LICOR Biosciences, Lincoln, NE, USA 
Wallac 1420 manager component 
version 2.00.0.13 
PerkinElmer, Waltham, MA, USA 
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5. METHODS 
5.1 Isolation of peripheral blood mononuclear cells (PBMCs) 
PBMCs were isolated from 1:1 diluted peripheral blood or bone barrow with PBS by Ficoll-
Hypaque density gradient centrifugation. For that, two volume fractions of diluted blood or 
bone marrow were layered above one volume fraction of Ficoll-Hypaque and centrifuged at 
500 g for 30 min at 20 °C without brake. Subsequently, the mononuclear cell layer was 
transferred into a new tube and washed twice with PBS. The isolated PBMCs were 
resuspended in PBS and kept on ice until further use. 
 
5.2 MACS® immunomagnetic cell separation 
Cells were MACS® immunomagnetic separated according to the manufacturer’s protocol. 
Briefly, cells for separation were transferred into precooled MACS buffer prior to incubation 
with microbeads for 15 min on ice. After a washing step, cells were positively selected with a 
LS column and MidiMACS separator. 
 
5.3 Determination of cell number  
Cell numbers and vitality were determined using disposable C-Chip® Neubauer improved 
counting chambers and trypan blue. Trypan blue negative vital cells were counted in the four 
main squares. The cell concentration was calculated as indicated in the following formula: 
 
 
 
5.4 Cell culture treatment with ATO/ G-CSF 
Cells were plated in a concentration of 0.5x 106 cells/ml and treated with 10 ng/ml G-CSF, 
0.5 – 2 µM ATO or with the combination of both for 24 – 120 h. For long incubation times, 
media were changed after 72 h and pharmaceuticals were freshly added. Cells were 
subsequently analyzed for cell viability (paragraph 5.8.3), for inhibition of the side populations 
as a model of AML-derived LSCs (paragraph 5.8.4), for cell cycle (paragraph 5.9), for 
proliferation (paragraph 5.10) as well as for AQP9 stimulation by FACS (paragraph 5.8.2) 
and by western blot (paragraph 5.11). 
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5.5 Lentivirus production 
5x 106 HEK293T cells were plated in a 10 cm Petri dish one day before transfection with 
Lipofectamin®3000 according to the manufacturer’s protocol with Opti-MEM® I reduced 
serum medium and 30 µg of the transgene (#7, #9, #10), 15 µg of the envelope (VSV-G) and 
30 µg of the packing (gag/pol) plasmid. After two days, supernatants containing the produced 
lentiviruses were harvested and run through a 0.45 µM cell strainer prior to centrifugation at 
4 °C, 20 000 g for 4 h and following snap freezing. Viruses were stored at -80 °C until use. 
 
5.6 CAR T cell production 
PBMCs from healthy volunteers were isolated (paragraph 5.1) and MACS® immunomagnetic 
separated for CD4/CD8-positive cells (paragraph 5.2). After transfer into Tex-MACS medium 
(1x 106 cells/ml), cells were stimulated with 1:100 TransActTM according to the manufacturer’s 
protocol. The next day, cells were transduced with thawed transgene containing lentivirus 
(paragraph 5.5) by spin inoculation at 32 °C, 800 g for 30 min. CAR T cells were expanded 
for six days until they were MACS® immunomagnetic separated for LNGFR positivity or 
directly used for experiments. 
 
5.7 Co-cultivation of CAR T and leukemia cells 
5.7.1 FACS-based cytotoxicity assay  
CAR T cells and leukemia cells were co-cultivated with an E:T ratio of 1:1 with or without the 
addition of 100 ng/ml biotinylated mAb or mAb fragment. After 48 h, CAR T cells were 
analyzed by FACS for activity, exhaustion and differentiation surface markers as well as 
leukemia cells for viability (paragraph 5.8.1). 
 
5.7.2 Luciferase activity-based cytotoxicity assay  
CAR T cells and effluc-leukemia cells were co-cultivated with E:T ratios of 10:1 – 1:1 with or 
without the addition of 100 ng/ml biotinylated mAb as well as with 3 µg/ml/well D-luciferin. 
After 24 h, the luciferase activity in effluc-leukemia cells was measured based on 
luminescence signal detection with a Wallac victor2 1420 multilabel counter and an 
acquisition time of 1 s/ well at 37 °C. 
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5.8 FACS analyses 
Samples were measured on a 14-colours LSR II cytometer, equipped with 4 lasers (488 nm 
blue, 640 nm red, 405 nm violet, 355 nm ultraviolet), and analyzed by using BD FACSDivaTM 
software. In any FACS analysis, vital mononuclear cells were selected, and doublets 
excluded based on scatter characteristics. 
 
5.8.1 Immunofluorescent staining of cell surface antigens 
For cell surface staining, 0.1 – 1x 106 cells were transferred into FACS tubes and washed 
once with FACS buffer. Fluorochrome-labelled antibodies were added to a final concentration 
of 1 – 5 μg/ml and incubated in the dark at 4 °C for 30 min. After that, cells were washed 
twice with FACS buffer. A subsequent additional staining with the live/dead discrimination 
marker Zombie Aqua (1:400) was performed for 30 min at 4 °C, followed by two washing 
steps with FACS buffer. All centrifugation steps were conducted at 400 g for 5 min. 
 
5.8.2 Intracellular staining of AQP9 
G-CSF-treated human healthy donor (HD) cells, mouse samples and ATO/G-CSF-treated 
AML cells were stained for intracellular AQP9 using BD Cytofix/Cytoperm™ kit according to 
the manufacturer’s protocol. First, 0.5 – 1x 106 cells were stained for cell surface markers 
(CD33 APC, CD34 PE-Cy7, CD45 PE-Cy7 or mCD45-AF647) (paragraph 5.8.1) prior to the 
permeabilization/ fixation step using Cytofix/CytopermTM solution for 20 min at 4 °C in the 
dark, followed by two washing steps with Cytofix/CytopermTM wash buffer. Cells were 
subsequently stained with 1 µg anti-AQP9-AF350 for 30 min on 4 °C. After cells were 
washed twice with Cytofix/ CytopermTM wash buffer, a fixation prior to analysis was 
performed. All centrifugation steps were conducted at 400 g for 5 min. 
 
5.8.3 Viability assay of ATO and G-CSF treated AML cells 
For cell viability determination after ATO/ G-CSF treatment, 2.5x 105 cells were washed twice 
with freshly diluted 1x Annexin V buffer. Subsequently, cells were stained with 1:20 Annexin 
V AF647 in 1x Annexin V buffer for 20 min at room temperature in the dark according to the 
manufacturer’s protocol. Without a previous washing step, 7-AAD was added in a final 
dilution of 1:50 and the cells were directly analyzed. All centrifugation steps were conducted 
at 400 g for 5 min. The data were analyzed as follows: viable cells are defined as 7-AAD-
/Annexin V-, early apoptotic cells as 7-AAD-/Annexin V+ and late apoptotic cells as 7-
AAD+/Annexin V+. 
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5.8.4. Hoechst 33342 staining for detection of stem cell-like side population 
4x 106 of ATO-treated patient-derived AML cells (1x 106 cells/ml) were stained with 5 µg/ml 
Hoechst 33342 in DMEM medium at 37 °C for 2 h, while shaking every 20 min. After a 
centrifugation step at 2 °C, 400 g for 5 min, cells were stained for surface markers (CD45 
PE-Cy7, mCD45 FITC) on ice for 30 min. Two more washing steps (2 °C, 400 g, 5 min) were 
performed before cells were analyzed by FACS. 
 
5.9 Cell cycle analyses  
Cell cycle analysis of ATO/ G-CSF-treated AML cells was performed with a NucleoCounter® 
NC-3000™, equipped with the NucleoView™ NC-3000 Software, and the two-step cell cycle 
analysis kit according to the manufacturer’s protocol. 0.5x 106 cells were washed once with 
PBS, followed by a combined cell lysis and DAPI staining step (mixture of solution 12 and 
10) for 5 min at 37 °C. A subsequent stabilization step was performed by adding solution 11. 
Measurement of DAPI fluorescence intensity, which correlates with the DNA content of the 
cells, allows the determination of G0/G1, S and G2/M cell cycle phases. Sub-G1 phase 
represents apoptotic/necrotic cells. 
 
5.10 Proliferation assay 
Proliferation analysis of ATO/ G-CSF-treated AML cells was performed using a 3H-thymidin 
incorporation assay. For that, 5x 104 cells/ well were treated in a 96-well plate for 72 h and 
afterwards incubated with 14.8 kBq 3H-thymidin/ well for 16 h. After washing three times with 
VE-water in vacuo, cells were dried for 24 h and resolved with a scintillation solution before 
measuring proliferation in counts per minute (cpm) with a MicroBeta LumiJET Microplate 
Counter. 
 
5.11 Protein extraction and western blot analyses  
All ATO/ G-CSF-treated samples were harvested, washed with precooled PBS and 
centrifuged at 300 g for 5 min. Cell pellets were homogenized in RIPA buffer by using 
ultrasonication for 10 s at 10% intensity. Subsequently, homogenates were incubated for 
25 min on ice and mixed with glycerol to a final concentration of 10 %. Protein concentrations 
were measured spectrophotometrically using Bradford reagent. Western blotting was 
performed as follows: 30 µg of protein, mixed with 4x LDS sample buffer and 100 mM DTT, 
was heat denatured for 10 min at 70 °C prior to electrophoretic separation using Bolt™ 4-
12% Bis-Tris Plus gels and MES running buffer. Proteins were transferred on 0.2 µm 
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AmershamTM ProtranTM Premium nitrocellulose membranes using Bicine/Bis-Tris transfer 
buffer at 80 V for 2 h. Afterwards, membranes were blocked for 1 h with 5% SlimFast in TBS 
at room temperature and incubated overnight at 4 °C with primary antibodies diluted in TBS-
T with 0.02% NaN3. On the next day, membranes were washed with TBS-T and incubated 
with the respective horseradish peroxidase (HRP)/ fluorochrome-conjugated secondary 
antibodies diluted in TBS-T at room temperature for 1 h. For chemiluminescence detection, 
membranes were incubated for 2 min with HRP substrate. Chemiluminescence and 
fluorescence signals were detected using the LI-COR ODYSSEYFC® and quantified with 
ODYSSEY® image studio software version 4.1. 
 
5.12 Quantitative real-time PCR 
Total RNA was extracted from ATO/ G-CSF-treated AML cells by using the RNeasy® Micro 
Kit. RNA concentration was measured with a NanoDrop™ 2000. Complementary cDNA was 
synthesized from 500 ng of RNA with the Omniscript Reverse Transcription (RT) Kit (200). 
Quantitative RT-PCR (qRT-PCR) for AQP9, Gli1 and Gli2 was performed using LightCycler® 
480 SYBR Green I Master Kit and LightCycler® 480 PCR-Cycler, the housekeeper genes β-
actin or TBP served as controls. The results were analyzed with the comparative CT (ΔΔCT) 
method. 
 
5.13 Microarray studies of G-CSF-treated healthy volunteers 
PBMC’s RNA from healthy volunteers – either treated with 5 µg/kg recombinant human G-
CSF for 3 days or not treated – was extracted using the RNeasy® Micro Kit. RNA 
concentration was measured with a NanoDrop™ 2000. Complementary cDNA was 
synthesized from 500 ng of RNA with the Omniscript Reverse Transcription (RT) Kit (200). 
Microarray studies were performed in cooperation with PD Dr. Gunnar Cario, Christian-
Albrechts University Kiel. 
 
5.14 Determination of ATO in murine peripheral blood by atomic absorption 
spectroscopy 
The murine EDTA blood samples were stored at -20 °C before use. Inhomogeneous blood 
samples were treated with ultrasound for 10x 60 s. Samples were vortexed and diluted 1:10 
with a dilution solution. The measurements were performed with an atomic absorption 
spectrometer (AAS) equipped with a graphite furnace and a FS95 furnace auto sampler. In 
the graphite furnace, samples were reduced to ashes at 1400 °C and atomized at 2400 °C. 
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An arsenic hollow cathode lamp operated at 193.7 nm and at 9 mA with a monochromatic 
spectral band pass of 0.5 nm. For the measurements, pyrolytically coated Omega Platform 
Extended Lifetime graphite cuvette and an argon carrier gas (purity of 99.998%) were used. 
8 µl from the diluted sample was injected into the graphite atomizer to get the analytical 
signal. All results were obtained in peak height measurement mode using the method of 
standard addition. The results were obtained as mean values from 2-3 batches and each 
single value consists of a double determination from one batch. 
 
5.15 Adoptive transfer and following treatment of AML cells in NSG mice 
5.15.1 ATO treatment for inhibition of LSCs and AML cell growth 
For the adoptive cell transfer, 2x 106 patient-derived AML cells were injected intravenously 
(i.v.) into 8-12 weeks old unirradiated NSG mice. When leukemia engraftment exceeded 1% 
in peripheral blood, mice were randomized to the treatment groups and daily intraperitoneally 
(i.p.) injected with 0.15 – 5 mg/kg ATO or PBS as a control (each group n = 2-7). Three 
weeks after starting the treatment, mice were euthanized, and the bone marrow and spleen 
were analyzed for leukemia burden and inhibition of side population by FACS (paragraph 
5.8). 
 
5.15.2 ATO/ G-CSF treatment for AML cell growth inhibition 
2x 106 AML cells were injected i.v. into 8-12 weeks old, unirradiated NSG mice. Four days 
after leukemia inoculation, mice were randomized to the treatment groups and daily injected 
i.p. with 4 mg/kg ATO, 250 µg/kg G-CSF or with the combination of both (each group n = 6). 
Mice treated with PBS served as control. Three weeks after starting the treatment, mice were 
euthanized, and the bone marrow, spleen and peripheral blood were analyzed for leukemia 
engraftment, AQP9 expression and viability markers by FACS (paragraph 5.8) and western 
blot (paragraph 5.11). 
 
5.16 G-CSF stimulation of AQP9 in NSG mice 
For G-CSF stimulation of murine AQP9, mice were injected i.p. with 300 µg/kg G-CSF three 
times per week. After one week, mice were euthanized, and the bone marrow was analyzed 
for AQP9 by FACS (paragraph 5.8.2). 
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5.17 Analysis of CD19-CD20-positive ALL- and mono-/bispecific CAR T cell-
transplanted NSG mice 
For the in vivo study, 2x 106 B-ALL blasts, positive for CD19 and heterogeneous for CD20, 
were injected i.v. into unirradiated 8-12 weeks old NSG mice. Before starting the treatment, 
CAR T cells were thawed and cultivated in RPMI 1640 medium for 48 h at 37 °C. Mice were 
randomized to the treatment groups with n = 4-5 animals per group. Ten days after leukemia 
inoculation, mice were injected i.v. with either 2x 107 CAR T cells (each group n = 5) or 
served as controls (leukemia without CAR T cells, n = 4). Seven weeks after leukemia 
induction, mice were euthanized, and bone marrow and peripheral blood were analyzed for 
leukemia burden and CAR T cell expansion by FACS (paragraph 5.8). Additionally, paraffin 
sections of bone marrow from tibia were performed by Prof. Dr. Hinrich Abken, Univeristy of 
Cologne. Sections were stained by haematoxylin and eosin stain (H&E) and for human CD10 
by immune histology. Microscope magnification for H&E staining is 20-fold, for human CD10 
40-fold. 
 
5.18 Bioluminescence imaging and analysis of ALL-effluc cells and adapter CAR T 
cell-transplanted mice 
For bioluminescence imaging of mice, 0.5x 106 ALL-effluc cells were injected i.v. into 8 – 12 
weeks old, unirradiated NSG mice. Mice received i.p. injections of 1.5 mg/mouse luciferin 
substrate resuspended in PBS. Afterwards, mice were anesthetized with isoflurane and 
imaged using a Caliper Life Science IVIS Spectrum imaging system. Five minutes after 
luciferin injection, unsaturated images with an acquisition time of 1 – 60 s were obtained. 
Luciferase activity was analyzed using Living Image Software. Six days after leukemia 
inoculation, mice were randomized to the treatment groups, transplanted i.v. with 1 – 25x 106 
CAR T cells or/and daily injected i.p. with 15 – 50 µg/mouse biotinylated antibody or antibody 
fragment three times or once a week (each group n = 5). Two or three weeks after CAR T 
cell transplantation, mice were imaged again and afterwards euthanized to isolate bone 
marrow and peripheral blood. Analysis for leukemia and CAR T cell engraftment/activity were 
performed by FACS (paragraph 5.8). 
 
5.19 Statistical analysis 
Statistical analysis was performed with GraphPad Prism 6.00 for Windows. Statistical 
significance of data sets obtained by FACS, cell cycle, qRT-PCR and western blot analyses 
was determined by using one-way-ANOVA. P-values < 0.05 were considered as statistically 
significant with * p < 0.05, ** p < 0.01, *** p < 0.001. 
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6. RESULTS 
6.1 Pharmaceutical-based therapy of AML cells with ATO in vitro and in vivo  
Since effective AML therapy is still limited because of the heterogeneous subtypes of AML, 
new therapeutic approaches are urgently needed. In this study, ATO, which is an already 
FDA-approved drug for APL, was considered as a good drug candidate for different AML 
subtypes not only for APL therapy (Litzow, 2008). First, ATO needed to be tested in vitro for 
its effectiveness against different AML cell lines. For that, the pediatric cell line Kasumi-1 and 
the adult cell line KG-1a were cultivated with different concentrations of ATO (0.5 – 2 µM) for 
72 h and analyzed for cell viability using 7-AAD/ Annexin V staining. KG-1a cells were further 
examined for side population modifications, as a model of AML-derived LSCs, by a FACS-
based Hoechst 33342 staining. The results demonstrated that both cell lines were 
susceptible to ATO treatment, which led to a decreased cell viability in a dose-dependent 
manner (FIGURE 6A). Interestingly and in contrast to the reduced cell viability, a massive and 
dose-dependent increase of diploid (SP 2n) and tetraploid (SP 4n) side populations in KG-1a 
cells were observed indicating an expansion of the AML-derived LSCs upon ATO treatment 
(FIGURE 6B). Kasumi-1 cells were further analyzed for alterations of the Hedgehog signaling 
pathway by using qRT-PCR after 24 – 48 h of ATO incubation. Analyzing the transcription 
factors Gli1 (FIGURE 6C) and Gli2 (FIGURE 6D), results demonstrated that ATO treatment led 
to a slightly downregulation of both transcription factors after 48 h of incubation.  
 
To further confirm the in vitro observed ATO cytotoxicity in vivo, 2x106 previously in vivo 
expanded patient-derived AML cells were injected intravenously into unirradiated NSG mice, 
followed by daily intraperitoneal injections with 0.15 – 5 mg/kg ATO. Two anonymous patient-
derived AML cells P84D (FIGURE 7) and P17R (FIGURE 9) were selected due to their fast 
engraftment kinetics in vivo and the existence of good-detectable stem cell-like side 
populations. Owing to difficulties in finding the right ATO dose for mice, a low dose of 
0.15 mg/kg (human dose) and a high but good tolerable dose of 2.5 mg/kg were tested in the 
first in vivo experiment using the patient-derived AML cells P84D. After three weeks of 
treatment, mice were sacrificed and the ATO-dependent effect on leukemia cell growth 
(hCD45-positive cells) as well as on side populations (SP 2n/SP 4n) was determined in bone 
marrow and spleen by FACS. Compared to PBS-treated control mice, ATO did not 
demonstrate a beneficial anti-leukemic effect on leukemia burden in the bone marrow 
(FIGURE 7A) and showed just a slightly leukemia reduction in the spleen (FIGURE 7D). Similar 
to the in vitro results (FIGURE 6B), but with a much fewer intensity, ATO stimulated the 
proliferation of the splenic LSCs that resided within the side populations (FIGURE 7E+F), 
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whereas in the bone marrow, no differences were detectable between the treatment groups 
(FIGURE 7B+C). 
 
 
 
Figure 6: Anti-leukemic effect of ATO on AML cell lines KG-1a and Kasumi-1 in vitro. 
AML cell lines KG-1a and Kasumi-1 were treated with ATO for 72 h and analyzed for cell viability. 
KG-1a cells were also screened for the percentage of side cell population and Kasumi-1 for alterations 
of the Hedgehog signaling pathway. Data are shown as means ± SD, n = 3. * p < 0.05, ** p < 0.01, 
*** p < 0.001 compared to control. (A) Cell viability of treated AML cells were measured by FACS 
analysis using 7-AAD/Annexin V staining. Viable cells were defined as 7-AAD/Annexin V double 
negative cells. B) ATO-dependent effects on KG-1a side populations (SP 2n/ SP 4n) were analyzed by 
FACS using Hoechst 33342 staining. (C+D) ATO-treated Kasumi-1 cells were screened for regulations 
of the Hedgehog signaling pathway analyzing the mRNA expression of the transcription factors Gli1 
(C) and Gli2 (D) in relation to the TATA box binding protein (TBP) by qRT-PCR. Data were analyzed 
with the ΔΔCT method. 
 
Because of the little impact of 0.15 mg/kg and 2.5 mg/kg ATO on P84D AML cell growth in 
vivo (FIGURE 7), non-transplanted mice were treated with different ATO doses (0.15 – 
5 mg/kg) for seven days to find the right dosage for further mouse experiments. To evaluate 
the ATO bioactivity, peripheral blood of mice treated with 0.15 – 5 mg/kg was collected post-
mortem and analyzed for their ATO content by atomic absorption spectrometer (AAS). The 
analysis showed that the ATO blood concentration in mice treated with 0.15 mg/kg of ATO 
was below the ATO detection level of AAS, while the treatment with 2.5 mg/kg and 5 mg/kg 
of ATO resulted in ATO blood concentrations of 76.38 µg/l (± 9.67 SEM) and 129 µg/l (± 
10.15 SEM), respectively (FIGURE 8). The ATO concentration in peripheral blood of ATO-
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treated patients is about 100 µg/l (internal control, not published) rendering 2.5 – 5 mg/kg 
ATO a good dose for further mouse experiments. 
 
 
 
Figure 7: ATO treatment has no effect on AML patient sample P84D cell growth in vivo. 
2x 106 AML patient cells (P84D) were injected intravenously into NSG mice. After leukemia burden 
exceeded 1% in peripheral blood, mice were daily injected intraperitoneally with 0.15 mg/kg or 
2.5 mg/kg of ATO for three weeks. PBS treated mice served as controls. After euthanization, bone 
marrow (A–C) and spleen (D–F) were screened for leukemia cells (hCD45-positive cells) (A+D) and 
for inhibition of the diploid (SP 2n) (B+E) and tetraploid side population (SP 4n) (C+F) by FACS using 
Hoechst 33342 staining. Data are presented as means ± SEM of n = 6-7 per group.  
 
 
 
Figure 8: ATO concentration in murine peripheral blood. 
Peripheral blood of PBS or 0.15 – 5 mg/kg ATO-treated mice were analyzed for ATO concentrations 
(µg/l) by AAS. Data are shown as means ± SEM of n = 3-6 per group.  
Results 
56 
In the second in vivo experiment, the patient-derived sample P17R was treated with ATO 
doses of 2.5 mg/kg and 5 mg/kg for three weeks. FACS-based analysis of the bone marrow 
demonstrated an obvious ATO dose-dependent decrease of the leukemia burden (hCD45-
positive cells) (FIGURE 9A), whereas no differences were observed regarding the side 
populations (SP 2n/SP 4n) (FIGURE 9B+C). Despite successful leukemia reduction, treatment 
with the high dose of 5 mg/kg ATO caused severe side effects, such as apathy and disturbed 
escape response of the mice as well as local hyperkeratosis at the ATO injection site in two 
of three mice (FIGURE 9D). However, the ATO dose of 2.5 mg/kg was well tolerated. 
Therefore, in the following mouse experiments an ATO dosage between 2.5 – 4 mg/kg was 
used. 
 
 
 
Figure 9: High dose ATO inhibits cell growth of AML patient sample P17R in vivo. 
NSG mice were injected intravenously with 2x 106 AML patient cells (P17R). After leukemia burden 
exceeded 1% in peripheral blood, mice were daily injected intraperitoneally with 2.5 mg/kg or 5 mg/kg 
ATO for three weeks. PBS treated mice served as controls. Mice were sacrificed, and the bone 
marrow was analyzed for leukemia burden (hCD45-positive cells) (A) and for inhibition of the side 
population SP 2n (B) and SP 4n (C) by FACS using Hoechst 33342 staining. (D) ATO 5 mg/kg 
treatment caused severe side effects resulting in a local hyperkeratosis. Data are presented as means 
± SEM of n = 3 per group.  
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6.2 Pharmaceutical-based targeting of AML cells with ATO and G-CSF 
6.2.1 Synergistic effect of ATO and G-CSF induces apoptosis, cell cycle arrest and 
reduces proliferation in vitro 
To increase the ATO sensitivity of AML cells and to reduce the ATO dose and accompanied 
side effects, combinatorial ATO treatment studies needed to be established. The cytokine G-
CSF was considered as a good candidate because of its ability to potentiate differentiation, 
to promote quiescent AML cells for entering the cell cycle, as well as to increase ATO 
sensitivity potentially by stimulating the ATO transporter AQP9 (Kitagawa et al., 2010; 
Iriyama et al., 2012, 2013). Initially, to test a potential enhanced cytotoxic effect of ATO and 
G-CSF in vitro, the adult AML cell line U-937 and the pediatric AML cell line Kasumi-1 were 
incubated with 0.5 – 2 µM ATO, 10 ng/ml G-CSF and with a combination of both for 24 – 
120 h. Cells were subsequently analyzed for cell viability using 7-AAD/Annexin V staining by 
FACS (FIGURE 10A+B) and for cell cycle progression with DAPI staining using a 
NucleoCounter® NC-3000™ (FIGURE 10C+D). Moreover, treated cells were examined for 
proliferation capacity by 3H-thymidin incorporation assay using a MicroBeta LumiJET 
Microplate Counter (FIGURE 10E+F). Cell viability results demonstrated that ATO had a 
cytotoxic effect on both cell lines which led to a reduced number of viable cells after 48 h of 
treatment. Compared to control, the ATO-G-CSF combination showed a significantly 
increased cytotoxic effect after 72 h, compared to ATO alone after 96 h of treatment (FIGURE 
10A+B). Consequently, the synergistic anti-leukemic effect of ATO and G-CSF was superior 
to ATO alone in inducing apoptosis of AML cell lines in a long-term in vitro treatment. 
Cell cycle analyses after 72 h of treatment demonstrated that ATO affected all cell cycle 
phases (G0/G1, S, and G2/M), especially the S phase in both AML cell lines. In comparison 
to the control and ATO groups, a highly significant reduction of the S phase was detected 
upon combinatorial treatment with ATO and G-CSF. As a consequence, the sub-G1 phase 
(apoptotic cells) was significantly increased after ATO-G-CSF exposure (FIGURE 10C+D). In 
addition, the drug combination led to a G2/M phase arrest in U-937 cells (FIGURE 10C) and 
G0/G1 phase arrest in Kasumi-1 cells (FIGURE 10D). Thus, the combination of ATO and G-
CSF was more efficient than ATO alone in inhibiting the cell division of AML cells in vitro. 
Proliferation assay results showed that ATO inhibited significantly the proliferation ability of 
both cell lines after 72 h of incubation. However, a superior effectiveness of the drug 
combination was only observed in U-937 cells. In Kasumi-1 cells, the combination appeared 
to ameliorate the effect of ATO alone (FIGURE 10E+F). 
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Figure 10: Synergistic anti-leukemic effect of ATO and G-CSF in AML cell lines U-937 and 
Kasumi-1 in vitro. 
Viability assays, cell cycle and proliferation analyses of control and ATO-G-CSF-treated U-937 and 
Kasumi-1 cells. (A) Cell viability of treated AML cells was measured at different time points by FACS 
analysis using 7-AAD/Annexin V staining. Viable cells are defined as 7-AAD/Annexin V double 
negative cells. (B) Cell cycle differences of treated AML cells were evaluated by DAPI staining after 
72 h of incubation and performed with a NucleoCounter® NC-3000™. (C) Proliferation analyses of 
treated AML cells using 3H-thymidin incorporation assay were conducted after 72 h of incubation with 
a MicroBeta LumiJET Microplate Counter. Data are presented as means ± SD, n = 3. * p < 0.05, 
** p < 0.01, *** p < 0.001 compared to control; + p < 0.05, ++ p < 0.01, +++ p < 0.001 compared to ATO 
alone.  
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6.2.2 G-CSF induces AQP9 expression in AML cells in vitro 
To further investigate an AQP9 expression-stimulating effect of G-CSF, which may have 
resulted in an increased ATO sensitivity and caused the enhanced synergistic anti-leukemic 
effect of ATO and G-CSF, U-937 and Kasumi-1 cells were primarily screened for the basal 
AQP9 and G-CSFR protein expression levels by western blot (FIGURE 11A+B) and FACS 
(FIGURE 11C). As indicated in FIGURE 11, AQP9 protein expression levels were comparable 
in both cell lines, while the expression level of G-CSFR was multifold higher in Kasumi-1 
cells. 
 
 
 
Figure 11: Basic protein expression levels of AQP9 and G-CSFR in U-937 and Kasumi-1 cells. 
(A+B) AQP9 and G-CSFR protein levels were analyzed by western blot. Protein expression was 
normalized to vinculin and represents means ± SD, n = 3. (C) AQP9 and G-CSFR expression levels 
were measured by FACS. Data are presented as mean fluorescence intensity (MFI).  
 
To prove an AQP9 expression-stimulating effect of G-CSF in vitro, U-937 and Kasumi-1 cells 
were cultivated with 0.5 – 2 µM ATO, 10 ng/ml G-CSF and with a combination of both for 
24 – 72 h. Cells were subsequently analyzed for AQP9 protein expression by western blot 
(FIGURE 12A+B) and FACS (FIGURE 12C+D), as well as Kasumi-1 cells for AQP9 mRNA 
expression by qRT-PCR (FIGURE 13). The analyses demonstrated that G-CSF induced an 
upregulation of AQP9 protein levels in both cell lines already after 24 h of treatment. 
However, the response to G-CSF differed between both cell lines. Kasumi-1 cells were much 
more prone to G-CSF’s AQP9-stimulating effect compared to U-937 cells. Kasumi-1 cells 
showed significant increased AQP9 protein expression levels after 48 h of G-CSF incubation 
(FIGURE 12B+D). This AQP9 expression-inducing effect of G-CSF was also confirmed for 
AQP9 mRNA expression levels especially observed in combination with ATO (FIGURE 13). 
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Conversely, in U-937 cells, G-CSF just slightly increased the AQP9 protein levels after 48 h 
of incubation. Only G-CSF in combination with the highest ATO dose showed a significant 
upregulation of AQP9 expression observed in FACS analysis (FIGURE 12A+C).  
 
 
 
Figure 12: Increased AQP9 protein levels in G-CSF-treated U-937 and Kasumi-1 cells. 
Data of U-937 cells is shown in A+C and of Kasumi-1 cells in B+D. (A+B) AQP9 protein levels of ATO-
G-CSF-treated AML cells were analyzed by western blot. Protein expression was normalized to 
vinculin and is presented relative to the control of each time point. (C+D) AQP9 protein levels of ATO-
G-CSF-treated AML cells were measured by FACS analysis. Data are presented as mean 
fluorescence intensity (MFI) and represent means ± SD, n = 3. * p < 0.05, ** p < 0.01, *** p < 0.001 
compared to control; + p < 0.05, ++ p < 0.01, +++ p < 0.001 compared to ATO alone. 
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Figure 13: Increased AQP9 mRNA expression levels in ATO-G-CSF-treated Kasumi-1 cells. 
AQP9 mRNA expression of ATO-G-CSF-treated Kasumi-1 cells was analyzed by qRT-PCR. AQP9 
expression level was normalized to β-actin and analyzed with the ΔΔCT method. Data are presented 
as means ± SD, n = 3. * p < 0.05, ** p < 0.01, *** p < 0.001 compared to control. 
 
6.2.3 Synergistic anti-leukemic effect of ATO and G-CSF in vivo 
The in vitro observed synergistic anti-leukemic effect of ATO and G-CSF was also tested in 
vivo. For that, U-937 cells were selected as target cells because of their fast and predictable 
engraftment kinetics in vivo. The dose of 4 mg/kg ATO was designated as a good medication 
for mice due to previously measured ATO concentrations in murine blood by AAS (paragraph 
6.1). 2x 106 U-937 cells were injected into unirradiated mice, followed by daily intraperitoneal 
injections of 4 mg/kg ATO, 250 µg/kg G-CSF or the combination of both for three weeks. 
Mice were sacrificed, and the bone marrow, peripheral blood and spleen were analyzed for 
leukemia burden (CD33-positive cells) by FACS (FIGURE 14A-C). The bone marrow was also 
screened for AQP9 expression levels as well as for the cell death markers α-spectrin and 
caspase-3 (CASP3) cleavage by western blot (FIGURE 14D-G).  
The analysis showed that the combinatorial ATO-G-CSF treatment significantly reduced the 
number of engrafted CD33-positive leukemia cells in the bone marrow (FIGURE 14A) and in 
the peripheral blood (FIGURE 14B) compared to control and ATO alone. In the spleen, the 
combination of both drugs significantly decreased the leukemia burden compared to ATO 
alone (FIGURE 14C). However, treatment with G-CSF alone also led to diminished numbers 
of leukemia cells, which was especially evident in the peripheral blood and spleen (FIGURE 
14B+C). The anti-leukemic effect of G-CSF was not clearly observed in the bone marrow 
(FIGURE 14A). In all three organs, the treatment with ATO alone stimulated the leukemia cell 
growth instead of reducing it (FIGURE 14A-C). The analysis for AQP9 expression in the bone 
marrow showed that the levels barely varied among the treatment groups (FIGURE 14D+E). 
Additionally, in the bone marrow, increased apoptotic markers 120 kDa α-spectrin and 
cleaved CASP3 confirmed the enhanced synergistic anti-leukemic effect of ATO and G-CSF 
compared to control and to each single drug (FIGURE 14D+F+G). Based on these 
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observations, the combination of ATO and G-CSF was superior to each single drug in 
preventing leukemia cell growth in vivo. 
 
 
 
Figure 14: Synergistic effect of ATO and G-CSF inhibits leukemia cell growth in vivo. 
2x 106 U-937 cells were injected intravenously into NSG mice. After four days, treatment with daily 
intraperitoneal injections of 4 mg/kg ATO, 250 µg/kg G-CSF or the combination of both were started 
for three weeks. PBS-treated mice served as controls. Mice were euthanized and bone marrow (BM) 
(A), peripheral blood (B) and spleen (C) were screened for U-937 leukemia cells (CD33-positive) by 
FACS. (D–G) CD33-positive isolated BM cells were analyzed by western blot for AQP9 expression 
(D+E), spectrin (full-length, 150 kDa-, 120 kDa-fragment) (D+F) and caspase-3 (CASP3) cleavage 
(full-length, cleaved 28kDa-fragment) (D+G). Protein expression was normalized to β-actin. (A–C) 
Data are presented as fold change to control, means ± SEM of n = 6 per group. (D–G) Data represent 
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pooled BM samples from three mice from two independent experiments. * p < 0.05, ** p < 0.01, 
*** p < 0.001 compared to control; + p < 0.05, ++ p < 0.01, +++ p < 0.001 compared to ATO alone. 
 
6.2.4 Treatment of AML patient samples with ATO and G-CSF 
To prove the synergistic anti-leukemic effect of ATO and G-CSF also on patient-derived AML 
cells, freshly isolated PBMCs of adult AML patients were cultivated in vitro with 1 µM ATO, 
10 ng/ml G-CSF and with the combination of both for 72 – 96 h. Harvested cells were 
subsequently analyzed for the cell count (FIGURE 15A+C+E) and AQP9 expression by FACS 
(FIGURE 15B+D+F). In only three of six patient samples (FIGURE 15), a slight cell count 
reduction was observed upon ATO-G-CSF treatment (FIGURE 15A+C+E). Regarding the 
AQP9 expression levels, no obvious upregulation was detected (FIGURE 15B+D+F). 
Owing to the difficulties in growing patient-derived AML cells in vitro, previously in vivo 
expanded pediatric patient-derived AML cells were used to test the synergistic effect of ATO 
and G-CSF in vivo. For that, 2x 106 P49S AML cells (FAB M5) were injected into unirradiated 
mice, followed by daily intraperitoneal injections of 4 mg/kg ATO, 250 µg/kg G-CSF or the 
combination of both for three weeks. Mice were sacrificed, and the bone marrow, peripheral 
blood and spleen were analyzed for leukemia burden (CD33-positive cells) (FIGURE 
16A+B+C) as well as the bone marrow was screened for AQP9 expression levels (FIGURE 
16D) by FACS. The results demonstrated a clearly reduced leukemic cell number in the bone 
marrow (FIGURE 16A), peripheral blood (FIGURE 16B) and spleen (FIGURE 16C) upon 
treatment with ATO and G-CSF compared to control and ATO alone. ATO alone did not 
show an anti-leukemic effect. However, G-CSF alone also inhibited the leukemia cell growth 
in all three organs, similar to that observed in the study with ATO-G-CSF-treated U-937 cells 
in vivo (paragraph 6.2.3; FIGURE 14). The bone marrow analysis revealed increased AQP9 
expression levels upon G-CSF and ATO-G-CSF treatment compared to control and ATO 
alone (FIGURE 16D). Hence, the combination of ATO and G-CSF was capable to decelerate 
AML patient-derived cell growth in vivo while AQP9 was upregulated, but obviously without 
the need of ATO. 
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Figure 15: G-CSF tends to increase the toxicity of ATO in AML patient samples in vitro. 
Cell count and AQP9 protein expression measurements were performed for AML patient samples. 
Three out of six with promising results are shown (A–F). Each sample was incubated with ATO/G-CSF 
for 72 h (patient 2 and 3) or 96 h (patient 1). Data are presented as mean ± SD, n = 2 for each patient. 
(A+C+D) Cell count was performed with trypan blue staining, absolute cell counts are shown. (B+D+F) 
AQP9 protein level was measured by FACS and is presented as mean fluorescence intensity (MFI). 
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Figure 16: G-CSF inhibits cell growth of the AML patient sample P49S in vivo. 
2x 106 AML patient cells (P49S) (FAB M5) were injected intravenously into NSG mice. After four days, 
daily intraperitoneal injections of 4 mg/kg ATO, 250 µg/kg G-CSF or the combination of both were 
started for three weeks. PBS-treated mice served as controls. Mice were euthanized, and bone 
marrow (A), peripheral blood (B) and spleen (C) were screened for leukemia cells (CD33-positive) by 
FACS. (D) Bone marrow was also screened for AQP9 expression by FACS and is presented as mean 
fluorescence intensity (MFI). Data are shown as means ± SEM of n = 3 per group. + p < 0.05, 
++ p < 0.01, +++ p < 0.001 compared to ATO alone. 
 
To decrease the anti-leukemic effect of G-CSF as a single agent, the G-CSF medication was 
reduced from daily injections of 250 µg/kg to 300 µg/kg three times a week in the following 
mouse experiment. The ATO dosage was also reduced from daily injections of 4 mg/kg to 
2.5 mg/kg. 2x 106 of patient-derived AML cells P93A (FAB M4) were injected into 
unirradiated mice, followed by daily intraperitoneal injections of 2.5 mg/kg ATO, 300 µg/kg G-
CSF three times a week or the combination of both for three weeks. Mice were sacrificed, 
and the bone marrow, peripheral blood and spleen were analyzed for leukemia engraftment 
(CD33-positive cells) (FIGURE 17A+B+C). The bone marrow was screened for AQP9 
expression levels by FACS (FIGURE 17D). In addition, bone marrow cells were also analyzed 
for their immature CD34+CD38- immunophenotype (FIGURE 17E). The results show that the 
combination of ATO and G-CSF reduced the leukemia burden in the bone marrow (FIGURE 
Results 
66 
17A), peripheral blood (FIGURE 17B) and spleen (FIGURE 17C). The lower ATO dose resulted 
in a stimulation of leukemia growth in all three organs. Whereas, even a reduced dose of G-
CSF also decreased the leukemia burden in all examined organs (FIGURE 17A+B+C) as 
observed in the study with ATO-G-CSF-treated P49S cell in vivo (FIGURE 16). The AQP9 
expression level in the bone marrow was also significantly increased upon G-CSF and ATO-
G-CSF treatment in comparison to control and ATO alone (FIGURE 17D). The analysis of 
bone marrow cells for the immunophenotype demonstrated that immature CD34+CD38- cells 
were obviously reduced upon G-CSF and ATO-G-CSF treatment, while CD34-CD38+ cells 
were increased, and CD34+CD38+ slightly decreased compared to control and ATO alone 
groups (FIGURE 17E). Taken together, for the treatment of AML patient-derived cells, G-CSF 
alone was capable to decrease the leukemia growth in vivo while AQP9 expression was 
induced. 
 
6.2.5 G-CSF modifies AQP9 expression in human and murine cells 
To test whether the previously observed AQP9-stimulating effect of G-CSF on leukemia cells 
is generally applicable to non-cancerous human cells, healthy volunteers were treated with 
5 µg/kg/day G-CSF for three days (FIGURE 18A) or healthy donor PBMCs were cultured in 
the presence of 10 ng/ml G-CSF in vitro for 72 h (FIGURE 18B). CD33-positive cells from 
peripheral blood of G-CSF-treated and non-treated healthy volunteers were analyzed by 
microarray analysis and AQP9 mRNA expression was evaluated. Data of G-CSF-treated 
volunteers were normalized to the untreated ones. Microarray results showed a massive and 
significant increase of AQP9 mRNA expression upon G-CSF treatment compared to non-
treated control samples (FIGURE 18A). However, in vitro cultured and G-CSF-treated CD33- 
and CD34-positive cells of healthy donors did not demonstrate an increase in AQP9 protein 
expression level as measured by FACS (FIGURE 18B).  
Therefore, the AQP9 expression-stimulating effect of G-CSF was further tested in vivo using 
NSG mice. For that, mice were treated with 300 µg/kg G-CSF three times a week for one 
week. Mice were sacrificed, and mouse CD45-positive bone marrow leukocytes (FIGURE 
19A) as well as mouse CD34-positive hematopoietic stem cells were screened for AQP9 
expression by FACS (FIGURE 19B). After one week of treatment, mouse CD45- and CD34-
positive cells showed a significant increase of the AQP9 expression level upon G-CSF 
medication. 
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Figure 17: G-CSF inhibits AML patient sample P93A engraftment in vivo. 
2x 106 AML patient cells (P93A) (FAB M4) were injected intravenously into NSG mice. After 14 days, 
daily intraperitoneal injections of 2.5 mg/kg ATO, three times a week 300 µg/kg G-CSF or the 
combination of both were started for three weeks. PBS-treated mice served as controls. Mice were 
euthanized, and bone marrow (A), peripheral blood (B) and spleen (C) were screened for leukemia 
CD33-positive cells by FACS. (D) Bone marrow was also screened for AQP9 expression by FACS and 
is presented as mean fluorescence intensity (MFI). Data are shown as means ± SEM of n = 3 per 
group. * p < 0.05, ** p < 0.01, *** p < 0.001 compared to control; + p < 0.05, ++ p < 0.01, +++ p < 0.001 
compared to ATO alone. 
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Figure 18: AQP9 expression levels in CD33+ cells of healthy volunteers treated or non-treated 
with G-CSF. 
(A) Microarray analysis of AQP9 mRNA expression from CD33-positive cells of healthy individuals 
treated with 5 µg/kg/day G-CSF for three days compared to non-treated individuals. AQP9 expression 
of G-CSF-treated volunteers was normalized to controls without G-CSF treatment and is presented as 
fold change to control. (B) FACS analysis of AQP9 protein levels from healthy donor CD33- and 
CD34-positive cells treated daily with 10 ng/ml G-CSF for 72 h compared to control non-treated cells. 
AQP9 level is shown as mean fluorescence intensity (MFI). Data are presented as means ± SEM of 
n = 4-7 per group. 
 
 
 
 
Figure 19: Increased murine AQP9 expression in bone marrow mCD45- and mCD34-positive 
cells. 
NSG mice were injected intraperitoneally with 300 µg/kg G-CSF or PBS (control) three times a week 
for one week. Mice were euthanized, and bone marrow mouse CD45 (mCD45)-positive and CD34 
(mCD34)-positive cells were screened for AQP9 expression by FACS, shown as mean fluorescence 
intensity (MFI). Data are presented as means ± SEM of n = 3 per group.  
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6.3 CAR T cell-based therapy of ALL cells 
6.3.1 Monospecific anti-CD19 and bispecific anti-CD20-CD19 CAR T cells eradicate 
CD19-CD20-positive patient-derived B-ALL in vivo 
Redirected CAR T cells are a novel highly promising approach for targeted immunotherapy 
of hematological malignancies, especially for ALL. Because of tumor antigen-loss during 
treatment, difficulties with heterogeneous tumor antigen patterns and severe therapy-
associated complications, further optimization of CAR T cell therapy is absolutely necessary 
(Davila et al., 2014; Ruella and Maus, 2016). To explore the power of bispecific CAR T cells 
in controlling leukemia with a heterogeneous antigen pattern, 2x 106 of previously in vivo 
expanded pediatric patient-derived ALL cells (P94H) with a CD19+CD20+/- phenotype were 
injected into unirradiated mice. Ten days later, 2x 107 monospecific anti-CD19, anti-CD20 or 
bispecific anti-CD20-CD19 CAR T cells were inoculated. Mice injected with CAR T cells of 
irrelevant specificity and untreated mice served as controls (FIGURE 20+21). Mice were 
sacrificed after seven weeks, and bone marrow (FIGURE 20A+C) as well as peripheral blood 
(FIGURE 20B+D) were screened for leukemia burden (CD10-positive cells) and circulating 
CAR T cells (CD45-CD3-positive cells) by FACS. The results demonstrated that the 
CD19+CD20+/- ALL cells were efficiently eliminated by the bispecific anti-CD20-CD19 and 
monospecific anti-CD19 CAR T cells in the bone marrow (FIGURE 20A) and peripheral blood 
(FIGURE 20B) compared to controls. In addition, the detection of these CAR T cells also 
confirmed highly active and circulating CAR T cells in the bone marrow and peripheral blood 
(FIGURE 20C+D). The monospecific anti-CD20 CAR T cells, however, did not show an anti-
leukemic effect (FIGURE 20A+B) neither did they circulate in both tissues (FIGURE 20C+D).   
Moreover, paraffin sections of the bone marrow from tibia of the CAR T cell-treated mice 
were stained with haematoxylin and eosin (H&E) and analyzed for human CD10 by immune 
histology (FIGURE 21). Bone marrow infiltration was markedly decreased by the bispecific and 
monospecific anti-CD19 CAR T cells compared to controls, which was also confirmed by 
FACS analysis (FIGURE 20). An anti-leukemic effect of anti-CD20 CAR T cells was also not 
observed in bone marrow sections. 
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Figure 20: Monospecific anti-CD19 and bispecific anti-CD20-CD19 CAR T cells eradicate CD19-
CD20-positive patient-derived ALL cells (P94H) in vivo. 
NSG mice were transplanted intravenously with 2x 106 B-ALL patient cells (P94H). After ten days, 
2x 107 CAR T cells engineered with an anti-CD19, anti-CD20 or anti-CD20-CD19 CAR construct were 
injected intravenously. As controls, mice received T cells with a CAR of irrelevant specificity or no 
T cells. Mice were sacrificed after seven weeks, and the bone marrow (A+C) and peripheral blood 
(B+D) were analyzed for leukemia cells (CD10-positive) (A+B) and for CAR T cells (CD45-CD3-
positive) (C+D) by FACS. Data are presented as means ± SEM of n = 4-5 per group. * p < 0.05, 
** p < 0.01, *** p < 0.001 compared to control.  
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Figure 21: Paraffin sections of bone marrow from tibia.  
Histology of the bone marrow of CAR T cell-treated mice transplanted with the human B-ALL P94H. 
Mice were sacrificed in week seven and paraffin sections of bone marrow from tibia were stained by 
haematoxylin and eosin stain (H&E) and for human CD10 by immune histology. Microscope 
magnification for H&E staining is 20-fold, for human CD10 40-fold.  
 
6.3.2 Adapter CAR T cells specifically kill CD19-positive B-ALL cells in the presence of 
a biotinylated antibody in vitro 
To control the CAR T cell intensity and off-tumor toxicities based on a non-lethal ‘on-switch’ 
strategy, the generation of universal adapter CAR T cells is a great improvement in 
optimizing CAR T cell therapy (Kloss et al., 2012; Juillerat et al., 2016). With the herein 
introduced universal adapter anti-biotin CAR T cells – targeting biotin-conjugated mAbs and 
mAb fragments – generally all kinds of tumor antigens which are accessible to mAbs can be 
targeted. Thus, this modularity allows approaching a wide range of tumors. In this study, anti-
biotin CAR T cells (60 – 80 % positive for LNGFR as a CAR marker) were primarily tested in 
vitro against the CD19-positive B-ALL cell line Nalm-6 to evaluate the killing efficacy as well 
as the state of differentiation and exhaustion in the presence or absence of a biotinylated 
mAb. Moreover, several types of anti-biotin CAR T cells with different spacer length (#7-, 
#10- and #9 CAR with decreasing spacer lengths) and various forms of anti-CD19 mAbs 
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(unconjugated/ biotin-conjugated Fc-optimized 4G7SDIE (4G7) anti-CD19 mAb or Fab 
fragment and biotinylated anti-CD19 mAb clone REA675 (REA)) were tested (FIGURE 22). 
For that, enhanced firefly luciferase transduced Nalm-6 cells (Nalm-6-effluc-mCherry) were 
co-cultivated with different types of anti-biotin CAR T cells in a 1:1 E:T cell ratio and with 
various forms of mAbs for 48 h. A subsequent analysis revealed that #9 CAR T cells with a 
very short spacer length (spacer domain consists of only a hinge region) (FIGURE 22A) were 
much more effective in killing Nalm-6 cells in the presence of a biotinylated mAb than #7- 
and #10 CAR T cells with longer spacer length (#7 CAR spacer domain is composed of 
hinge-CH2-CH3, #10 CAR spacer consists of hinge-CD8) (FIGURE 22D). #9 CAR T cells 
efficiently killed the target cells when a biotinylated mAb was added, whereas the power of 
#7- and #10 CAR T cells was limited. As a consequence, only #9 CAR T cells were further 
analyzed for exhaustion (PD-1), activation (CD25, CD69) (FIGURE 22B) and differentiation 
markers (CD62L, CD45RA, CD45RO, CD95) upon co-culture experiments (FIGURE 22C). 
The analysis for exhaustion showed that PD-1 was upregulated after co-cultivation with 
biotinylated mAbs and Nalm-6 cells compared to unbiotinylated/ biotinylated mAbs or Nalm-6 
cells alone. Based on the obviously increased activation markers CD25 and CD69, #9 CAR T 
cells were highly active after co-incubation with biotinylated mAbs and Nalm-6 cells. But the 
incubation with single biotinylated mAbs resulted in a light upregulation of the activation 
markers as well (FIGURE 22B). The analysis for the differentiation status of #9 anti-biotin CAR 
T cells showed a markedly decrease of naïve T cells (CD62L+CD45RA+CD45RO-CD95-) and 
increase of effector T cells (CD62L-CD45RA+CD45RO-CD95+) after co-cultivation with 
Nalm-6 cells and biotinylated mAbs in comparison to Nalm-6 cells or unbiotinylated/ 
biotinylated mAbs alone. The number of effector memory T cells (CD62L-CD45RA-CD45RO+ 
CD95+) increased upon cultivation with Nalm-6 cells independently of an absence or 
presence of a mAb, whereas central memory T cells (CD62L+CD45RA-CD45RO+CD95+) 
decreased upon stimulus of biotinylated mAbs and Nalm-6 cells. Number of T memory stem 
cells (CD62L+CD45RA+ CD45RO-CD95+) did not change upon treatment (FIGURE 22C). 
Taken together, #9 anti-biotin CAR T cells showed an efficient killing capability in vitro in the 
presence of biotinylated mAbs, which resulted in increased exhaustion and activation 
markers as well as in expansion of differentiated effector T cells. 
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Figure 22: Adapter CAR system for targeting of CD19-positive B-ALL cell line Nalm-6-effluc-
mCherry in vitro. 
#9 CAR T cells were co-cultivated with or without 100 ng/ml of monoclonal antibody (mAb) (anti-CD19 
(aCD19) 4G7SDIE (4G7), aCD19 4G7-biotin, aCD19 4G7-biotin Fab fragment, aCD19 REA675 
(REA)-biotin) and with or without Nalm-6-mCherry cells for 48 h. (A) In vitro killing potency was 
analyzed by FACS. (B+C) #9 CAR T cells were screened for exhaustion (PD-1+) and activation 
(CD25+/CD69+) (B) as well as for naivety markers (CD45RA, CD45RO, CD62L, CD95) (C) by FACS. 
Data are shown as means ± SD, n = 3. * p < 0.05, ** p < 0.01, *** p < 0.001 compared to #9 CAR; 
+ p < 0.05, ++ p < 0.01, +++ p < 0.001 compared to CAR + Nalm-6. TCM, central memory T cell 
(CD62L+CD45RA-CD45RO+CD95+); TEFF, effector T cell (CD62L-CD45RA+CD45RO-CD95+); TEM, 
effector memory T cell (CD62L-CD45RA-CD45RO+CD95+); TN, naïve T cell (CD62L+CD45RA+ 
CD45RO-CD95-); TSCM, T memory stem cell (CD62L+CD45RA+CD45RO-CD95+).  
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6.3.3 Adapter CAR T cells specifically kill CD19-positive B-ALL cells in the presence of 
a biotinylated antibody in vivo 
After validation of the specific killing capability in the presence of a biotinylated mAb in vitro, 
the universal adapter anti-biotin CAR T cells were further tested for their efficacy and 
specificity against the CD19-positive B-ALL cell line Nalm-6 in vivo. Despite not showing a 
high efficacy in vitro (FIGURE 22D), #7- and #10 anti-biotin CAR T cells were included in the 
in vivo experiments. For this purpose, unirradiated NSG mice were inoculated with 0.5x 106 
Nalm-6-effluc-mCherry cells and six days later injected with 25x 106 freshly produced #9, #10 
or #7 adapter CAR T cells. In addition, mice were treated with 50 µg/mouse of biotinylated 
anti-CD19 Fc-optimized 4G7SDIE mAb three times a week. Untreated mice as well as mice 
which were injected with #9 CAR T cells and additionally treated with a non-biotinylated anti-
CD19 4G7SDIE mAb (“mock”) served as negative controls. Monospecific CD19 CAR T cell-
injected mice were used as positive controls. Three weeks after, mice were analyzed for 
leukemia burden by bioluminescence imaging prior to euthanization (FIGURE 23A+B). For 
post-mortem analysis, bone marrow was screened for leukemia cells (Nalm-6-mCherry-
positive cells) (FIGURE 23C) and peripheral blood for circulating CAR T cells (LNGFR-positive 
cells) by FACS (FIGURE 23D). Bioluminescence imaging demonstrated a significantly 
reduced signal of Nalm-6-effluc-mCherry cells in all CAR T cell injected mice compared to 
untreated mice, regardless of the previously treatment with a biotinylated or non-biotinylated 
mAb (FIGURE 23A+B). Likewise, analysis of the bone marrow by FACS confirmed that 
leukemia was non-specifically eradicated by the adapter CAR T cells in all CAR T cell-
transplanted mice (FIGURE 23C). Examining the peripheral blood, circulating CAR T cells 
were evident in all CAR T cell-inoculated mice, even in the mock mice which were treated 
with an unbiotinylated mAb. However, the number of #7 CAR T cells in the peripheral blood 
was reduced in comparison to #9- and #10 CAR T cells. This observation led to an exclusion 
of #7 CAR T cells in further in vivo experiments (FIGURE 23D). 
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Figure 23: Adapter CAR system for targeting of CD19-positive B-ALL cell line Nalm-6-effluc-
mCherry with the mAb anti-CD19 4G7SDIE-biotin in vivo. 
NSG mice were injected intravenously with 0.5x 106 Nalm-6-effluc-mCherry cells. Six days after 
leukemia inoculation, mice were randomized to the treatment groups, transplanted intravenously with 
25x 106 CAR T cells or/and injected intraperitoneally with 50 µg/mouse biotinylated CD19 mAb three 
times a week. Three weeks after CAR T cell transplantation, mice were imaged bioluminescently 
(A+B) and euthanized to screen for leukemia burden in the bone marrow (C) and for CAR T cell 
expansion in the peripheral blood (D) by FACS. Data are presented as means ± SEM of n = 3-5 per 
group. * p < 0.05, ** p < 0.01, *** p < 0.001 compared to control. A’ control, B’ mock, C’ anti-CD19 
CAR, D’ #9 CAR + mAb, E’ #10 CAR + mAb, F’ #7 CAR + mAb. 
 
To minimize unspecific CAR T cell activity in the following mouse experiment, the amount of 
inoculated CAR T cells were markedly reduced from 25x 106 to 2x 106. In addition, the 
biotinylated 4G7SDIE Fab antibody was used instead of the prior applied 4G7SDIE mAb to 
avoid any potential interaction between the Fc domain within the CAR spacer and the Fc 
receptor-bearing myeloid cells, which might result in a proinflammatory immune response. 
Like in the preceding in vivo experiment, unirradiated NSG mice were injected with 0.5x 106 
Nalm-6-effluc-mCherry cells and six days later inoculated with 2x 106 freshly produced #9- 
and #10 adapter CAR T cells. In addition, mice were treated daily with 15 µg/mouse 
biotinylated anti-CD19 4G7SDIE Fab antibody. Untreated mice as well as mice treated only 
with anti-CD19 4G7SDIE Fab served as controls. Three weeks later, mice were analyzed for 
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leukemia burden by bioluminescence imaging (FIGURE 24A+B) as well as the bone marrow 
was screened for leukemia cells (FIGURE 24C) and peripheral blood for CAR T cells (FIGURE 
24D). Similar to preceding observations, bioluminescence imaging demonstrated that 
adapter CAR T cells did not specifically kill the Nalm-6 cells in the presence of a biotinylated 
Fab. All CAR T cell-transplanted mice showed a reduced leukemia burden, especially mice 
which were injected with #9 CAR T cells (FIGURE 24A+B). FACS analysis of the bone marrow 
confirmed the bioluminescence imaging results. CAR T cells alone were able to inhibit 
leukemia cell growth in vivo, regardless of the presence or absence of a biotinylated mAb 
(FIGURE 24C). Both bioluminescence imaging and FACS indicated that also the biotinylated 
Fab alone was able to decelerate leukemia cell growth in vivo (FIGURE 24A+B+C). Based on 
FACS results, CAR T cells were evident in the peripheral blood but only in a low amount 
(FIGURE 24D). 
 
 
 
Figure 24: Adapter CAR system for targeting of CD19-positive B-ALL cell line Nalm-6-mCherry 
with the Fab fragment anti-CD19 4G7SDIE-biotin in vivo. 
0.5x 106 Nalm-6-effluc-mCherry cells were injected intravenously into NSG mice. Six days after 
leukemia inoculation, mice were randomized to the treatment groups, transplanted intravenously with 
2x 106 CAR T cells or/and daily injected intraperitoneally with 15 µg/mouse biotinylated anti-CD19 
mAb Fab fragment. Three weeks after CAR T cell transplantation, mice were imaged bioluminescently 
(A+B) and euthanized to screen for leukemia cells in the bone marrow (C) and for CAR T cell 
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expansion in the peripheral blood (D) by FACS. Data are presented as means ± SEM of n = 3-5 per 
group. * p < 0.05, ** p < 0.01, *** p < 0.001 compared to control. A’ control, B’ Fab, C’ #9 CAR, 
D’ #9 CAR + Fab, E’ #10 CAR, F’ #10 CAR + Fab. 
 
To further minimize the non-specific CAR T cell activity and to optimize the in vivo 
experiments, CAR T cell number was reduced from 2x 106 to 1x 106 per mouse. Instead of 
using freshly produced CAR T cells, they were firstly frozen and thawed again for attenuating 
the hyperactivity. To prevent non-specific antibody activity, the Fc-optimized therapeutic 
4G7SDIE Fab antibody was replaced by an anti-CD19-biotin mAb (clone REA675), which 
also displays negligible binding to Fc receptors. Similar to preceding mouse experiments, 
unirradiated NSG mice were transplanted with 0.5x 106 Nalm-6-effluc-mCherry cells and six 
days later injected with 1x 106 previously thawed #9 adapter CAR T cells. Additionally, mice 
were treated with 50 µg/mouse biotinylated anti-CD19 mAb (clone REA675) three times a 
week. Untreated, only mAb-injected and CAR T cell-transplanted mice served as controls. 
Three weeks later, mice were analyzed for leukemia burden by bioluminescence imaging 
(FIGURE 25A+B) as well as the bone marrow was screened for leukemia cells (FIGURE 25C) 
and peripheral blood for CAR T cell expansion (FIGURE 25D). The bioluminescence imaging 
demonstrated that #9 CAR T cells in combination with biotinylated mAb reduced the 
leukemia burden compared to untreated control mice (FIGURE 25A+B). Once again, mAb 
alone decreased leukemia burden as observed with 4G7SDIE Fab treated mice (FIGURE 
24A+B). The FACS analysis of the bone marrow confirmed the bioluminescence imaging 
results, but without an obvious anti-leukemic effect of the biotinylated anti-CD19 mAb alone 
(FIGURE 25C). In contrast to freshly produced CAR T cells in preceding mouse experiments 
(FIGURE 23+24), thawed CAR T cells showed barely non-specific activity and killed the 
leukemia cells generally in the presence of a biotinylated mAb. Examination of the peripheral 
blood demonstrated that circulating CAR T cells were present in all CAR T cell-transplanted 
mice (FIGURE 25D).  
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Figure 25: Adapter CAR system for targeting of CD19-positive B-ALL cell line Nalm-6-effluc-
mCherry with the mAb anti-CD19 REA675-biotin in vivo. 
NSG mice were injected intravenously with 0.5x 106 Nalm-6-effluc-mCherry cells. Six days after 
leukemia inoculation, mice were randomized to the treatment groups, transplanted intravenously with 
thawed 1x 106 CAR T cells or/and injected intraperitoneally with 50 µg/mouse biotinylated CD19 mAb 
(clone REA675) three times a week. Three weeks after CAR T cell transplantation, mice were imaged 
bioluminescently (A+B) and euthanized to screen for leukemia burden in the bone marrow (C) and for 
CAR T cell expansion in the peripheral blood (D) by FACS. Data are shown as means ± SEM of 
n = 3-5 per group. * p < 0.05, ** p < 0.01, *** p < 0.001 compared to control. A’ control, B’+C’ mAb, 
D’-F’ #9 CAR, G’-I’ #9 CAR + mAb. 
 
To achieve a significant decrease of leukemia burden in CAR T cell and biotinylated mAb-
injected mice, the cell number of thawed CAR T cells was increased from 1x 106 to 2x 106 
per mouse in the following in vivo experiment. To additionally reduce the anti-leukemic effect 
of the biotinylated anti-CD19 mAb (clone REA675) alone, the mAb application frequency was 
decreased from three times to once a week. Again, unirradiated mice were inoculated with 
0.5x 106 Nalm-6-effluc-mCherry cells and six days later injected with 2x 106 previously 
thawed #9 adapter CAR T cells. Mice were treated with 50 µg/mouse biotinylated anti-CD19 
mAb (clone REA675) once a week. Untreated, only mAb-injected and CAR T cell-
transplanted mice served as controls. Three weeks later, mice were screened for leukemia 
burden by bioluminescence imaging (FIGURE 26A+B), and the bone marrow was analyzed for 
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leukemia cells (FIGURE 26C) and the peripheral blood for circulating CAR T cells (FIGURE 
26D). Both bioluminescence imaging and FACS demonstrated that #9 CAR T cells in 
combination with a biotinylated mAb significantly reduced the leukemia burden compared to 
control untreated mice (FIGURE 26A+B+C). However, also #9 CAR T cell-transplanted mice 
showed a significant reduction of the leukemia burden analyzed by FACS (FIGURE 26C). The 
biotinylated mAb alone did not substantially decrease the leukemia cells (FIGURE 26A+B+C). 
Nevertheless, the superiority of the combination of CAR T cells with a biotinylated mAb in 
killing leukemia cells was apparent in vivo, when compared to CAR T cells alone. This was 
also confirmed by an increased level of circulating CAR T cells in the peripheral blood in the 
presence of a biotinylated mAb (FIGURE 26D). 
 
 
 
Figure 26: Adapter CAR system for targeting of CD19-positive B-ALL cell line Nalm-6-effluc-
mCherry with the mAb anti-CD19 REA675-biotin in vivo II. 
0.5x 106 Nalm-6-effluc-mCherry cells were injected intravenously into NSG mice. Six days after 
leukemia inoculation, mice were randomized to the treatment groups, transplanted intravenously with 
thawed 2x 106 CAR T cells or/and injected intraperitoneally with 50 µg/mouse biotinylated CD19 mAb 
(clone REA675) once a week. Three weeks after CAR T cell transplantation, mice were imaged 
bioluminescently (A+B) and euthanized to screen for leukemia burden in the bone marrow (C) and for 
CAR T cell expansion in the peripheral blood (D) by FACS. Data are presented as means ± SEM of 
n = 3-5 per group. * p < 0.05, ** p < 0.01, *** p < 0.001 compared to control. A’+B’ control, C’+D’ mAb, 
E’-G’ #9 CAR, H’-J’ #9 CAR + mAb. 
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6.3.4 Adapter CAR T cells specifically kill γδ-TCR/ CD231-positive T-ALL cells in the 
presence of an antibody in vitro 
The prognosis for patients with T cell malignancies is still poor due to limited options for 
targeted therapies. CAR T cell therapy for T-ALL might result in self-targeting and 
compromising the therapeutic ability due to a shared surface antigen pool between normal 
and malignant T cells (K. H. Chen et al., 2016; Chen et al., 2017). Instead of using other 
competent immune cells (for example NK cells), universal adapter CAR T cells could also 
help to overcome the lack of therapy options, for example by using αβ-TCR-positive CAR T 
cells to kill γδ-TCR-positive T-ALLs (FIGURE 27A) as well as by targeting only malignant T cell 
antigens such as CD231 (Talla-1) (FIGURE 27B). To test the modularity and efficacy of 
universal adapter CAR T cells in targeting T-ALLs in vitro, the T cell lines Molt-14-effluc-
mCherry (γδ-TCR-positive) and Jurkat-effluc-mCherry (CD231-positive) were co-cultivated 
with αβ-TCR-positive #9 CAR T cells in E:T ratios of 10:1 – 1:1, with or without the addition of 
the appropriate biotinylated mAb for 24 h. Cells were finally analyzed by a luciferase activity-
based cytotoxicity assay. The results demonstrate that the αβ-TCR-positive CAR T cells 
significantly killed the γδ-TCR-positive Molt-14 cells in all tested E:T ratios of 5:1 to 1:1 
compared to controls without the addition of a biotinylated anti-γδ-TCR mAb (FIGURE 27A). 
Analysis of the Jurkat cells showed that the universal adapter CAR T cells were also able to 
kill CD231-positive Jurkat cells but in a much less efficient way. A higher E:T ratio just 
increased the non-specific activity of the CAR T cells (FIGURE 27B).   
 
 
 
Figure 27: Adapter CAR T cells specifically kill γδ-TCR-/ CD231-positive T-ALLs with the 
appropriate biotinylated mAb. 
Molt-14-effluc-mCherry (A) and Jurkat-effluc-mCherry (B) were co-cultivated with αβ-TCR-positive 
#9 CAR T cells in different E:T ratios (10:1 – 1:1) for 24 h with or without the addition of 100 ng/ml of 
an anti-γδ-TCR or anti-CD231 monoclonal antibody (mAb), respectively. In vitro killing potency of CAR 
T cells was analyzed by a luciferase activity-based cytotoxicity assay. Data are shown as means ± SD, 
n = 3. * p < 0.05, ** p < 0.01, *** p < 0.001 compared to each E:T without mAb. 
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7. DISCUSSION 
7.1 ATO has a dose-dependent impact on AML cells and induces resistant LSCs  
AML is a severe blood cell malignancy derived from the myeloid lineage and associated with 
a poor prognosis because of limited therapy possibilities for the highly heterogeneous AML 
subtypes (Roboz, 2012; Fernandes et al., 2014). It is proposed, that the quiescent leukemia-
initiating LSCs play an important role in the leukemogenic process and are often resistant to 
chemotherapeutic agents due to for example an overexpression of ABC transporters 
(Goodell et al., 1996; de Jonge-Peeters et al., 2007). When chemotherapeutics spare LSCs, 
it is likely that residual cells reinitiate tumor growth which may result in a relapse. The 
therapeutic agent ATO has been traditionally used in Chinese medicine for chronic leukemia 
treatment and is nowadays a FDA-approved single drug for the second-line therapy of the 
FAB M3 AML subtype APL (Zhu et al., 2002; Y. Zhang et al., 2016). Since then, many 
studies tried to evaluate an anticancer effect of ATO on other AML subtypes or cancer cell 
types (Halicka et al., 2002; Kumar et al., 2014; Leung et al., 2017).  
To assess ATO’s applicability on AML cells, this study investigated firstly the drug’s effect on 
the well-established cell lines KG-1a (described as undifferentiated AML cells) and Kasumi-1 
(FAB M2). For that, cells were treated with different doses of ATO in vitro and analyzed for 
cell viability. Higher doses of ATO (1 – 2 µM) induced a significant reduction of viable cells 
and an increase of apoptotic cells in both cell lines after 72 h of treatment, whereas a low 
ATO dose (0.5 µM) showed only a limited cytotoxicity (FIGURE 6A). This dose-dependent 
dual effect of ATO was already observed on APL cells by Chen et al. two decades ago, 
where ATO at concentrations of 0.5 – 2 µM preferentially induced apoptosis, while low 
concentrations of 0.1 – 0.5 µM rather stimulated partial differentiation (Chen et al., 1997). 
The pro-apoptotic activity of ATO was also confirmed by Halicka et al. in U-937 and HL-60 
AML cells, independently of a present PML-RARα fusion protein. U-937 and HL-60 cells 
showed an increased level of DNA breaks already after 18 h of high dose ATO treatment in 
vitro (Halicka et al., 2002). Akao et al. demonstrated an apoptosis-inducing effect of ATO in 
B-ALL cells as well (Akao et al., 1998). Besides targeting PML-RARα, ATO is also able to 
antagonize aberrant activation of the Hedgehog signaling pathway by blocking the Gli 
transcription factors, particularly Gli2. Kim et al. and Beauchamp et al. showed the ATO 
cytotoxicity on medulloblastoma allografts is associated with an abnormal Hedgehog 
signaling pathway activation (Kim et al., 2010; Beauchamp et al., 2011). Kerl et al. and 
Boehme et al. also observed that the pro-apoptotic effect of ATO on rhabdoid tumors was 
mediated by targeting the Hedgehog signaling pathway (Kerl et al., 2014; Boehme et al., 
2016). Based on this information, in vitro ATO-treated Kasumi-1 cells were also screened for 
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alterations in mRNA expression levels of the transcriptions factors Gli1 (FIGURE 6C) and Gli2 
(FIGURE 6D) by qRT-PCR. The results confirmed the preceding observations: ATO treatment 
reduced the mRNA expression levels of Gli1 and Gli2, especially for Gli2.  
 
To validate the cytotoxicity of ATO on AML cells in vivo, patient-derived cells (P84D and 
P17R) were injected into unirradiated mice and treated with different doses of ATO 
(0.15 mg/kg, 2.5 mg/kg and 5 mg/kg) for three weeks (FIGURE 7, 9). The analysis of bone 
marrow and spleen revealed again a dose-dependent effect of ATO comparable to the in 
vitro studies (FIGURE 6). Low doses of ATO did not inhibit AML cell growth (FIGURE 7A+D), 
only the high dose of 5 mg/kg reduced the leukemia burden in vivo (FIGURE 9A). Similar 
observations were made by Kim et al. with the ATO treatment of Hedgehog pathway-
dependent medulloblastoma allografts in nude mice. ATO treatment inhibited tumor growth in 
a dose-dependent manner (Kim et al., 2010). However, in this study, the high dose of 
5 mg/kg ATO caused severe side effects resulting in local hyperkeratosis at the injection site 
of the drug (FIGURE 9D). The same toxic effects were observed by Kim et al. testing ATO in 
vivo on human cholangiocarcinoma cancer cells (Kim et al., 2014). They validated a dose-
dependent pro-apoptotic effect of ATO on tumor cells in vitro and on subcutaneous injected 
tumors in vivo as well. But the tumor surface changed during high dose of ATO treatment 
revealing hardening and black discoloration (Kim et al., 2014). It is known that long-term 
exposure to high doses of arsenic leads to dermatological changes and affects the 
gastrointestinal, cardiovascular, neurological and genitourinary systems (Li et al., 2002; 
Ratnaike, 2003; Soffritti et al., 2006; Mathews et al., 2013; Wang et al., 2015). In addition, 
Wu et al. demonstrated that chronic ATO exposure inhibited osteoblast differentiation in bone 
marrow stromal cells of rats resulting in an increased bone marrow loss (Wu et al., 2014).  
Nevertheless, in this study ATO showed its potency as an anti-leukemic and pro-apoptotic 
drug in vitro. Hence, ATO is a future hope for AML therapy as well as for the treatment of 
different cancer types like chondrosarcoma, breast cancer or neuroblastoma (Gesundheit et 
al., 2008; Jiao et al., 2015; S. Zhang et al., 2016; Shi et al., 2017). 
 
Several studies indicated that ATO can deplete cancer stem cells or at least sensitize them 
to chemotherapy by promoting the dormant cells to enter into the cell cycle or differentiation 
(Essers and Trumpp, 2010; Tomuleasa et al., 2010; Wu et al., 2013). In this study, a 
potential LSC-inhibiting effect of ATO was investigated by analyzing the LSCs residing in the 
so-called side populations (SP 2n/SP 4n). It was observed that ATO increased the diploid 
and tetraploid side populations in a dose-dependent manner in the KG-1a cell line in vitro. 
High dose ATO led to a significant increase of the side populations, while low dose of 0.5 µM 
ATO slightly stimulated them (FIGURE 6B). Although high dose ATO obviously decreased the 
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cell viability of AML cells (FIGURE 6A), it also initiated an accumulation of LSCs indicating that 
LSCs were resistant to ATO and had a survival selection advantage. The in vivo experiments 
with patient-derived AML cells displayed results similar to the in vitro observations (FIGURE 
6). LSCs, which reside in the side-populations, appeared to be resistant to ATO, but to a 
lower extent (FIGURE 7, 9). The patient-derived sample P84D did not respond to ATO with a 
decreased cell viability or decelerated growth (FIGURE 7A+D), but the diploid and tetraploid 
side populations in the spleen were stimulated upon daily ATO injections (FIGURE 7E+F). The 
patient sample P17R however, responded to the high dose of 5 mg/kg ATO with a reduced 
leukemia burden (FIGURE 9A), while the LSCs remained resistant (FIGURE 9B+C). 
Similar results were described by Tokar et al. for ATO-treated non-cancerous prostate 
epithelial cells. ATO reduced significantly the cell viability of mature prostate epithelial cells, 
whereas the prostate stem cells appeared to be resistant to ATO and started to over-
accumulate due to a higher expression of several anti-apoptotic factors (BCL2 and MT1), 
stress-related factors (including NF-E2–related factor-2 and superoxide dismutase-1) and 
arsenic efflux-related genes (for example ABCC1) as well as a lower expression of pro-
apoptotic factors (like BAX and caspases 3) (Tokar et al., 2010). Based on overexpression 
experiments with AML cells, Martelli et al. and Tabellini et al. hypothesized that the PI3K/Akt 
signaling pathway is involved in the resistance of LSCs to ATO-induced apoptosis (Martelli et 
al., 2005; Tabellini et al., 2005). Roszak et al. also confirmed the ATO resistance of human 
T cell leukemia stem cell clones (Jurkat cells) due to a predominantly active PI3K/Akt 
signaling pathway (Roszak et al., 2013).  
 
In conclusion, ATO as a monotherapy displayed an anti-leukemic effect on AML cells, but 
without depleting LSCs in vitro and in vivo. Nevertheless, ATO in combination with other cell 
cycle promoting agents might bring LSCs into the cell cycle and by this increase the 
treatment efficacy and avoid relapse of future AML patients. 
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7.2 G-CSF potentiates cytotoxicity of ATO on AML cells potentially by inducing AQP9 
expression 
ATO in combination with other agents has been proven to be an efficient drug for the 
treatment of different cancer cell types. For example, the most noted and already FDA-
approved combination of ATO and ATRA shows a superior efficacy in APL therapy 
compared with either single agent. ATO improved notably the clinical outcome of APL 
patients by inducing the degradation of the PML-RARα protein (Niu et al., 1999; Zhang et al., 
2010). ATO can also be potentiated in its pro-apoptotic function on AML cells by several 
agents such as vitamin D3 (Rogers et al., 2014), the demethylating agent azacytidine (Chau 
et al., 2015), the antifungal drug itraconazole (Wu et al., 2017) or the naturally occurring 
substance curcumin (Fan et al., 2014). In this study, G-CSF, which is a hematopoietic 
cytokine, was tested as a candidate for potentiating the ATO treatment efficacy on AML cells.  
For that, the AML cell lines U-937 (FAB M5) and Kasumi-1 (FAB M2) were treated in vitro 
with different doses of ATO (0.5 – 2 µM) and G-CSF (10 ng/ml) and analyzed for cell viability, 
cell cycle and proliferation arrest (FIGURE 10). Cell viability analyses of long-term treatments 
revealed that the combination of ATO and G-CSF was superior in decreasing the number of 
viable cells in both cell lines compared to either single agent and to control (FIGURE 10A+B). 
Likewise, many groups termed ATO as a pro-apoptotic drug for AML cells (Halicka et al., 
2002; Kumar et al., 2014) and APL cells (Iriyama et al., 2012). Yoshinari et al. firstly 
described G-CSF as a potent pro-apoptotic agent for APL cells based on morphology 
changes and DNA fragmentation (Yoshinari et al., 1999). Kitagawa et al. further confirmed 
this observation for AML cells by showing a decreased cell viability of U-937 and 32Dcl3 cells 
as well as an increased level of apoptotic cells upon G-CSF treatment (Kitagawa et al., 
2010). Hence, the synergistic anti-leukemic effect of ATO and G-CSF might result from an 
additive pro-apoptotic effect of both drugs. Contrary to the demonstrated results in this study, 
Iriyama et al. indicated that G-CSF has rather an anti-apoptotic effect on APL cells, which 
may result in an increased cell viability (Iriyama et al., 2012). In addition, Morris et al. 
demonstrated that inhibition of G-CSF induces a protective tumor immunity in mouse colon 
cancer by promoting immune cell responses (Morris et al., 2015), rather suggesting an anti-
G-CSF treatment as a potential therapeutic approach for cancer.  
 
In this study, cell cycles analyses of ATO and G-CSF-treated AML cells revealed a significant 
reduction of the S phase accompanied with an increased number of cells in the apoptotic 
sub-G1 phase (FIGURE 10C+D). In addition, U-937 cells showed a G2/M phase arrest 
(FIGURE 10C), while Kasumi-1 cells displayed a G0/G1 phase arrest after exposure to the 
combination of both agents (FIGURE 10D). Comparable results were shown by Halicka et al., 
where ATO induced a G2/M phase arrest in AML cells, which culminated in apoptosis 
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(Halicka et al., 2002). On the other hand, Kitagawa et al. observed that G-CSF mobilized 
resting AML cells from G0/G1 into S phase. This resulted in an increased number of cells in 
the S phase, which implicates a cell cycle-promoting effect of G-CSF (Kitagawa et al., 2010). 
However, this cell cycle promoting-effect of G-CSF could not be confirmed in this study. In 
fact, G-CSF as a single agent rather reduced the number of U-937 cells in the S phase 
instead of increasing it (FIGURE 10C). No changes of the S phase were observed in Kasumi-1 
cells (FIGURE 10D). The response to G-CSF seemingly differed between the cell lines 
regarding their proliferation ability. The proliferation capacity of U-937 cells was significantly 
reduced upon ATO and G-CSF treatment, whereas Kasumi-1 cells did not show a good 
response (FIGURE 10E+F). U-937 cells appeared to be more sensitive to G-CSF than 
Kasumi-1 cells regarding cell cycle and proliferation capability, even though U-937 cells 
showed a lower expression level of G-CSFR than Kasumi-1 cells (FIGURE 11). 
 
G-CSF is also known for its capability to stimulate myeloid differentiation of hematopoietic 
progenitor cells (Welte et al., 1985; Skokowa et al., 2009; Lachmann et al., 2015). In 
addition, Weng et al. demonstrated that the blocked differentiation in myeloid LSCs can be 
reinitiated by granulocyte-macrophage colony-stimulating factor (GM-CSF) administration 
(Weng et al., 2017). The synergistic anti-leukemic effect of ATO and G-CSF might also result 
from the cell cycle and differentiation promoting-effect of G-CSF by recruiting quiescent AML 
cells into the cell cycle for further differentiation and, thereby, rendering them more sensitive 
to ATO. In accordance with this hypothesis, Iriyama et al. demonstrated that G-CSF 
augmented ATO’s potential for inducing the differentiation of APL cells, which might result in 
a higher vulnerability to ATO (Iriyama et al., 2012). Furthermore, Lemarie et al. showed that 
ATO is able to induce apoptosis of human blood monocytes during differentiation of 
macrophages stimulated by GM-CSF (Lemarie et al., 2006).  
 
Another possible explanation for the synergistic anti-leukemic effect of ATO and G-CSF 
could be an enhanced AQP9 expression upon G-CSF treatment. AQP9 is the main 
transporter for arsenic uptake and elimination (Liu et al., 2002; Carbrey et al., 2009). Many 
studies revealed that an increased AQP9 expression leads to an enhanced sensitivity to ATO 
and, thereby, accumulation of arsenic within the cells (Bhattacharjee et al., 2004; Lee et al., 
2006; Leung et al., 2007; Iriyama et al., 2013). Indeed, the in vitro cultivated U-937 and 
Kasumi-1 cells showed an increased AQP9 protein expression level upon G-CSF stimulation, 
validated by western blot and FACS (FIGURE 12). Kasumi-1 cells appeared to be more 
responsive to G-CSF than U-937 cells, resulting in a significant increase of the AQP9 protein 
(FIGURE 12) and mRNA expression level (FIGURE 13). This was accompanied by the 
observation that the basic G-CSFR protein level was much higher in Kasumi-1 cells than in 
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U-937 cells (FIGURE 11). Leung et al. observed the same AQP9-stimulating effect of ATRA 
and Chau et al. of azacytidine in AML cell culture experiments (Leung et al., 2007; Chau et 
al., 2015). In both studies, co-treatment of ATRA or azacytidine with ATO led to an increased 
ATO level within the cells and decreased cell viability. Iriyama et al. already tested G-CSF as 
a potential AQP9 stimulator for APL cells in vitro. They observed that the combination of G-
CSF and ATO enhanced the vulnerability of these cells. But, they could not detect an 
increased AQP9 expression level upon G-CSF stimulation (Iriyama et al., 2012). In this 
study, however, G-CSF appeared to sensitize AML cells to ATO treatment by upregulation of 
AQP9 expression in vitro. 
 
To test the synergistic anti-leukemic efficacy of ATO and G-CSF on patient-derived AML 
cells, freshly isolated CD33-positive leukemic cells were treated in vitro with 1 µM ATO, 
10 ng/ml G-CSF and with the combination of both for 72 – 96 h. However, the combinatorial 
ATO-G-CSF treatment did not convincingly show a synergistic effect on the cell count 
(FIGURE 15A+C+E) and AQP9 expression (FIGURE 15B+D+F). In only three of six patient 
samples, a slight reduction of the cell count was observed. Regarding AQP9 expression 
levels, no obvious upregulation was detected. Many studies have tried to establish optimal 
culture conditions for patient-derived AML cells in vitro, such as using serum-free media 
(Bruserud et al., 2000) or co-culturing with mesenchymal stromal cells, which support the 
growth and long-term maintenance of HSCs and LSCs (Ito et al., 2015). In this study, the 
optimal in vitro culturing of patient-derived AML cells appeared to be problematic. Without the 
addition of cytokines, AML cells often show a rapid differentiation (Ito et al., 2015).  
Therefore, the synergistic anti-leukemic efficacy of ATO and G-CSF was further examined on 
AML cells in vivo. For that, U-937 cells were injected into unirradiated mice and treated daily 
with the combination of 4 mg/kg ATO and 250 µg/kg G-CSF or with the single agents for 
three weeks (FIGURE 14). The analysis of bone marrow, peripheral blood and spleen 
revealed again a synergistic anti-leukemic effect of ATO and G-CSF compared to control and 
ATO alone (FIGURE 14A-C), comparable to the in vitro studies with U-937 and Kasumi-1 cells 
(FIGURE 10). Furthermore, the detection of increased apoptotic markers (activated CASP3 
and cleaved α-spectrin) by western blot confirmed the enhanced anti-leukemic effect of the 
drug combination in the bone marrow compared to either single agent (FIGURE 14D+F+G). 
However, G-CSF alone revealed a distinct anti-leukemic effect in vivo especially in the 
peripheral blood and spleen as well, but without upregulation of apoptotic markers (FIGURE 
14B+C). The same anti-leukemic efficacy of G-CSF as a single agent was observed in all 
analyzed organs of mice, which were transplanted with patient-derived AML cells and treated 
with ATO, G-CSF or with the combination of both for three weeks (FIGURE 16,17). Even a 
reduced application frequency of G-CSF did not reduce the efficacy of G-CSF as single drug 
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in inhibiting leukemia cell growth in vivo (FIGURE 17). Interestingly, the different ATO doses 
did not show an impact on both the patient AML (FIGURE 16,17) and on the U-937 cell growth 
(FIGURE 14) in vivo. Bessho et al. observed the same leukemia suppressing effect of G-CSF 
in vivo, when treating murine myeloid leukemia cell line-transplanted mice with G-CSF. A 
preincubation of the murine myeloid leukemia cells with G-CSF for 48 h even prevented the 
leukemia engraftment in syngeneic mice. In vitro experiments elucidated that apoptosis plays 
a role in the anti-leukemic effect of G-CSF (Bessho et al., 1994), whereas in this study, no 
increased apoptotic markers could be detected in G-CSF-treated U-937 cells in vivo (FIGURE 
14D+F+G). In addition, also clinical trials for alternative cancer therapeutic approaches 
showed occasional tumor regression, when using GM-CSF to enhance immune stimulation 
and bolster specific T cell and antitumor responses (Baeuerle and Reinhardt, 2009; Marr et 
al., 2012). 
 
Further analyses of the immunophenotype revealed that G-CSF reduced the CD34+CD38- 
LSC population, which was accompanied by an increase in CD34-CD38+ cells. This indicates 
a G-CSF-induced differentiation of LSCs in vivo. ATO alone did not show any differentiation-
promoting effect on LSCs (FIGURE 17E). The ATO resistance of LSCs was already observed 
in the in vitro studies with KG-1a cells (FIGURE 6B). The results of the in vivo studies suggest 
that G-CSF might promote the differentiation of dormant LSCs leading to a deceleration of 
the leukemia cell growth independently of ATO administration.  
 
In the in vivo experiment with U-937 cells, G-CSF treatment did not result in increased AQP9 
levels (FIGURE 14D). However, the patient-derived AML cells were susceptible to G-CSF 
resulting in a significant increase of AQP9 expression (FIGURE 16,17). In the in vivo study 
with the P49S patient-derived AML cells, G-CSF even restored AQP9 levels, which were 
decreased upon ATO treatment (FIGURE 16). U-937 cells appeared to have an attenuated 
response to G-CSF compared to patient-derived cells in regard to their AQP9 expression 
levels. The same trend was observed in the in vitro experiments, where the AQP9 
expression was only slightly increased in U-937 cells treated with G-CSF or ATO-G-CSF. In 
contrast, Kasumi-1 cells responded with a highly AQP9 upregulation (FIGURE 12). 
Nevertheless, the combination of ATO and G-CSF was superior to each single agent in 
decelerating the leukemia cell growth in vivo.  
 
All these observations led to the assumption that the synergistic anti-leukemic effect of ATO 
and G-CSF might be a multifactorial effect, in which the pro-apoptotic, differentiation-
promoting and AQP9-stimulating features of G-CSF play an interactive role for the treatment 
of AML cells. Although most AML cells express G-CSFR, some AML subtypes are not 
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responsive to G-CSF (Kitagawa et al., 2010). Therefore, prior analysis for the AQP9 and G-
CSFR status of AML patients can help to predict the response to ATO and G-CSF. 
 
7.3 G-CSF stimulates AQP9 expression in healthy human and murine hematopoietic 
precursor cells 
G-CSF is known to stimulate the bone marrow to produce and to induce a release of mature 
neutrophils (Welte et al., 1985; Semerad et al., 2002). AQP9 is expressed on many tissues 
such as spleen, liver and brain as well as on hematopoietic cells and neutrophils (Tsukaguchi 
et al., 1999; Moniaga et al., 2015). To validate an AQP9-stimulating effect of G-CSF on non-
cancerous human hematopoietic cells, healthy donor CD33- and CD34-positive cells were 
tested for AQP9 expression upon G-CSF treatment (FIGURE 18). CD33-positive cells from 
healthy volunteers, which were treated daily with G-CSF for three days, were analyzed for 
AQP9 mRNA expression by microarray analysis. The results revealed a significant increase 
of AQP9 mRNA expression in cells of G-CSF-treated volunteers compared to cells of non-
treated controls (FIGURE 18A). However, in vitro G-CSF-treated CD33- and CD34-positive 
cells from healthy donors showed no difference in the AQP9 protein expression level in 
comparison to the non-treated cells (FIGURE 18B).  
Similar to the results of the in vitro cultivated patient-derived AML cells (FIGURE 15), an 
AQP9-inducing effect could not be observed for in vitro cultured healthy donor cells. It is 
known that G-CSFR is mainly expressed on myeloid precursor cells, which start to 
differentiate into mature myeloid cells upon G-CSF stimulation (Tsuji and Ebihara, 2001; 
Marino and Roguin, 2008). It might be that the in vitro cultured healthy CD33- and CD34-
positive cells started to differentiate into mature myeloid cells due to cytokine starvation and 
suboptimal culture conditions as it was observed by Ito et al. for LSCs (Ito et al., 2015). 
Consequently, they might not appropriately express G-CSFR and react to G-CSF stimuli any 
more resulting in a non-increased AQP9 expression level.  
Therefore, to further examine an AQP9-inducing effect of G-CSF on healthy hematopoietic 
cells in vivo, NSG mice were treated with G-CSF for one week. After euthanization, murine 
CD45- and CD34-positive bone marrow cells were analyzed for AQP9 protein expression 
levels. Both cell types showed a significant increase in AQP9 expression levels after one 
week of G-CSF application (FIGURE 19).  
These results indicated that G-CSF has also an AQP9-stimulating effect on healthy 
hematopoietic cells comparable to its effect on immature myeloid leukemia cells (FIGURE 12). 
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7.4 Hypothetical network between G-CSF and AQP9 
In this study, the combination of ATO and G-CSF showed a synergistic anti-leukemic effect 
on AML cell lines in vitro (FIGURE 10) and in vivo (FIGURE 14). This was potentially mediated 
via an increased AQP9 expression triggered by G-CSF stimulation (FIGURE 12). Myeloid 
leukemia cells are usually resistant to ATO treatment due to a modest AQP9 expression 
level. But using this AQP9 expression-inducing effect of G-CSF, combinatorial ATO-G-CSF 
treatment might lead to a better ATO uptake and, hence, better targeting of acute myeloid 
leukemia cells (FIGURE 28). 
 
 
 
Figure 28: G-CSF-mediated ATO-induced cell death of AML cells. 
Myeloid leukemia cells are usually resistant to ATO-induced cell death due to the low expression level 
of the main arsenic transporter AQP9. Administration of rhG-CSF could lead to an enhanced 
expression of AQP9 channels and, thus, to a better uptake of ATO by myeloid leukemia cells. This 
might result in G-CSF-mediated ATO-induced cell death. 
 
The questions why G-CSF leads to an upregulation of AQP9 and whether it is a direct or 
indirect effect still need to be answered. A potential link could be via the enzyme 
nicotinamide phosphoribosyltransferase (NAMPT), which is known to be a rate-limiting factor 
in the biosynthesis of the oxidized form of nicotinamide adenine dinucleotide (NAD+) and to 
mediate G-CSF-triggered granulopoiesis in healthy individuals and in CN patients (Rongvaux 
et al., 2002; Revollo et al., 2004; Skokowa et al., 2009). Furthermore, G-CSF increases the 
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intracellular NAMPT and NAD+ amounts in myeloid cells to induce differentiation (Skokowa 
et al., 2009). Increased amounts of NAMPT were also observed in ATRA-induced 
granulocytic differentiation of the AML cell line HL-60 (Jia et al., 2004), rending NAMPT 
essential for differentiation. Moreover, J. Skokowa and colleagues showed that the 
administration of NAMPT alone also induces myeloid differentiation of HL-60 cells (Skokowa 
et al., 2009). In this study, G-CSF triggered AQP9 expression to potentially induce 
differentiation of the leukemia cells. Like AQP9 via its expression on neutrophils, NAMPT is 
also involved in response to inflammatory stimuli and inflammatory diseases (Jia et al., 2004; 
Mesko et al., 2010; Moniaga et al., 2015). This suggests a potential role of AQP9 in 
differentiation of precursor neutrophils into mature neutrophils under participation of NAMPT 
and G-CSF. Another co-factor might be IL-1β (and possibly its processing enzyme caspase-
1) which also induces NAMPT expression (Jia et al., 2004; Kendal and Bryant-Greenwood, 
2007). NAMPT occurs both as an extracellular and intracellular enzyme, converting 
nicotinamide (NAM) to nicotinamide mononucleotide (NMN) in both spaces (Revollo et al., 
2007; Bogan and Brenner, 2008; Ratajczak et al., 2016). These metabolites can be excreted 
and taken up by cells, which might be also mediated by channel proteins like AQP9. AQP9 
allows the passage of several non-charged solutes, including carbamides, purines and 
pyrimidines, whereas amino acids and cyclic sugars are excluded (Tsukaguchi et al., 1998). 
In conclusion, G-CSF might upregulate NAMPT and AQP9 to trigger NAD+ biosynthesis and, 
thereby, to initiate differentiation of immature myeloid cells (FIGURE 29).  
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Figure 29: Hypothetical network between G-CSF and AQP9 in granulopoiesis. 
Stimulated by inflammatory and extrinsic signals like IL-1β and G-CSF stromal/ endothelial/ myeloid 
cells induce expression of nicotinamide phosphoribosyltransferase (NAMPT), which is an important 
enzyme for the nicotinamide adenine dinucleotide (NAD+) biosynthesis and mediates G-CSF-triggered 
granulopoiesis. NAMPT’s substrate nicotinamide (NAM) and its product nicotinamide mono-nucleotide 
(NMN) might pass the membranes via the G-CSF upregulated AQP9 channels. Within precursor 
myeloid cells, intracellular NAMPT triggers NAD+-dependent sirtuin-1 (Sirt1) activation to further 
induce granulocytic differentiation of immature myeloid cells.   
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7.5 Bispecific CAR T cell therapy for prevention of leukemia antigen-loss 
Due to a massive progress in targeted therapy strategies for ALL patients over the last years, 
the prognosis of refractory and relapsed ALL patients has improved significantly. Particularly 
noteworthy are the newly FDA-approved CAR T cell therapies for BCP-ALL and B cell 
lymphoma (U.S. Food & Drug Administration, 2017). Nevertheless, CAR T cell therapy needs 
further optimization because of severe therapy-associated complications and antigen-loss as 
observed upon therapy with therapeutic antibodies (Davis et al., 1999; Ruella and Maus, 
2016). To reduce the ‘on-target off-tumor’ toxicities of CAR T cell therapy and to overcome 
the large heterogeneity of antigen patterns, one strategy is targeting two leukemic blast 
antigens simultaneously with a bispecific CAR. In this study, a bispecific CAR with a 
(glycin4serin)4 linker between anti-CD19 and anti-CD20 scFvs was tested for its superiority to 
monospecific CARs in eradicating a CD19+CD20+/- heterogeneous patient-derived B-ALL in 
vivo (FIGURE 20,21). The analysis of the bone marrow and peripheral blood of the 
transplanted mice revealed that both the bispecific and the anti-CD19 CAR T cells eradicated 
completely the leukemia burden (FIGURE 20A+B), while they further circulated in both organs 
(FIGURE 20C+D). Comparable results were observed by Zah et al. that a bispecific CAR, 
specific for CD19 and CD20, was able to control both wildtype CD19+CD20+ and mutant 
CD19-CD20+ B cell lymphomas with equal efficacy in vivo (Zah et al., 2016). Also other 
studies examined successfully bispecific CAR T cells in terms of treating cancer, such as Qin 
et al. for targeting CD19- and CD22-positive B-ALL as well as Schneider et al. for targeting 
CD19- and CD20-positive B cell lymphoma (Qin et al., 2015; Schneider et al., 2017). 
Schneider et al. further proved bispecific CAR T cells both more effective and less toxic than 
an admixture of two monospecific CAR T cell populations (Schneider et al., 2017).  
 
In this study, the monospecific anti-CD20 CAR T cells did not demonstrate an anti-leukemic 
effect in vivo (FIGURE 20A+B), neither did they circulate in bone marrow and peripheral blood 
(FIGURE 20C+D). In vitro analysis of the bispecific, anti-CD19 and anti-CD20 CAR T cells, 
however, showed equal killing effectiveness as well as antigen specificity (data shown in 
published paper, Martyniszyn et al., 2017). Anti-CD19 CAR T cells are already well explored 
in their efficacy and tolerability for BCP-ALL patient therapy (Gill and June, 2015; U.S. Food 
& Drug Administration, 2017). Many studies have also been performed to investigate anti-
CD20 CAR T cells for B cell malignancy treatment (Wang et al., 2014; Chen et al., 2015; 
Watanabe et al., 2015; Rufener et al., 2016). But the design of the optimal anti-CD20 CAR is 
challenging due to the complex nature of the multi-pass transmembrane CD20 protein 
(Einfeld et al., 1988). It is necessary to achieve the right conjugation distance between the 
T cell and its target antigen and to match the size of the antigen (Marr et al., 2012). 
Moreover, Long et al. revealed that CAR T cells often mediate potent in vitro cytolysis, but 
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show limited expansion, persistence and antitumor efficacy in vivo as a result of T cell 
exhaustion. They further showed that the CD28 co-stimulation domain promotes exhaustion 
of CAR T cells by inducing a persistent CAR signaling (Long et al., 2015). Thus, the CAR 
design with a scFv-Fc-CD28-CD3ζ cassette, used in this study, might have triggered 
exhaustion of the anti-CD20 CAR T cells. Furthermore, the CD20 antigen density might have 
been suboptimal for the recognition, compromising the effectiveness of the anti-CD20 CAR 
T cells in vivo. Similar results were also observed by Watanabe et al. who reported that a low 
antigen density can cause an insufficient efficacy of CAR T cells (Watanabe et al., 2015). It is 
also known that the extracellular spacer length plays an important role in enabling robust 
T cell-mediated response to tumor antigens (Almåsbak et al., 2015; Hudecek et al., 2015). 
Taken together, the anti-CD20 CAR construct was probably not appropriately designed for 
the CD20 target antigen and, thus, could not demonstrate an anti-leukemic effectiveness in 
vivo, while the bispecific CAR T cells proved their capability in successfully killing leukemia 
cells. In conclusion, bispecific CAR T cells appear to be superior to monospecific CAR 
T cells, demonstrating an effective and clinically applicable tool to prevent antigen escape 
and to further optimize the efficacy of CAR T cell therapy for cancer. 
 
7.6 Short-spacer adapter CAR T cells specifically kill B cell leukemia in the presence 
of a biotinylated mAb 
Another strategy to decrease ‘on-target off-tumor’ toxicities of CAR T cell therapy is to use 
universal adapter CAR T cells, which can be functionally controlled by an integration of an 
‘on-switch’ mechanism. This non-lethal control of CAR T cells allows T cell activation via the 
addition of a switch molecule. The modularity of this approach enables universal CAR T cells 
to target a wide range of tumor antigens (Kloss et al., 2012; Wu et al., 2015). In this study, 
universal adapter anti-biotin CAR T cells with different spacer lengths (#7-, #10- and #9 CAR 
with decreasing spacer lengths) were tested for their effectiveness in controlling the CD19-
positive B-ALL cell line Nalm-6 in vitro (FIGURE 22) and in vivo (FIGURE 23-26). The in vitro 
results demonstrated that #9 CAR T cells with a very short spacer domain, consisting of only 
a hinge region, were much more superior in killing leukemia cells in the presence of a 
biotinylated mAb compared to #7- and #10 CAR T cells with longer spacer domains (FIGURE 
22A+D). Further analysis of #9 CAR T cells revealed a high expression of activation 
(CD25/CD69) and exhaustion markers (PD-1) (FIGURE 22B) as well as a decrease of naïve 
T cells (CD62L+CD45RA+CD45RO-CD95-) and increase of effector T cells (CD62L-
CD45RA+CD45RO-CD95+) (FIGURE 22C) upon co-cultivation with Nalm-6 cells and a 
biotinylated mAb. The activation and differentiation status of the CAR T cells confirmed the 
power of #9 CAR T cells in killing leukemia cells in the presence of a biotinylated mAb in 
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vitro. Similar results were observed by Ma et al. and Cao et al. showing that universal 
adapter CAR T cells are able to target CD19- and CD22-positive B cell malignancies (Ma et 
al., 2016) and HER2/neu-positive breast cancer cells (Cao et al., 2016) in vitro and in vivo by 
adding FITC-conjugated tumor-targeting antibodies. 
 
In contrast to the in vitro results, all three CAR constructs appeared to have comparable 
power in controlling leukemia cell growth in the first in vivo experiment (FIGURE 23). However, 
also the control mock mice, which were injected only with #9 CAR T cells and an 
unbiotinylated mAb, revealed a significant decrease of the leukemia burden by 
bioluminescence imaging (FIGURE 23A+B) and FACS analysis (FIGURE 23C). These results 
indicated that the leukemia cells were eradicated, either from a non-specific effect of the 
adapter CAR T cells and/ or from the anti-CD19 4G7SDIE therapeutic mAb alone. Seidel et 
al. already proved the Fc-optimized anti-CD19 4G7SDIE mAb a potent therapeutic with an 
enhanced ADCC against leukemic blasts in 14 pediatric patients with refractory and relapsed 
B-ALL at the stage of MRD (Seidel et al., 2016). Further Fc-optimized anti-CD19 mAbs, 
MEDI-551, MOR208 and CD19-DE, have revealed their effectiveness in B-ALL therapy by an 
increased ADCC and recruitment of proinflammatory immune cells as well (Kellner et al., 
2013; Matlawska-Wasowska et al., 2013; Schewe et al., 2017).  
Additionally, in the first in vivo study, #7 CAR T cells did not circulate and accumulate 
properly within the peripheral blood upon stimulus with a biotinylated mAb (FIGURE 23D), 
whereas the leukemia burden in the bone marrow was eradicated (FIGURE 23A+B+C). This 
observation supported the theory that the anti-CD19 4G7SDIE mAb alone was also 
responsible for the inhibition of leukemia cell growth in all CAR T cell transplanted mice. But 
most importantly, these results indicated a disadvantage of CAR T cells with a longer spacer 
length in vivo. Hudecek et al. and Almåsbak et al. already observed that CAR T cells with a 
short spacer length are superior to CAR T cells with a long spacer length regarding T cell 
function and proliferation. CAR T cells with long spacer domains show in vitro but no in vivo 
antitumor activity due to an interaction between the Fc domain within the spacer and the Fc 
receptor-bearing myeloid cells. This results in an activation-induced T cell death (Almåsbak 
et al., 2015; Hudecek et al., 2015). Also Hombach et al. observed a unintended initiation of 
an innate immune response due to interaction between the Fc domain within the CAR spacer 
and the IgG Fc gamma receptors of innate immune cells (Hombach et al., 2010). Therefore, 
it is highly probable that an interaction between the Fc domain within the #7 CAR spacer 
domain and the Fc receptor-sustaining murine myeloid cells could have led to an activation-
induced death of #7 CAR T cells.  
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Many studies showed that the use of liposomal clodronate leads to a depletion of Fc 
receptor-bearing murine monocytes and macrophages in various organs (van Rooijen and 
Hendrikx, 2010; Hayden et al., 2014; Hanna et al., 2016). In this study, leukemia and CAR 
T cell-transplanted mice were also treated with liposomal clodronate to prevent the 
recruitment of proinflammatory immune cells and activation-induced CAR T cell death (data 
not shown). But almost all mice died immediately after liposomal clodronate injection or 
within the next days, emphasizing the toxicity of monocytes depletion in immunodeficient 
mice. Comparable observations were also described by Fraser et al. and Hu et al. that NSG 
mice are highly sensitive to the toxicity of clodronate (Fraser et al., 1995; Hu et al., 2011). 
 
To elucidate the specificity of the adapter CAR system and to avoid unintended initiation of 
an innate immune response in the following mouse experiment, the cell number of CAR 
T cells was markedly reduced and only #9 and #10 CAR T cells with short spacer lengths 
were used. To prevent ADCC, a biotinylated Fab fragment of the anti-CD19 4G7SDIE mAb 
was added as a switch molecule (FIGURE 24). However, the #9 and #10 adapter CAR T cells 
still demonstrated a non-specific antibody-independent effect in vivo (FIGURE 24A-C) while 
circulating in the peripheral blood (FIGURE 24D). Based on these results, the assumption 
emerged that the Nalm-6 cell line might not be an appropriate target because of its sensitivity 
to any kind of cell response. Other groups have also shown that the Nalm-6 cell line are 
extremely sensitive to cytokine- and cell-mediated cytotoxicity (Schneider et al., 2017). 
However, it was more likely that the CAR T cells were overstimulated and, therefore, 
hyperactive. CAR T cells are usually cultured with the cytokines IL-2, IL-7 or IL-15 (Ma et al., 
2006). Some studies have shown that culturing with IL-7 and IL-15 is superior to IL-2 
regarding CAR T cell expansion, persistence and in vivo engraftment (Caserta et al., 2010; 
Xu et al., 2014). In this study, in vitro culturing of CAR T cells with IL-7 and IL-15 could have 
led to an overstimulation of the cells and later to a non-specific anti-leukemic effectiveness in 
vivo.  
 
For further optimization in the following mouse experiment, the anti-CD19 biotinylated mAb 
clone REA675 was used as a switch molecule, instead of the anti-CD19 4G7SDIE mAb or 
Fab, due to its negligible binding to Fc receptors to exclude non-specific antibody activity 
(FIGURE 25). Furthermore, it exhibits a longer half-life than Fab fragments, which persists 
only for a few hours in the system (Flanagan and Jones, 2004; Adams et al., 2016). 
Additionally, CAR T cells were attenuated in their activity prior to use by a freeze-thawing 
step. With a further reduction of the CAR T cell number and under the optimized conditions, 
CAR T cells showed barely non-specific activity and were able to kill the leukemia cells in the 
presence of the biotinylated mAb in vivo (FIGURE 25A-C), while they circulated in the 
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peripheral blood (FIGURE 25D). However, the anti-CD19 biotinylated mAb clone REA675 also 
revealed a slightly anti-leukemic effect on its own.  
By a further reduction of the mAb application frequency from three times to once a week,  
CAR T cells showed an improved capability for inhibiting the leukemia cell growth in the 
presence of the biotinylated mAb in vivo (FIGURE 26A-C). These results demonstrated the 
ability and potency of an adapter-CAR T cell system to further reduce ‘on-target off-tumor’ 
toxicities of CAR T cell therapy, as recently shown by Cao et al. and Ma et al. (Cao et al., 
2016; Ma et al., 2016). 
 
7.7 Short-spacer adapter CAR T cells for treatment of T cell malignancies 
The capability of the adapter CAR T cell system in killing the CD19-positive B-ALL cell line 
Nalm-6 was discussed in the previous paragraph. The modularity to target different types of 
tumors, however, needed to be elucidated. Since CAR T cell therapy for T-ALLs is still 
difficult due to the shared surface markers between normal and malignant T cells, other 
immune competent cells can be used such as CAR NK cells (K. H. Chen et al., 2016; Chen 
et al., 2017) or CAR T cells targeting tumor-specific antigens. Typical markers confined to 
malignant T cells are CD7 (Gomes-Silva et al., 2017), CD231 (Talla-1) and overexpressed 
antigens like chemokine receptor CCR4 (Perera et al., 2017). Also, universal adapter CAR T 
cells targeting T cell subset-specific or tumor-associated antigens could be used for future 
CAR T cell therapy of T cell malignancies. In vitro co-culture experiments showed that the 
adapter anti-biotin #9 CAR T cells were able to kill γδ-TCR-positive Molt-14 T-ALL cells as 
well as CD231-positive Jurkat T-ALL cells in the presence of a biotinylated tumor-specific 
mAb (FIGURE 27). These results emphasize the modular concept of the universal adapter 
CAR T cells in targeting different kind of tumors. However, targeting common T cell antigens 
like CD3 or CD5 would probably result in self-targeting and autolysis, and would finally 
compromise the efficacy of the CAR T cell therapy or even lead to T cell aplasia in the 
human system (Chen et al., 2017; Gomes-Silva et al., 2017). The best way to circumvent 
self-targeting and to improve the adapter system would be a knockout of the T cell receptor 
complex in CAR T cells without destroying the CAR construct.  
In general, universal adapter CAR T cells are capable of targeting a wide range of tumors 
accompanied with a decrease of ‘on-target off-tumor’ toxicities. For that reason, they will play 
an important role in future CAR T cell therapy. 
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7.8 Conclusion and outlook 
Within this study, two different therapeutic approaches were pursued, a pharmaceutical-
based therapy for AML and a CAR T cell-based treatment approach for B-/ T-ALL. Since 
AML is a widely heterogeneous disorder with many subtypes, a predominant malignant 
antigen is not clearly given. Targeting a common antigen might also interfere with the normal 
blood cell formation. Therefore, a new pharmaceutical approach with ATO and G-CSF was 
tested and proven an effective drug combination for AML therapy. Even G-CSF as a single 
agent displayed an anti-leukemic effectiveness in vivo. With its observed AQP9-stimulating 
effect, G-CSF might play a more important role in future AML therapy, not only for handling 
neutropenia and reducing the incidence of infections, but also as an anti-leukemic drug. 
Furthermore, the AQP9-stimulating effect of G-CSF could be used for several other tumors in 
which AQP9 is involved, such as hepatocellular carcinomas and prostate cancer (Q. Chen et 
al., 2016; W. guang Zhang et al., 2016). Also, alternative small molecules might enhance 
AQP9 expression rendering AQP9 a novel therapeutic target for several cancers. 
The predominant antigens of B-ALL CD19, CD20 and CD22 are highly qualified for CAR 
T cell-based therapy. To reduce ‘on-target off-tumor’ toxicities of CAR T cell therapy 
approaches, two strategies were proposed: bispecific CAR T cells and universal adapter 
CAR T cells. Both demonstrated good effectiveness in vitro and in vivo. Bispecific CAR 
T cells are a good tool to prevent specific escape strategies of leukemic blasts like antigen 
loss. Furthermore, the modularity of the adapter CAR T cells enables targeting of several 
antigens at the same time as well as many different cancer cell types. Any antigen 
recognized by an antibody can be detected by this ‘on-switch’ mechanism. Using adapter 
CAR T cells, each tumor patient could be individually treated by their antigen profile, which 
represents a further step towards a personalized medicine (Van ’t Veer and Bernards, 2008). 
CAR T cell therapy could even be the treatment of choice for T cell malignancies if autolysis 
of CAR T cells could be prevented, which might be facilitated by knocking out the T cell 
receptor complex of CAR T cells.  
In conclusion, two treatment approaches for two types of acute leukemia resulted in a 
therapeutic success in respective ways. The heterogeneity among acute leukemia is high 
and, therefore, demands a development of a wide spectrum of treatment possibilities.  
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9. SUPPLEMENT 
9.1 FACS gating strategies 
9.1.1 Hoechst 33342 staining for detection of stem cell-like side population 
 
 
9.1.2 Viability assay – Annexin V staining 
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9.1.3 Detection of AQP9 expression level 
 
 
9.1.4 Detection of leukemia in ATO/G-CSF-treated transplanted mice 
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9.1.5 Detection of leukemia and CAR T cells in transplanted mice 
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9.2 Abbreviations 
7-AAD   7-aminoactinomycin 
a-   anti 
AAS   atomic absorption spectrometer 
ABC   ATP binding cassette 
ADCC   antibody-dependent cell-mediated cytotoxicity 
AF   Alexa Fluor 
ALL   acute lymphoblastic leukemia 
AML   acute myeloid leukemia 
APC   allophycocyanin 
APL   acute promyelocytic leukemia 
AQP   aqua(glycero)porin 
Ara-C   cytosine arabinoside 
ATO   Arsenic trioxide 
ATRA   all-trans retinoic acid 
B-ALL   B cell-ALL 
BCP-ALL  B cell precursor-ALL 
BCR/ABL breakpoint cluster region/Abelson murine leukemia viral oncogene 
homolog 1 
BM   bone marrow 
BUV   brilliant ultra violet 
CAR   chimeric antigen receptor 
CASP3  caspase-3 
CD   cluster of differentiation 
CLL   chronic lymphoblastic leukemia 
CML   chronic myeloid leukemia 
CN   severe congenital neutropenia 
CNS   central nervous system 
CRS   cytokine release syndrome 
CTLA-4  cytotoxic T lymphocyte-associated antigen 4 
DMEM   Dulbecco’s Modified Eagle Medium 
DNA   deoxyribonucleic acid 
E:T   effector-to-target ratio 
effluc   enhanced firefly luciferase 
FAB   French-American-British 
FACS   fluorescence-activated cell sorting 
FCS   fetal bovine serum 
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FDA   Food and Drug Administration 
FITC   fluorescein isothiocyanate 
FLAG   fludarabine + high-dose Ara-C + G-CSF 
FLT3   Fms-related typrosine kinase 3 
Fc   fragment crystallizable 
G-CSF   granulocyte-colony stimulating factor 
G-CSFR  G-CSF receptor 
GM-CSF  granulocyte-macrophage colony-stimulating factor 
GO   Gemtuzumab Ozogamicin 
GvHD   graft-versus-host disease 
H&E   haematoxylin and eosin staining 
HD   healthy donor 
HRP   horseradish peroxidase 
HSC   hematopoietic stem cell 
HSCT   allogeneic hematopoietic stem cell transplantation 
i.p.   intraperitoneally 
i.v.   intravenously 
IDH   isocitrate dehydrogenase 
IFN   interferon 
Ig   immunoglobulin 
IL   interleukin 
ITD   internal tandem duplication 
JAK   Janus tyrosine kinase 
LEF-1   enhancer-binding factor 1 
LSC   leukemic stem cell 
LT-HSC  long-term HSC 
mAb   monoclonal antibody 
MAPK   mitogen-activated protein kinase 
MDS   myelodysplastic syndromes 
MHC   major histocompatibility complex 
MRD   minimal residual disease 
NAD   nicotinamide adenine dinucleotide 
NAM   nicotinamide 
NAMPT  nicotinamide phosphoribosyltransferase 
NK cells  natural killer cells 
NMN   nicotinamide mononucleotide 
NSG   NOD.Cg-PrkdcscidIL2rgtmWjl/SzJ 
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pAb   polyclonal antibody 
PB   peripheral blood 
PBMC   peripheral blood mononuclear cells 
PBS   Phosphate buffered saline 
PCR   polymerase-chain-reaction 
PD-1   programmed cell death 1 
PE   phycoerythrin 
PI3K   phosphoinositide 3-kinase 
PLK1   polo-like kinase 1 
PML   promyelocytic leukemia 
qRT-PCR  quantitative RT-PCR 
RARα   retinoic acid receptor α 
rhG-CSF  recombinant human G-CSF 
RNA   ribonucleic acid 
ROR-1   receptor tyrosine kinase-like orphan receptor 1 
scFv   single-chain variable fragments 
SD   standard deviation 
SEM   standard error of the mean 
SP   side population 
STAT   signal transducer and activator of transcription protein 
ST-HSC  short-term subset 
T-ALL   T cell-ALL 
TBP   TATA box binding protein 
TCR   T cell receptor 
TIL   tumor-infiltrating lymphocyte 
TM   transmembrane 
WHO   World Health Organization 
Wnt   wingless-related integration site 
ΔΔCT method  comparative CT method 
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